Programme book

OCTOBER 5-8

www.ever.be

EVER 2016

Science for Sight

EUPO course in conjunction with EVER

NICE

22 CME

The power of simplicity

XEN™
GLAUCOMA GEL IMPLANT

Allergan

Rethink glaucoma management

Word from the President

Dear EVER members, colleagues and friends,

2016 heralds an exciting and animated month of October as EVER and EUPO (the European Professors of Ophthalmology group) come together for a grand event. This meeting is not to be missed!

As in previous years, EVER offers a varied menu of fundamental fare and house specialties. These include board preparation sessions, clinical courses, topic-specific symposia, state-or-the-art research platforms, keynote lectures and a broad palette of scientific posters The "extra" in 2016 will be the EUPO courses dedicated to neuro-ophthalmology and strabismus. These are CME accredited courses which will run in parallel with the EVER scientific program during Friday and Saturday (October 7-8). EUPO courses are intended to assist the preparation of young ophthalmologists for the European Board of Ophthalmology examination and also serve as excellent refresher courses for any practicing ophthalmologist.

I am delighted to announce that EVER offers open general admission to EUPO courses for all EVER meeting registrants (without an increase in registration fee from the previous year!). Likewise, EUPO attendees will have open access to the EVER program on those 2 shared days. And as EVER and EUPO boast a strong international faculty, this is a win-win situation for all!

At EVER, we strive for growth, advancement and improvement in ophthalmology and visual science. This may sound like the oft-heard rally cry of "more, bigger and better" which, in practice, often translates to harried, stressed and rushed. Rest assured that EVER is none of that. The beautiful relaxed atmosphere of the French Riviera is once again home to the EVER meeting. Over 4 sunny days in Nice, after the scientific day, enjoy a stroll through the fresh market , take a dip in the Mediterranean waters and savor tasty gourmet dishes on an open terrace.

So join me at EVER-EUPO 2016. It will be a stimulating experience!

Aki KAWASAKI
President EVER 2016



L'innovation en Ophtalmologie va bien au-delà des médicaments

Téléchargez l'Application Retina Base pour tablettes tactiles sur l'App Store® ou le Google Play® et découvrez plus de 120 cas cliniques de pathologies rétiniennes rédigés par des experts, disponibles en Français et en Anglais.

- Naviguez à travers l'organisation planétaire des pathologies et cas cliniques.
- Recherchez facilement les clichés grâce au moteur de recherche intuitif et filtrez les résultats par mot-clé, technique d'imagerie et auteur.
- Recevez les notifications dès que de nouveaux cas sont disponibles.

Rendez-vous sur www.viaopta.fr pour découvrir ou redécouvrir tous les services ViaOpta ™ dédiés à l'ophtalmologie

C65306 - Août 2014

NOVARTIS PHARMACEUTICALS

ViaOpta™

Votre partenaire en Ophtalmologie

Table of contents

Word from the president 1
About EVER 4
Composition of the board 2016 8
Congress information 10
Grants and prizes 14
Floorplan 16
Partners of EVER 18
About the programme book 20
Scientific sections 2016 21
Industry Sponsored Symposia 22
Courses 23

Wednesday, October 5 25
- Noon session 26
- First afternoon session 30
- Opening Ceremony 35
- Second afternoon session 36
- European Ophthalmology Heritage Lecture - Luc MISSOTTEN 40
- Keynote Lecture - Robert MACLAREN 41
- Welcome reception 43

Thursday, October 6 45
- First morning session 46
- EVER-Acta lecture - John GREENWOOD 51
- Second morning session 52
- Lunchtime session - CIS 56
- Keynote Lecture - Shigeru KINOSHITA 59
- First afternoon session 60
- Poster session 1 65
- Second afternoon session 74
- Evening session 79

Friday, October 7 81
- First morning session 82
- Keynote Lecture - Marcela VOTRUBA 87
- Second morning session 88
- First afternoon session 92
- Poster session 2 97
- Second afternoon session 106
- Section Business Meetings 107
- Second afternoon session 108
- General Assembly 113

Saturday, October 8 115
- First morning session 116
- Ophthalmic Research Lecture - Marie-José TASSIGNON 119
- Second morning session 120
- Poster session 3 121
- First afternoon session 130
- Prize award ceremony and Closing Remarks 133

EUPO Course programme overview 134-135

Presenting first authors 147
Presenting all authors 153
Authors by Country 163
Congress time schedule 164-165
Sponsors ..... back cover

About EVER, European Association for Vision and Eye Research

The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.
EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress and is an excellent place for networking.

Membership

EVER currently has members from 50 countries all over the world and represented by 11 scientific sections. Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research. Applications for membership - available on www.ever.be - may be submitted at any time, membership is on calendar year basis and starts on January 1. Every member must select one of the 11 scientific sections that best represents his or her primary area of interest.

The benefits of EVER membership are:

- significantly reduced registration fees for annual meeting
- submission of abstracts at annual meeting
- organizing Special Interest Symposia (SIS) and Courses
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 2.844)
- voting rights for the election of the Board Members
- travel grants and poster prizes
- quarterly E-Newsletter

Elections 2016

In 2016 new representatives of the scientific sections

- **IM** **Immunology / Microbiology**
- **PBP** **Physiology / Biochemistry / Pharmacology**

will be elected through electronic voting. Voting 2016 will close on October 6, midnight. The result of the elections will be announced at the General Assembly on Friday, October 7, 18:00 -18:30.

Website: www.ever.be

On this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2016 meeting and view the status (session, hour, place) of your presentation
- pay on-line and print your invoice
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- cast your vote for officers
- print CME certificate after each congress you attended

Speakers' affiliation to scientific sections



G	Glaucoma
RV	Retina / Vitreous
COS	Cornea / Ocular Surface
NSPH	Neuro-ophthalmology / Strabismology / Paediatric / History
PBP	Physiology / Biochemistry / Pharmacology
MBGE	Molecular Biology / Genetics / Epidemiology
ACB	Anatomy / Cell Biology
PO	Pathology / Oncology
LC	Lens / Cataract
IM	Immunology / Microbiology
EOVS	Electrophysiology, physiological Optics, Vision Sciences

About EVER, European Association for Vision and Eye Research

EVER
European Association for Vision and Eye Research
www.ever.be

EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.

EVER f
EVER Foundation
www.ever-f.eu

In 2010, the EVER Foundation was created to raise money to organize EVER f Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

Fellowships 2016:

1. Dr. Mahajan DEEPTI, India, host institute : Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Narine ADZHEMIAN, Russia - host institute : Medical University of Vienna, Austria

Fellowships 2015:

1. Dr. Sepehr FEIZI, Iran - host institute : Queens Medical Centre, Nottingham, UK
2. Dr. Sabina SAPETA, Poland - host institute : Medical University of Vienna, Austria

Fellowships 2014:

1. Dr. Ganne PRATYUSHA, India - host institute : Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Mohamed Shafik Mohamed ELALFY, Egypt - host institute : Queens Medical Centre, Nottingham, UK

Fellowships 2013:

1. Dr. Reka ALBERT, Hungary - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Minika JASIELSKA, Poland - host institute: Department of Experimental Ophthalmology at the Charite University Medicine in Berlin, Germany

Acta Ophthalmologica
EVER's journal
eu.wiley.com

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 2.844)

Composition of the board 2016

Executive committee

Aki KAWASAKI
President

Bart P LEROY
Past President

Catherine CREUZOT
Secretary General

Andrew DICK
President Elect

Steffen HEEGAARD
Treasurer

Laurence DESJARDINS
Vice President

Marcela VOTRUBA
Programme Secretary

Gerhard GARHÖFER
Vice President

Leopold SCHMETTERER
EVER *f* liaison

EVER office by Mecodi

Marlene VERLAECKT
Executive Officer

Lies VAN EYCKEN
Executive Assistant

Mieke AKKERS
Executive Assistant

Kapucijnenvoer 33, 3000 Leuven, Belgium - ever@ever.be

www.mecodi.eu

Website and onsite support

COVR
IT solutions for scientific and medical associations

www.covr.be

Composition of the board 2016

Section chairs

Kai KAARNIRANTA
Anatomy / Cell Biology

Thomas FUCHSLUGER
Cornea / Ocular Surface

Miguel CASTELO-BRANCO
Electrophysiology, physiological Optics, Vision Sciences

Alain BRON
Glaucoma

Andrew DICK
Immunology / Microbiology

Rafael BARRAQUER
Lens / Cataract

Jochen GRAW
Molecular Biology / Genetics / Epidemiology

Dominique BREMOND-GIGNAC
Neuro-ophthalmology / Strabismology / Paediatric / History

Frédéric MOURIAUX
Pathology / Oncology

Gerhard GARHÖFER
Physiology / Biochemistry / Pharmacology

Peter WIEDEMANN
Retina / Vitreous

EVER representatives in Acta Board

Constantin POURNARAS

Leopold SCHMETTERER

Senior advisory committee

Jean-Jacques DE LAEY

Jost JONAS

Graham HOLDER

Einar STEFANSSON

Representatives

Bozena ROMANOWSKA-DIXON
Representative East Europe

Stephanie BAILLIF
Local representative France

Congress information

Venue

EVER 2016 will be held at the Acropolis Convention Center in Nice, France
⇨ **www.nice-acropolis.com**
The scientific programme of the EVER congress starts on Wednesday, October 5 at 11:30 and concludes on Saturday, October 8 at 15:00.

Registration

Everyone attending the scientific sessions - whether or not an EVER member - must register and pay the registration fee. Onsite registration starts on Wednesday, Oct 5, 9:00.
Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- if you register as an Eye-care, Technician or Nurse, you need to prove your status

Registration fees on-site

	EUR	EUR *
EVER member / Course invited speakers	455	390
Member-in-training	250	200
Non-member	800	645
Non-member-in-training	400	310
Eye-Care / Technician / Nurse	200	180

* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Congo, Egypt, Georgia, Iran, Libya, Macedonia, Moldova, Montenegro, Morocco, Ouzbekistan, Pakistan, Serbia, Tunesia, Ukraine

Welcome reception

The Welcome reception is open for all participants and exhibitors.

- Wednesday 19:30 - 21:30 in the Exhibition area, Acropolis Convention Center

Coffee / tea / refreshments

Included in the registration fee are the coffee / tea and soft drinks offered throughout the whole meeting. In addition coffee & croissants will be served early morning.

Internet access

Wi-Fi internet access is available in the Convention Center.

Photographs

It is strictly forbidden to take photographs or videos of the presentations in all lecture halls. The hostess will ask you to leave the lecture hall immediately and your name will be noted.

No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

CME - Continued Medical Education credits

The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 22 European CME credits (ECMEC) to the EVER 2016 congress on Oct 5 - 8 in Nice, France. CME credit certificates can be printed from the EVER website after the congress.

Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants must make their own arrangements with respect to health and travel insurance.

EVER 2016 Congress App

All congress information in a nutshell:

- About EVER
- Floorplan and sponsors
- My congress bag
- My schedule
- News Feeds
- Notes
- Session rating
- etc.

Publication of the abstracts

The abstracts of the EVER 2016 congress are published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access for members-only through EVER homepage.

Section Business Meetings

EVER Section Business Meetings of the scientific sections
Friday, 16:00 - 16:30

- ACB ..... Gallieni 4
- COS ..... Rhodes 2
- EOVS ..... Rhodes 1
- G ..... Rhodes 1
- IM ..... Gallieni 1 & 2
- LC ..... Gallieni 5
- MBGE ..... Gallieni 1 & 2
- NSHP ..... Rhodes 2
- PO ..... Rhodes 3
- PBP ..... Rhodes 3
- RV ..... Hermes

The sections
- COS - Cornea / Ocular Surface
- G - Glaucoma

will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2017.
Agenda see page 107

EVER General Assembly

Friday, 18:00 - 18:30 in room Hermes
Agenda see page 113

Prize award ceremony and conclusion of the congress

Saturday, 14:30 - 15:00 in room Hermes
Agenda see page 133

Women 4 EVER

Saturday, October 8 from 13:00 to 14:30 in Hermes

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed. *See page 130.*

Meet the Experts

Thursday, October 6 from 16:00 - 17:00 in poster area

In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a one hour session called "Meet the Experts". This will be a table of 6-8 "guests" at a table headed by one of the EVER speakers.
The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.
This initiative is scheduled on Thursday, October 6 from 16:00 - 17:00 in poster area. *See page 73.*
Please sign in at the registration desk.

NEW!

YOS for EVER - young ophthalmologist/scientist

Thursday, October 6 from 17:00 - 18:30 in Rhodes 2

EVER 2016 will introduce a new symposium entitled YOS for EVER. YOS is a well-recognized acronym for "young ophthalmologist" and as not only ophthalmologists attend EVER, YOS stands for "young ophthalmologist/scientist". YOS for EVER represents the trainee and young specialist group within EVER. This is a networking assembly of students, residents, post-docs and junior scientists to focus on objectives and goals relevant to the early stages of career development. Such topics include board examinations, information exchange, research and/or educational programs, fellowship and job opportunities. The 2016 inaugural symposium will be organized by Gauti Jóhannesson, a young ophthalmologist/scientist and member of the organization committee for YOS sessions at the Nordic Ophthalmologic Congress. All interested parties are encouraged to attend as guidelines and objectives and representatives for this new subgroup will be discussed at this first meeting. Immediately following the symposium, there will be a reception with light food and beverages on site. *See page 75.*

EUPO course - European University Professors of Ophthalmology

Friday, October 7 and Saturday, October 8 in Rhodes 4.
Each year EUPO organises a 2 days course for residents in training.
This year, the course is on Neuro-ophthalmology (Friday, Oct 7) and Strabismus (Saturday, Oct 8) organized by Aki Kawasaki

The EUPO programme can be consulted in pages 134-135.

EVER section Travel Grants

We are pleased to announce that the following 14 members have received an EVER section Travel Grant of 750 EUR each:

- ACB - Daria AFANASYEVA - Russia
  1375 - Angiogenic potential of orbital adipose derived stromal cells
- COS - Mette CORRELL - Denmark
  1146 - Graft functionality after DSAEK surgeries in Denmark from 2006 to 2009
- COS - Wojciech CZAK - Poland
  2673 - Communication between the researcher and the researched. Designing an application based study regarding effects of air pollution on ocular surface diseases
- EOVS - Kevin Sean JENKINS - Australia
  3567 - Systematic Assessment of Clinical Methods to Diagnose and Monitor Diabetic Retinal Neuropathy
- G - Shiama BALENDRA - United Kingdom
  1162 - A Curry A Day Keeps Glaucoma Away? - A Curcumin Study
- G - Kendrick Co SHIH - China
  1163 - Transcorneal electrical stimulation prevents secondary retinal ganglion cell death after acute ocular hypertensive injury through modulation of microglia-mediated local inflammatory response
- IM - Dafina DRAGANOVA - Belgium
  3373 - Validation of an antiretinal antibody detection strategy for the diagnosis of autoimmune retinopathies
- LC - Xiaodi QIU - China
  2352 - Effects of histone acetylation on superoxide dismutase 1 gene expression in the pathogenesis of senile cataract
- MBGE - Andrea GARCÍA LLORCA - Iceland
  3585 - Autophagy is affected by Mitf in mouse primary RPE cells
- NSPH - Ségolène ROEMER - Switzerland
  1551 - Reduced post-illumination pupil response in patients with mild-moderate cataracts is associated with impaired sleep quality
- PBP - Olga KUDRYAVTSEVA - Denmark
  2381 - Ca2+ activity during ATP-induced tone changes in porcine retinal arterioles in vitro spreads along the processes of perivascular cells
- PO - Joni TURUNEN - Finland
  S087 - BAP1 germline mutations in uveal melanoma patients without family history of eye cancer
- RV - David CORDEIRO SOUSA - Portugal
  2685 - Hypoxia and retinal blood flow changes: a study using OCT-Angiography
- RV - Koen WILLEKENS - Belgium
  1566 - Robot assisted retinal vein cannulation in an in vivo porcine retinal vein occlusion model

The Travel Grant awards will be handed over during the Prize Award Ceremony on Saturday, 14:30 - 15:00 in room Hermes.

EVER Poster Prizes

Poster Prizes of 500 EUR will be awarded for the best posters across all sections.

The winners will be chosen by the poster moderators and will be announced in the Prize Award Ceremony on Saturday, 14:30 - 15:00 in room Hermes. No prize will be given after the congress.

EVER Award Ceremony 2015

Floorplan

Acropolis Convention Center, 2nd floor



Exhibitors



114 - Allergan
112 - BAYER
110 - Bioptigen
116 - Cambridge Research Systems Limited
111 - Charles River
117 - Diagnosys UK Ltd
109 - Heidelberg Engineering
105 - Horus Pharma
106 - Iris Pharma
108 - LKC Technologies
107 - Metrovision
118 - Novartis
120 - NuVision
101 - Santhera Pharmaceuticals
102 - Thea Pharma
115 - Topcon
119 - VITO
103 - Wisepress

Non-profit
104 - ARVO

Partners

ARVO

Association for Research in Vision and Ophthalmology www.arvo.org

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005. *See page 88.*

EBO

European Board of Ophthalmology ebo-online.org

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress.
See pages 27, 31.

EUPO

European University Professors of Ophthalmology www.eupo.eu

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe. The EUPO 2016 course on Neuro-ophthalmology and Strabismus is organized in conjunction with the EVER congress in Nice, France.
EUPO course in Rhodes 4 on Friday, October 7 and on Saturday, October 8.
Programme EUPO course on pages 134-135.

FAN

European Fluorescein Angiography Club www.fan-int.org

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and lasercoagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress. *See page 108.*

FRO

Belgian Fund for Research in Ophthalmology www.fro-online.org

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002. *See pages 118, 132.*

GOA

Groupe Ophtalmo Allergo

In ocular surface pathologies the cooperation between clinical ophthalmology and allergology created the GOA. The GOA allowed the development of clinical research in ocular allergic disease. Vernal keratoconjunctivitis and atopic keratoconjunctivitis create severe ocular inpairment that must be recognized and treated. *See page 111.*

OOG

The Ophthalmic Oncology Group www.oog.eu

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions. *See pages 109, 117 and 131.*



Optic Nerve Meeting www.optic-nerve-online.com

Intended for basic scientists and clinicians to address important topics in translational research, including scientists in interdisciplinary areas such as neurology, neurodegenerations and autoimmunity. 2016 meeting: December 13-15, 2016 in Obergurgl, Austria.
See page 92.

About the programme book

Sessions

- BM — Business Meeting
- C — Course
- CIS — Industry Sponsored Symposium
- FP — Free Paper session
- GA — General Assembly
- JM — Joint Meeting
- KN — Keynote lecture
- SIS — Special Interest Symposium
- SOC — Social
- POS — Poster session
- PS — Plenary session

Symbols

	=	EVER section travel grant recipient
rf	=	Rapid fire presentation
✶	=	Conflict of interest disclosed

Scientific sections

ACB	=	Anatomy / Cell Biology
COS	=	Cornea / Ocular Surface
EOVS	=	Electrophysiology, Physiological Optics, Vision Sciences
G	=	Glaucoma
IM	=	Immunology / Microbiology
LC	=	Lens and Cataract
MBGE	=	Molecular Biology / Genetics / Epidemiology
NSPH	=	Neuro-ophthalmology/Strabismology / Paediatric Ophthalmology / History of Ophthalmology
PBP	=	Physiology / Biochemistry / Pharmacology
PO	=	Pathology / Oncology
RV	=	Retina / Vitreous Section programme secretaries

Programme Secretary, Marcela VOTRUBA

EVER programme committee meeting in Leuven on June 11

2016 Section programme secretaries + representatives*

ACB	Anatomy/Cell Biology	Goran PETROVSKI
COS	Cornea/Ocular Surface	Jean-Jacques GICQUEL
EOVS	Electrophysiology, Physiological Optics, Vision Sciences	Franziska RAUSCHER *Rebekka HEITMAR* *
G	Glaucoma	Francesca CORDEIRO
IM	Immunology/Microbiology	Piergiorgio NERI *Joachim VAN CALSTER* *
LC	Lens and Cataract	Stefan LÖFGREN
MBGE	Molecular Biology/Genetics/Epidemiology	Petra LISKOVA
NSPH	Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/ History of Ophthalmology	Patrick YU-WAI-MAN
PBP	Physiology/Biochemistry/Pharmacology	Alexandre MOULIN
PO	Pathology/Oncology	Neville OSBORNE *Gerhard GARHÖFER* *
RV	Retina/Vitreous	Stephanie BAILLIF *Anita LEYS* *

Industry Sponsored Symposia throughout the EVER 2016 congress

Thursday, October 6

THÉA Pharma

12:40 - 13:40 | Rhodes 2

Demodex: innocent or guilty in blepharitis? 57

Santhera Pharmaceuticals

12:40 - 13:40 | Rhodes 1

Leber's hereditary optic neuropathy (LHON): latest advances in diagnosis, staging and patient management..... 56

Courses throughout the EVER 2016 congress:

B Beginner
I Intermediate
A Advanced

Wednesday, October 5

EOVS	11:30	Rhodes 1	B	A clinician's guide to visual electrophysiology: a road map for neuro-ophthalmology	26
IM	11:30	Rhodes 2	I	EBO course: Intraocular inflammation and infection (part I)	27
ACB	11:30	Gallieni 4	I	Tear fluid proteome	29
RV	14:00	Hermes	I	Management of Aphakia	30
IM	14:00	Rhodes 2	I	EBO course: Intraocular inflammation and infection (part II)	31
EOVS	14:00	Rhodes 4	A	Optical principles of state-of-the-art ophthalmic instrumentation	32
PBP	16:50	Gallieni 4	B	High-resolution imaging of the anterior eye segment	39

Thursday, October 6

COS	8:30	Rhodes 2	I	Corneal dystrophies - diagnosis and treatment	47
PO/RV	11:00	Rhodes 3	I	Mistakes in the diagnosis of fundus tumors	53
PBP/RV	14:30	Rhodes 3	B	ABC in retina structure and function	61
PO	14:30	Rhodes 4	I	Challenges in management of orbital tumors	62
NSPH	14:30	Gallieni 1+2	A	Update in clinical features and genetics in microphthalmia	62
G	17:00	Rhodes 2	B	YOS for EVER - Young Ophthalmologist/Scientist	75

Friday, October 7

PBP	16:30	Gallieni 1+2	I	Ocular pulse amplitude - from pole to pole	110

Saturday, October 8

COS	8:30	Rhodes 2	I	Corneal infectious diseases	117
COS	13:00	Rhodes 2	I	Maximising success in deep anterior lamellar keratoplasty	131

EVER 2016
Wednesday, Oct 5

Wednesday, Oct 5 - Noon session

SIS

11:30 - 13:00 | HERMES

PBP/RV - Retinal perfusion imaging

Imaging of the human retina has in the recent years undergone tremendous changes. Whereas decades these techniques have only been used experimentally, the introduction of OCT-based technology has gained widespread clinical use. It is particularly OCT angiography that has revolutionized ocular vascular imaging. Most likely the technique will replace classical fluorescein and ICG angiography in the near future. In addition, several investigators have worked on quantification of ocular blood flow. The present SIG will give an overview on these developments from a clinical view, but will also provide an update on latest technology.

SCHMETTERER L , NAGAOKA T

1111		11:30	Role of Glial Cells in Regulating Retinal Blood Flow during Flicker-Induced Hyperemia and Systemic Hyperoxia-Induced Hyporemia in Cats *NAGAOKA T - Asahikawa*
1112	*	11:48	Retinal Oximetry and Blood Flow *HUDSON C , Rose K , Kulasekara S , Cheng R , Wong B - Waterloo*
1113		12:06	OCT angiography: evaluation of the macular perfusion *POURNARAS C - Genève*
1114		12:24	Retinal Oxygen Extraction *WERKMEISTER R , Aschinger G , Linsenmeier R , Schmetterer L - Vienna*
1115		12:42	The oxygen saturation in retinal arterioles is predictive for the effect of intravitreal anti-VEGF treatment on diabetic macular edema *BEK T - Århus C*

C

11:30 - 13:00 | RHODES 1

EOVS - A clinician's guide to visual electrophysiology: a road map for neuro-ophthalmology

Beginner

Learning outcomes: at the end of the course the participant will be able to
· understand the purpose of the main visual electrophysiological tests (and their acronyms)
· recognise indications for visual electrophysiological tests
· inform patients of what they will experience
· understand the physiological principles underpinning each response
· recognise the response measurements and nomenclature associated with different tests
· interpret overall patterns of visual electrophysiological results to localise the site of visual pathway dysfunction
· prepare requests that optimise test selection and give context for result interpretation
· access ISCEV standards as a resource for test procedure and guidance

THOMPSON D , SMITH R

1121	11:30	The tests *THOMPSON D - London*
1122	11:48	The indications *SMITH R - Aylesbury*
1123	12:06	Retinal tests *ROBSON A - London*
1124	12:24	Visual Evoked Potentials *LIASIS A - London*
1125	12:42	In the neuro-ophthalmology clinic *SMITH R - Aylesbury*

C

11:30 - 13:00 | RHODES 2

IM - EBO course: intraocular inflammation and infection (part I)

Intermediate

The aim of this course is to review major topics of intraocular inflammation and infection. MCQs will be proposed online before the course to evaluate the basic knowledge of the participants. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The course will be interactive allowing general discussion and the participation of the audience. MCQs will be discussed during each presentation. At the end of this course, participants will be prepared for the MCQ part of the EBO examination in uveitis.

BODAGHI B , HERBORT CP

1131	11:30	Pathophysiology of uveitis *DICK A - Bristol*
1132	11:45	Classification of uveitis *ANDROUDI S - Thessaloniki*
1133	12:00	Signs and symptoms of uveitis *NERI P , Bisceglia P , Cesari C , Carrozzi G , Pirani V - Agugliano*
1134	12:15	Laboratory work-up and specialized investigations *PLEYER U - Berlin*
1135	12:30	Imaging in uveitis : techniques and indications *HERBORT C P - Lausanne*
1136	12:45	Therapeutic management of uveitis *DICK A - Bristol*

FP

11:30 - 13:00 | RHODES 3

COS - FP session - Corneal grafting

GICQUEL J , THURET G

1141		11:30	Immunosuppression with a subconjunctival implant releasing dexamethasone in a rabbit model of penetrating keratoplasty *CROUZET E , He Z , Perrache C , Basset T , Delavenne X , Peoc'h M , Gain P , Thuret G - Saint Priest en Jarez*
1142		11:42	Infectious keratitis after penetrating keratoplasty: predisposing risk factors and prognosis *HASSAIRI A , Limaiem R , Ben Mrad A , Rayhan H , Turki R , El Matri L - Tunis*
1143		11:54	Mid-term clinical outcomes of collagen-phosphorylcholine cornea substitutes for therapeutic anterior lamellar keratoplasty *BUZNYK O , Islam M M , Iakymenko S , Pasyechnikova N , Griffith M - Odessa*
1144		12:06	Chondro-keratoprosthesis: an alternative to OOKP ? *HOFFART L , Guyot L - Marseille*
1145	*rf*	12:18	Peter's anomaly in twins: a rare incidence with novel associations *ALZAHRANI S, Khayat H , Tayyib A , Alsulami R , Alkahtani A, Almarzoki H - Jeddah*
1146	*rf*	12:24	Graft functionality after DSAEK surgeries in Denmark from 2006 to 2009 *CORRELL M , Stormly Hansen M , Hovlykke M , Hjortdal J , Olsen Julian H - Glostrup*

Wednesday, Oct 5 - Noon session

SIS

11:30 - 13:00 | RHODES 4

LC - Controversies in cataract surgery pharmacology

The exciting evolution of best care practice in the use of pharmacological substances before, during, and after cataract surgery also creates controversies in the ophthalmic community. The dispersion of and adhesion to improved evidenced based treatments are hampered by local traditions, bureaucracy and national legislation. The speakers will present their take on past and current controversies in the use of pharmaceuticals relevant to cataract surgery.

LOFGREN S , GRZYBOWSKI A

1151		11:30	Controversies in the use of NSAIDs *PLEYER U - Berlin*
1152		11:52	Controversies in the use of steroids *KUGELBERG M - Stockholm*
1153	*	12:14	Controversies in the use of mydriatics *LABETOULLE M - Le Kremlin Bicêtre*
1154		12:36	Controversies in the use of antibiotics *GRZYBOWSKI A - Olsztyn*

FP

11:30 - 13:00 | GALLIENI 1+2

G - FP session - Advances in glaucoma

BRON A , NORMANDO EM

1161		11:30	Racial differences in the extracellular matrix of the lamina cribrosa and the peripapillary sclera *KIM Y , Park H Y L - Seoul*
1162		11:42	A curry a day keeps glaucoma away? - A curcumin study *BALENDRA S I , Davis B M , Guo L , Cordeiro M F - London*
1163		11:54	Transcorneal electrical stimulation prevents secondary retinal ganglion cell death after acute ocular hypertensive injury through modulation of microglia-mediated local inflammatory response *SHIH K C , Fu L , Lo A C Y , Lai J S M - Island South*
1164		12:06	Normobaric hypoxia induces changes in mean ocular perfusion pressure *LEAL I , Cordeiro Sousa D , Moreira S , Dionisio P , Abegao Pinto L , Marques-Neves C - Lisbon*
1165	*rf*	12:18	Quantification of green fluorescent protein expression in mouse retinal ganglion cells following intravitreal injection of recombinant adeno-associated virus *KHATIB T , Osborne A , Widdowson P , Martin K - Cambridge*
1166	*rf*	12:24	Incidence and risk factors of elevated intraocular pressure following deep anterior lamellar keratoplasty *HUANG O , Mehta J , Htoon H , Tan D , Wong T - Singapore*
1167	*rf*	12:30	A vascular comparison between primary open-angle glaucoma and normal-tension glaucoma *VAN KEER K , Abegão Pinto L , Barbosa Breda J , Willekens K , Vandewalle E , Stalmans I - Leuven*
1168	*rf*	12:36	A link between Diabetes Mellitus and Glaucoma — Danish Nationwide Study *HORWITZ A , Petrovski B E , Petrovski G , Torp-Pedersen C , Kolko M - Copenhagen*

C

11:30 - 13:00 | GALLIENI 4

ACB - Tear fluid proteome

Intermediate

Ocular surfaces are delicate structures of the anterior segment of the eye protected, nourished and lubricated by tear fluid. The system has it's own regulatory mechanisms. Ocular surfaces are exposed environmental factors, topical ophthalmic drugs and affected by various ocular and systemic diseases. Inflammation and wound healing are vital processes involved in the defense mechanisms of the human body and pathogenesis of many eye diseases. It is also one of the most important factors in many ocular surgeries e.g. corneal, refractive and glaucoma surgery. Tear proteomics is a powerful tool to diagnose eye diseases and their risk factors. It is also a key to personalize the ocular therapies and health care processes. The course is focusing in the proteomics of the tear fluid and will give an practical owerview of the technologies in this field.

UUSITALO H

1171	11:30	When and why proteomic approach is needed? *UUSITALO H - Tampere*
1172	12:00	Proteomics of tear fluid *BEUERMAN R - Singapore*
1173	12:30	Practical examples of tear proteomic studies *HOLOPAINEN J - Helsinki*

Wednesday, Oct 5 - First afternoon session

C

14:00 - 15:30 | HERMES

RV - Management of Aphakia

Intermediate

Management of aphakia still represents challenge as many options are available. Contact lenses correction will be detailed. Then, different intraocular lenses implantation will be presented, giving more details on advantages and inconvenients for each lens. Finally, complex reconstruction with aniridia implants will be discussed.

POURNARAS J , PAPPAS G

1311	14:00	Contact lenses *PLAINIS S - Heraklion*
1312	14:15	Anterior chamber lenses *MOSCHOS M M - Athens*
1313	14:30	Iris claw *POURNARAS J A - La Conversion*
1314	14:45	Sleral structured iol *SIMCOCK P - Exeter*
1315	15:00	Sclear embedded iol *PAPPAS G - Heraklion*
1316	15:15	Aniridia implants *STAPPLER T - Liverpool*

SIS

14:00 - 15:30 | RHODES 1

G - The ideal glaucoma rotation

Glaucoma is one of the leading causes of irreversible blindness. It is therefore a major part in Ophthalmology education and a major focus of Ophthalmology residency programmes. The syllabus in these programmes usually involves providing the residents with a set of skills, ranging from surgical procedures or treatment decision-making, they should master by the end of their glaucoma rotations. However, there is a great diversity between training centers and there is not a clear definition of what constitutes the core values in glaucoma training for the general Ophthalmologists. Accordingly, a much needed debate is needed between al players involved, from residents, Directors of training and Institutional organizations such as a the European Glaucoma Society.

ABEGAO PINTO L , SUNARIC MEGEVAND G

1321	14:00	The view of the doctor in training *SCOTT A - London*
1322	14:18	The view of a director of training *GARCIA-FEIJOO J - Madrid*
1323	14:36	The view of the EGS and the subspecialty exam *SUNARIC MEGEVAND G - Geneva*
1324	14:54	How can we improve? *SUNARIC MEGEVAND G - Geneva*
1325	15:12	What did we learn from this session? *ABEGAO PINTO L - Lisbon*

C

14:00 - 15:30 | RHODES 2

IM - EBO course: intraocular inflammation and infection (part II)

Intermediate

The first part on general aspects of uveitis will be followed by case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine. At the end of this course, participants will be prepared for the viva voce part of the EBO examination in uveitis.

BODAGHI B , HERBORT CP

1331		14:00	B27-associated uveitis, Fuchs uveitis *WILLERMAIN F - Bruxelles*
1332		14:18	Infectious uveitis *PLEYER U - Berlin*
1333		14:36	Behçet's disease, VKH, sarcoidosis *KHAIRALLAH M , Khochtali S , Abroug N - Monastir*
1334		14:54	Inflammatory choroiditis *HERBORT C P - Lausanne*
1335		15:12	Retinal vasculitis *ABU EL ASRAR A - Riyadh*

FP

14:00 - 15:30 | RHODES 3

PBP - FP session - Drug delivery and biomarkers for ocular disease

SCHMETTERER L , HARDARSON S

1341	*	14:00	Trans-scleral delivery of novel anti-angiogenic small molecule inhibitors of SRPK1 *BATSON J , Toop H D , Allen C , Rowlinson J , Babaei-Jadidi R , Gibbons B , Zhang J , Wearmouth S F , Knapp S , Morris J C , Bates D O - Nottingham*
1342		14:12	Toward rational design of gene carriers: a novel ex vivo model to study the vitreoretinal interface as a barrier *PEYNSHAERT K , Fradot V , Picaud S , De Smedt S , Remaut K - Ghent*
1343		14:24	Results of microinvasive cross-linking of rabbit posterior eye pole sclera *IOMDINA E N , Tarutta E , Semchishen V , Sianosyan A , Milash S - Moscow*
1344		14:36	Retinal α-synucleinopathy: taking a new look at Parkinson's disease. *DE GROEF L , Normando E M , Andries L , Davis B , Lefevere E , Van den Haute C , Baekelandt V , Cordeiro M F , Moons L - Leuven*
1345		14:48	Exploration of human tear proteome *TURCK N , Dor M , Eperon S , Salvisberg C , Fouda C , Hainard A , Guex-Crozier Y , Hamedani M - Geneva*
1346	*rf*	15:00	In the search of biomarkers for thyroid associated orbitopathy (TAO) *TURCK N , Kishazi E , Dor M , Eperon S , Gracià M D L A , Fouda C , Oberic A , Hamédani M - Geneva*
1347	*rf*	15:06	Variation of accommodative process and anterior chamber parameters in diabetic patients *COSTA L , Passos I , Pires G , Proença R , Amado D , Ferreira J - Lisbon*

Wednesday, Oct 5 - First afternoon session

C

14:00 - 15:30 | RHODES 4

EOVS - Optical principles of state-of-the-art ophthalmic instrumentation

Advanced

This single-speaker course is aimed to provide an overview of the optical principles of various state-of-the-art ophthalmic instruments, such as scanning laser ophthalmoscopy, optical coherence tomography, including adaptive optics, to make it easy for the clinician and scientist to understand the underlying concepts of various devices, even if not familiar with the particular technology.
This course is designed for ophthalmologists in training or those in practice, aimed at addressing common optical pitfalls in general ophthalmology practice with easy-to-understand explanations enhanced by simple illustrations. Its goal is to make ophthalmic optics accessible and understandable with real-life, clinically relevant examples, such as why one should not switch myopes in their mid-life crises from wearing spectacles to contact lenses, or why aiming for a post-operative plano refraction with refractive or cataract surgery might not always yield the best vision or results.

IRSCH K

1351	14:00	Scanning Laser Ophthalmoscopy - Basic Optical Principles *IRSCH K - Paris*
1352	14:30	Optical Coherence Tomography - Basic Optical Principles *IRSCH K - Paris*
1353	15:00	Adaptive Optics - Basic Optical Principles *IRSCH K - Paris*

SIS

14:00 - 15:30 | GALLIENI 1+2

MBGE - Epidemiology of eye diseases

To better understand mechanisms of development of ocular diseases, it important to know their relationship to other diseases of the patients, to their genetic background, to their lifestyle, and to their whole environmental situation. The proportion of all these components is highly complex and cannot be resolved in small case-control studies. Therefore, large population-based cohorts are being developed at international and national levels to increase the power of such epidemiological studies. This Special Interest Symposium will share up-to-date information not only to stimulate discussions how to further improve epidemiological studies, but also to develop ideas for clinicians to include additional factors into their diagnostic and therapeutic considerations, and also for basic scientists to prove the molecular mechanisms behind epidemiological associations.

GRAW J

1361		14:00	The Global Vision Database – modeling the current and changing burden of eye disease *BOURNE R - Cambridge*
1362	*	14:22	The E3 consortium – European Eye Epidemiology *DELCOURT C - Bordeaux*
1363		14:44	The Montrachet Study *CREUZOT C , Bron A , Binquet C - Dijon*
1364		15:06	Molecular Genetics in Ocular Epidemiology *DEN HOLLANDER A - Nijmegen*

FP

14:00 - 15:30 | GALLIENI 4

ACB - FP session - Cell biology and imaging of retina and orbit

PETROVSKI G , KOLKO M

1371	14:00	Hypoxia and inflammation in human retinal cells *ARJAMAA O , Aaltonen V , Piippo N , Csont T , Petrovski G , Kaarniranta K , KIVELÄ A - Turku*
1372	14:12	Mitochondrial inhibition of retinal Müller cells alter glutamate homeostasis and their ability to sustain retinal ganglion cells *SKYTT D M , Vohra R , Toft-Kehler A K , Gurubaran I S , Bergersen L H , Kolko M - Copenhagen*
1373	14:24	LACTATE: A valuable energy substrate in maintaining survival and function in the inner retina *VOHRA R , Skytt D M , Bergersen L H , Kolko M - Copenhagen*
1374	14:36	Mechanisms behind the protein aggregation-related inflammasome activation in RPE cells *KAUPPINEN A , Piippo N , Korhonen E , Hytti M , Kinnunen K , Kaarniranta K - Kuopio*
1375	14:48	Angiogenic potential of orbital adipose derived stromal cells *AFANASYEVA D , Gushchina M , Borzenok S - Moscow*
1376	15:00	Description of the retinal vascular network by semi-automated computer software (SIVA) in the MONTRACHET study *ARNOULD L , Binquet C , Guenancia C , Alassane S , Kawasaki R , Daien V , Helmer C , Tzourio C , Bron A , Creuzot C - Dijon*
1377	15:12	Manufacturing of an ocular prosthesis based on the 3D printed anophthalmic socket *RUITERS S , Sun Y , De Jong S , Politis C , Mombaerts I - Leuven*

PS

15:40 - 16:30 | HERMES

Opening Ceremony

15:40 Welcome by the EVER President 2016

Aki KAWASAKI - Lausanne

1411

15:50 Word from the EVER f President

Highlights of EVER f
Update on EVER in EU-EYE

Leopold SCHMETTERER - Vienna

1412

16:00 EVER Past President lecture

Lessons from the Fascinating World of Bestrophinopathies

Bart LEROY - Ghent

Introduction by Aki KAWASAKI

End 16:30

SIS

16:50 - 18:20 | HERMES

MBGE/RV - Advances in gene-based therapies for ocular disorders

Gene-based therapies represents a very promising option for many inherited and acquired ocular disorders. The special interest symposium will focus on advances in gene therapy technologies, animal models that are a target for ocular gene therapy as well as current clinical gene therapy trials.

LISKOVA P

1511		16:50	Optimisation of RPE65 gene delivery for treatment of Leber congenital amaurosis patients *GEORGIADIS T - London*
1512		17:12	Animal models for ocular gene therapies *ARSENIJEVIC Y , Kostic C - Lausanne*
1513		17:34	Novel tissue-targeted localized gene therapy for corneal scarring and neovascularization *MOHAN R , Gupta S , Sharma A , Anumanthan G , Sinha P , Fink M , Tripathi R , Raikwar S , Giuliano E , Rieger F , Hesemann N , Sinha N , Chaurasia S - Columbia*
1514	*	17:56	Current gene therapy trials for inherited retinal disorders *LEROY B P , Maguire A M , Russell S R , Wellman J , Yu Z F , Chung D C , High K A , Bennett J - Ghent*

FP

16:50 - 18:20 | RHODES 1

G - FP session - New technologies in glaucoma

CORDEIRO MF , ROUSSEAU A

1521		16:50	Could 24-S-hydroxycholesterol play a role in Müller glial cell's membrane dynamics in the rat *BRON A , Ferrero A , Gambert-Nicot S , Brétillon L , Acar N , Creuzot C - Dijon*
1522		17:02	Reduced vascular response in patients with normal tension glaucoma in response to hypoxia *DALGAARD L M , Vibæk J , Jensen L T , Olsen N V , Kolko M - Copenhagen*
1523	*	17:14	Impact of gender-specific differences in corneal elasticity upon IOP measurements using vibration tonometry *BITOUN P , Chapelle P , Chambard J P , Lachkar Y , Pean V , Bouafia K , Benzacken L - Paris*
1524		17:26	Temporal macular ganglion-cell inner plexiform layer thinning is a hallmark of early glaucomatous damage *TRIOLO G , Monsalve P , Feuer W J , Mwanza J C , Gedde S J , Parrish R K , Budenz D L , Vazquez L E - Milano*
1526	* *rf*	17:38	Primary Open Angle Glaucoma treated by High Intensity Focused Ultrasound (HIFU). Results at 18 months of a prospective pilot study on patients treated with the 2nd generation probe *ROULAND J F , Aptel F - Lille*
1527	*rf*	17:44	High-intensity focused ultrasound cyclocoagulation: a 6-month study *VANDEWALLE E , Somers A , Vermorgen K , Stalmans I - Leuven*
1528	*rf*	17:50	A comparison of visual field testing with a new automated perimeter, the Compass visual field analyser, and the Humphrey visual field analyser *FENOLLAND J R , Bonnel S , Rosenberg R , Sendon D , Ghazal W , Giraud J M , Renard J P - Issy les Moulineaux*

SIS

16:50 - 18:20 | RHODES 2

IM - Inflammatory versus non-uveitic posterior segment diseases

Intraocular inflammatory disorders encompass a broad spectrum of diseases that are a major cause of severe visual impairment. They may be specific to the eye or be part of a systemic problem or a combination of both. In facts, there is frequently a blurring of distinction between these categories.
In addition, a pseudo-inflammatory eye disease can mimic the clinical findings and pattern of a real posterior uveitis.
Very often misdiagnosis is the first and major problem of posterior uveitis management.
The aim of this special interest symposium is to present the hottest topics in diagnostic challenges for posterior uveitis and the differentiation between real inflammation and pseudo-inflammation of posterior uveal tract.

NERI P , HERBORT CP

1531		16:50	Inflammatory versus non-uveitic serous/exudative retinal detachments *GUPTA V*
1532		17:08	Central serous chorioretinopathy misdiagnosed as posterior uveitis *KHAIRALLAH M , Kahloun R , Jelliti B - Monastir*
1533		17:26	Central serous chorioretinopathy complicating inflammation suppressive treatment *HERBORT C P , Papadia M - Lausanne*
1534		17:44	Primary vitreo-retinal lymphoma, an increasing pseudo-uveitis to be taken into account *NERI P , Cesare M , Baruffa D , Pirani V - Agugliano*
1535		18:02	Inflammatory versus non-uveitic posterior segment diseases in paediatric patients *BODAGHI B - Paris*

FP

16:50 - 18:20 | RHODES 3

RV - FP session - Surgery I

SOUBRANE G , BAILLIF S

1541	*	16:50	Visual function response to ocriplasmin for the treatment of vitreomacular traction: results from the oasis study *JACKSON T L , Lescrauwaet B , Duchateau L , Verstraeten T - London*
1542		17:02	Functional and anatomical changes after standard and half dose verteporfin PDT in central serous choroidopathy *MONTERO MORENO J A , Ruiz-Moreno O , Garcia-Martinez J , Sierra-Rodríguez M A , Ruiz-Moreno J M , Gonzalez Uruena C , Calvo Perez P , Ruiz del Tiempo P , Lopez Gaona A - Valladolid*
1543		17:14	The retinal macroglia in hypercholesterolemic rabbits: neuroprotective effect of a non-lipid-lowering statin dose *FERNANDEZ-NAVARRO J , Rojas B , De Hoz R , Ramirez A I , Gallego B I , Salazar J J , Triviño A , Ramirez J M - Madrid*
1544		17:26	Therapeutic potential of non-viral MRNA delivery to Müller cells for neuroprotection *DEVOLDERE J , Peynshaert K , De Smedt S , Remaut K - Ghent*
1545	*	17:38	Anti-VEGF therapies for retinal vein occlusion: real-world outcomes of a Portuguese multi-center study *SOUSA NEVES F , Ribeiro L , Barata A , Ruão M , Matos R , Vaz-Pereira S , Flores R - Vila Nova de Gaia*
1546		17:50	Incidence of macular oedema following pan-retinal photocoagulation using a multi-spot semi-automated pattern-scanning laser in one sit versus 4 monthly sits in mild proliferative diabetic retinopathy or pre-proliferative diabetic retinopathy *GABRIELLE P H , Massin P , Kodjikian L , Bron A , Creuzot C - Dijon*

Wednesday, Oct 5 - Second afternoon session

FP

16:50 - 18:20 | RHODES 4

NSPH - FP session - Neuro-ophthalmology and paediatric ophthalmology

BREMOND-GIGNAC D , BOSCHI A

1551		16:50	Reduced post-illumination pupil response in patients with mild-moderate cataracts is associated with impaired sleep quality *ROEMER S , Munch M , Ladaique M , Hashemi K , Kawasaki A - Lausanne*
1552	*	17:02	Consensus on guidelines for idebenone administration in Leber's hereditary optic neuropathy (LHON) *CARELLI V , On behalf of the Consensus Study Group - Bologna*
1553	*	17:14	Relationship between immune response and ocular inflammation after intravitreal injection of rAAV2/2–ND4 (GS010) in Leber Hereditary Optic Neuropathy (LHON) patients *VIGNAL CLERMONT C , Bouquet C , Uretsky S , Galy A , Thomasson N , Fitoussi S , Combal J P , Sahel J - Paris*
1554		17:26	Factors affecting the prognosis of visual acuity and visual fields in pituitary adenoma patients treated with endonasal endoscopic transsphenoidal surgery *LIINAMAA J , Luomaranta T , Raappana A , Saarela V - Oulu*
1555		17:38	Neuro-ophthalmological manifestations of Behcet's disease *ALGHAMDI A , Bodaghi B , Wechsler B , Cacoub P , LeHoang P , Saadoun D , Touitou V - Puteaux*
1556	*rf*	17:50	Visual outcomes of fractionated radiotherapy in optic nerve sheath meningioma *KHEIR V , Borruat F X - Lausanne*
1557	*rf*	17:56	Automated evaluation of peripapillary choroidal thickness in nonarteritic anterior ischemic optic neuropathy *MUNOZ - NEGRETE F J , Rebolleda G , Perez Sarriegui A , De Juan V - Madrid*

FP

16:50 - 18:20 | GALLIENI 1+2

RV - FP session - Surgery II

LEYS A , HUSSAIN R

1561		16:50	The Soft Shell Technique To Prevent Leakage of Perfluorocarbon Liquid Into The Subretinal Space *HUSSAIN R , Chan Y K , Lu Y , Wu J , Cheung H C , Shum H C , Sakamoto T , Wong D - Liverpool*
1562		17:02	Incidence and risk factors of cystoid macular edema after retinal detachment surgery *BERROD J P , El Kouhen N , Leroy B P , Conart J B - Vandoeuvre les Nancy*
1563		17:14	Retinal toxicity of intraocular silicone oil. A retrospective study *ROCHA DE SOUSA A , Roca A , Barbosa-Breda J , Falcão-Reis F - Porto*
1564		17:26	Heads-up eye surgery: pros and cons *LYTVYNCHUK L - Giessen*
1565		17:38	Vitreous and subretinal VEGF levels in fresh rhegmatogenous retinal detachment *SOZEN-DELIL F I , Cekic O - Istanbul*
1566	*	17:50	Robot assisted retinal vein cannulation in an in vivo porcine retinal vein occlusion model *WILLEKENS K , Gijbels A , Schoevaerdts L , Esteveny L , Janssens T , Jonckx B , Feyen J H M , Meers C , Reynaerts D , Vander Poorten E , Stalmans P - Leuven*

C

16:50 - 18:20 | GALLIENI 4

PBP - High-resolution imaging of the anterior eye segment

Beginner

In this course, we aim to introduce and review different optical technologies allowing the non-invasive imaging of the anterior eye segment with a resolution in the micrometer or sub-micrometer range.
At first, ultrahigh-resolution optical coherence tomography based on a broadband Ti:Sapphire laser will be introduced. Its application for both imaging of different features of the healthy and diseased eye as well as the investigation of surgical treatment will be shown. In the second part, the concepts of confocal and non-linear microscopy and the underlying physical principles of different contrast mechanisms will be presented. Exemplary experimental results based on various non-linear signals showing the ability to image structure of the cornea down to the cellular level are content of the presentations. Finally, the two modalities – OCT and IVCM – will be compared and their advantages and disadvantages for corneal imaging will be highlighted.

WERKMEISTER R

1571	16:50	Introduction to Ultrahigh-Resolution OCT *WERKMEISTER R - Vienna*
1572	17:05	OCT Imaging in Glaucoma and PEX *SAPETA S - Vienna*
1573	17:20	Imaging of Corneal Lesions and Wound Healing *SCHMIDL D - Vienna*
1574	17:35	Linear and nonlinear microscopy for AS imaging: principles and pathbreaking application *STACHS O - Rostock*
1575	17:50	Nonlinear microscopy for quantification of riboflavin diffusion in the cornea *HEISTERKAMP A - Hannover*
1576	18:05	OCT and IVCM in Corneal Imaging *DUA H S - Nottingham*

Wednesday, Oct 5 - European Ophthalmology Lecture

PS

18:35 - 19:00 | HERMES

European Ophthalmology Heritage Lecture by Luc Missotten

Introduction by Marcela VOTRUBA

1611

Magnificat

Luc MISSOTTEN - Leuven

Summary:

We will present some evidence showing that the use of a magnifying glass started in Greece in the fifth century BC.

Award presentation of the EVER Certificate of Honour

Biography Luc MISSOTTEN:

Professor emeritus of the Catholic University of Leuven, Belgium, he is one of the founding fathers of EVER. As the eldest amongst the EVER members may recall, the European Community Ophthalmic Research Association (ECORA) was founded by Professor Manfred Spitznas at the request of EUPO (European University Professors in Ophthalmology) and its first meeting was held in Bonn. Very soon ECORA joined forces with the Association of Eye Research of which Missotten was a past president and a prominent member and with other research associations. The new identity was called Joint European Research Meeting in Ophthalmology (JERMOV) and it held its first meeting in Montpellier in 1995. The meeting was successful. However two years later, because of financial problems JERMOV ceased to exist. Professor Missotten then created a temporary structure which he called EVER for EVER and organized the 1997 meeting. New statutes were written and EVER was born. Luc Missotten was its first secretary-general, post he kept till 2002. He was vice-president of the International Society for Eye Research, chair of the Scientific Committee of the Netherlands Ophthalmic Research Institute and President of the European Ophthalmological Society (1996-2000).
Professor Missotten obtained his medical degree at the Catholic University Leuven, wrote an impressive PhD thesis on "The ultrastructure of the human retina" and was "Visiting scientist" at the College of Physicians and Surgeons of the Columbia University, New York, on invitation by Prof. J.K. Smelser of the Department of Ophthalmology Research, (1967-1968). He became chair of the Eye Department of the Catholic University Leuven in 1969 till his retirement in 1997.

He is Doctor honoris causa of the University of Mansoura (Egypt) and a honorary member of various ophthalmological societies.

KN

19:00 - 19:30 | HERMES

Keynote Lecture by Robert Maclaren

Introduction by Bart LEROY

1711

Developing new treatments for inherited retinal degenerations

Robert MACLAREN - Oxford

Summary:

Retinal diseases are currently the leading causes of untreatable blindness in Europe. Most commonly, incurable blindness occurs when photoreceptors are lost and therapeutic strategies therefore aim to prevent photoreceptor cell death by genetic correction of single gene disorders. Once photoreceptors have degenerated, alternative strategies are required to regenerate the retina using biological approaches and subretinal electronic devices have also shown great promise in demonstrating that blindness may be potentially reversible. This lecture will provide an update on the application of scientific discovery in clinical trials for retinal degeneration and provide insight into the fascinating age of discovery that lies ahead.

Award presentation of the EVER Certificate of Honour

Biography Robert MACLAREN:

Robert MacLaren is Professor of Ophthalmology at the University of Oxford and a retinal surgeon. His research interests focus on developing novel treatments for currently incurable retinal disease, particularly retinitis pigmentosa. His laboratory work has explored scientific concepts in retinal regeneration using developing neurons and photoreceptor transplantation. More recently he has been leading gene therapy clinical trials for choroideremia which are now ongoing in several EU countries, the USA and Canada. He is the academic founder of Nightstarx, a retinal gene therapy company based at the Wellcome Trust in London and he works closely with Retina Implant AG, in clinical trials of the electronic retinal implant.

Wednesday, Oct 5 - Welcome Reception

SOC

19:30 - 21:30 | EXHIBITION AREA

EVER Welcome Reception

Open to EVER participants and exhibitors

EVER 2016
Thursday, Oct 6

SIS

8:30 - 10:00 | HERMES

RV - Diabetic retinopathy

LYTVYNCHUK L , WIEDEMANN P

2111		8:30	Vitrectomy in treatment naive diabetic macular edema *MICHALEWSKA Z , Michalewski J , Bednarski M , Nawrocki J - Lodz*
2112		8:48	Novel diagnostic tools in DRP - from science to clinical relevance *BRUNNER S - Vienna*
2113	*	9:06	OCT Angio imaging of the pathologic changes in PDR *GLITTENBERG C - Vienna*
2114		9:24	Treatment of hard exudates in CSME in PDR using Micropulse mode *SAKSONOV S , Teslenko A , Vitovska O - Kyiv*
2115		9:40	29G chandelier-assisted scleral buckling with new instruments *LYTVYNCHUK L , Binder S - Lviv*

SIS

8:30 - 10:00 | RHODES 1

G - You tube: different tubes for different glaucomas

YouTube is a SIS about the main three surgical glaucoma techniques that use tubes. It is a short introductory symposium of the new and old tubes that nowadays are being used in clinics. The instructors introduce the different surgical techniques with videos and didactic images. "When and how", with special focus in the niche for these procedures, and their specific indications.

DUCH S , MILLA E

2121	*	8:30	YouTube: Different tubes for different glaucomas. : XEN *ARCINIEGAS-PERASSO C A - Barcelona*
2122	*	8:52	YouTube: Different tubes for different glaucomas. : Ex Press *MUNOZ M - Barcelona*
2123		9:14	YouTube: Different tubes for different glaucomas. : Ahmed Valve *MILLA E - Barcelona*
2124		9:36	YouTube: Different tubes for different glaucomas. : Non valved Tube&Plate implants *DUCH S - Barcelona*

C

8:30 - 10:00 | RHODES 2

COS - Corneal dystrophies - diagnosis and treatment

Intermediate

Corneal dystrophies are the group of hereditary, slowly progressive disorders affecting all corneal layers.
In the past, histological examination was crucial in proper diagnosis of corneal dystrophies. In recent years, non invasive optical imaging systems such as optical coherence tomography (OCT) and confocal microscopy (CM) along with genetic testing have become a new standard procedures in the diagnostic process. Advances in diagnosis and treatment of corneal dystrophies including genetic analysis and confocal microscopy findings were included in the IC3D classification in 2008 and 2015. During this course we would like to present the current classification, methods of diagnosis including genetic testing, confocal microscopy and optical coherence tomography, as well as and different treatment options and its results.

WYLEGALA E , DOBROWOLSKI D

2131	8:30	Update on IC3D classification *NOWINSKA A - Bytom*
2132	8:45	Confocal microscopy findings in corneal dytrophies *SMEDOWSKI A , Wylegala E - Katowice*
2133	9:00	OCT in treatment planning *JANISZEWSKA D - Katowice*
2134	9:15	Photorefractive keratectomy for corneal dystrophies *DOBROWOLSKI D - Katowice*
2135	9:30	Surgical treatment of corneal dytrophies *WYLEGALA E - Katowice*
2136	9:45	Corneal imaging after treatment in dystrophic eyes (OCT, CM) *DOBROWOLSKI D - Katowice*

SIS

8:30 - 10:00 | RHODES 3

PBP - Drug delivery systems for the back of the eye. Translational research

Due to the aging of the population, the number of patients with chronic diseases affecting the back of the eye is increasing. Furthermore, there are rare diseases involving the retina that need therapeutic strategies to stop/delay degeneration. Nano-(1-1000nm) and Microscale (1-1000µm) drug delivery systems are emerging tools for the efficient treatment of posterior segment diseases. These devices can contain small and large molecules including proteins and genes. The election of the most appropriate device must be done according to the disease and the intraocular target site. The movement of particles after injection is a critical issue to determine the potential clinical translation of the pharmaceutical particulate formulation. Also, biocompatibility and pharmacokinetic studies are important tools to assure the efficiency of the pharmaceutical approach.

HERRERO-VANRELL R , RUPENTHAL ID

2141	8:30	Stimuli-responsive systems for tuneable ocular drug delivery *RUPENTHAL I D , Yasin N , Bisht R , Chen Y S , Jin J , Jaiswal J , Svirskis D - Auckland*
2142	8:48	Multiloaded Microparticulate Drug Delivery Systems for the Treatment of Retinal Diseases *HERRERO-VANRELL R , Arranz A , García-Caballero C , Guzmán M , Andres-Guerrero V , García-Feijoo J , Molina-Martínez I T , Bravo-Osuna I - Madrid*
2143	9:06	Intravitreal mobility of nanoparticles: how to make a move toward successful ocular gene delivery? *REMAUT K , Devoldere J , Peynshaert K , Martens T , Engbersen J , Braeckmans K , De Smedt S - Gent*
2144	9:24	Ocular drug delivery and pharmacokinetics: Influence of drug properties and delivery systems *KOMPELLA U B - Aurora*
2145	9:42	Ocular pharmacokinetics assessed by in-vivo microdialysis *GARHÖFER G - Vienna*

Thursday, Oct 6 - First morning session

FP

8:30 - 10:00 | RHODES 4

RV - FP session - Surgery III

PRUENTE C , POURNARAS J

2151		8:30	Retinal structural changes before and after idiopahic epiretinal membrane peeling - a study using OCT segmentation *SOUSA F , Pinto J , Marques-Neves C - Lisbon*
2152		8:42	Morphological, phisiological and immunocytochemical evaluation in patients with idiopathic epiretinal membranes *MINIEWICZ J , Romanowska Dixon B , Petka O , Elas M , Sarna M , Kubicka-Trzaska A - Krakow*
2153		8:54	Mechanism of "Flap Closure" After the Inverted Internal Limiting Membrane Flap Technique *MICHALEWSKA Z , Boninska K , Michalewski J , Nawrocki J - Lodz*
2154		9:06	Accuracy of retinal layers optical coherence tomography automated segmentation before and after epiretinal peeling *MEDEIROS PINTO J , Caiado F , Marques-Neves C - Lisbon*
2155	*rf*	9:18	Unexplained vision loss with intra-ocular silicone oil tamponade in situ; a case series *SILVESTER A , Cazabon S - West Kirby*

SIS

8:30 - 10:00 | GALLIENI 1+2

EOVS/MBGE - Doctor, I can't see in the dark

The SIS will address the clinical problem of night blindness (nyctalopia). It will commence with the initial consultation and examination; what to look for and what questions to ask. It will then proceed to address the underlying causes of night blindness, both genetic and acquired, followed by a discussion of how electrophysiological testing can assist the diagnosis. The final presentation will discuss the effects on the patient of being night blind.

HOLDER G

2161	8:30	The initial consultation *SPILEERS W - Leuven*
2162	8:52	Causes of night blindness *LEROY B - Ghent*
2163	9:14	The electrophysiology of patients with nyctalopia *HOLDER G - London*
2164	9:36	What limits normal visual performance in the dark? *FITZKE F W - London*

SIS

8:30 - 10:00 | GALLIENI 4

ACB - Proteostasis in the pathogenesis of age-related macular degeneration

Age-related macular degeneration (AMD) is a complex chronic neurodegenerative disease associated with many environmental, lifestyle, and genetic factors. Oxidative stress and the production of reactive oxygen species seem to play a pivotal role in AMD pathogenesis. During aging accumulation and aggregation of misfolded proteins can be recognized in retinal pigment epithelial (RPE) cells. This lead to the degeneration of RPE that is a hallmark of AMD. Molecular chaperones, proteasomes and lysosomes are key elements to refold misfolded proteins or degrade damaged proteins in the RPE cells. Autophagy, a part of lysosomal clearance system, has a cytoprotective role in diseases associated with protein aggregates. Failure in proteostasis may be one of the underlying mechanisms responsible for the cascade of events leading to AMD. This SIS covers the major cytoprotective and degradative pathways in the RPE and summarizes evidence of their involvement in AMD.

KAARNIRANTA K , UUSITALO H

2171	8:30	Age-related changes of cystatin C and effects on protein turnover in RPE cells *PARAOAN L - Liverpool*
2172	8:52	Cytoprotective alpha crystallins in the regulation of RPE cell proteostasis *KANNAN R - Los Angeles*
2173	9:14	The marine n-3 PUFA DHA evokes cytoprotection by inducing autophagy and NFE2L2 in human retinal pigment epithelial cells *BJORKOY G - Trondheim*
2174	9:36	Nrf2- and PGC-1α-deficient mice: A novel animal model for disturbed proteostasis and RPE degeneration *KAARNIRANTA K - Kuopio*

SIS

8:30 - 10:00 | GALLIENI 5

LC - Lens and IOL - optics and accommodation

Our SIS will present new findings related to the optical properties of the crystalline lens and new evidence for a possible relation between cortical cataract and accommodation forces. Furthermore, we will attempt to explain the optical imaging properties of new multifocal intraocular lenses. Some of which show benefits that must be put into realistic technical and clinical contexts, beyond their commercial names. We will give an update on light-adjustable intraocular lenses and conclude showing new developments of accommodative intraocular lenses.

BARRAQUER RI , MICHAEL R

2181	8:30	Optical properties of the lens: An explanation for the zones of discontinuity *PIERSCIONEK B , Bahrami M , Hoshino M , Regini J , Uesugi K , Yagi N - Kingston*
2182	8:48	Cortical cataracts: The case for mechanical stress *MICHAEL R , Pinilla Cortés L , Montenegro G A , D'Antin J C , Barraquer R I - Barcelona*
2183	9:06	Optical imaging properties of multifocal IOL *MILLAN M S , Vega F , Alba-Bueno F , Ríos-López I - Terrassa*
2184	9:24	Light-Adjustable Lens: A non-invasive approach to adjust remaining refractive errors after cataract surgery *HENGERER F , Conrad-Hengerer I - Frankfurt*
2185	9:42	Accommodative IOLs: An update on recent developments *VEGA-ESTRADA A , Alio J - Alicante*

PS

10:20 - 10:50 | HERMES

EVER-Acta Lecture by John Greenwood

Introduction by Andrew DICK

2211

The pathogenic role of LRG1 in ocular neovascularisation: From discovery to targeted therapy

John GREENWOOD - London



Summary:

We have reported that the secreted glycoprotein, leucine-rich alpha-2-glycoprotein 1 (LRG1), promotes neovascularisation in various models of ocular disease (Wang et al., Nature 2014; 499: 306-311). LRG1 is up-regulated in many disease conditions and mediates its pro-angiogenic effect by modifying the TGFß signalling network. Loss of LRG1, or blocking its biological activity, results in attenuation of neovascular complications in the rodent models of laser-induced choroidal neovascularisation and oxygen-induced retinopathy. Recently, we have observed that loss of LRG1 results in vessel normalisation, suggesting that in the pathological setting LRG1 corrupts the normal physiological angiogenic process. Early indications suggest that LRG1 interferes with vascular recruitment of pericytes resulting in failure of vessel maturation. These findings have important implications in diseases such as diabetic retinopathy where there is a need to promote a normal functioning vasculature. Consistent with the concept of LRG1 causing vascular dysfunction, we have additionally observed that loss of LRG1 reduces vascular permeability in ocular inflammation. Together these findings have led us to develop a humanised blocking antibody that will be taken into clinical trials for the treatment of wet age-related macular degeneration. In this seminar I will present our work on LRG1 in ocular disease and describe the development of an anti-LRG1 therapeutic for clinical use.

Award presentation of the ACTA Certificate of Honour

Biography John GREENWOOD:

Professor John Greenwood holds the Hugh Davson Chair of Biomedical Research at the Institute of Ophthalmology, University College London. He obtained his PhD in 1984 from the Institute of Psychiatry, University of London following studies on the pathobiology of the blood-brain barrier (BBB). After leaving the Institute of Psychiatry he took up a postdoctoral fellowship within the BBB research group at King's College London. In 1990 he was awarded the Renee Hock Fellowship at the Institute of Ophthalmology to investigate the role of the blood-retinal barrier in inflammatory eye disease. In 1993, he was made Senior Lecturer and in 2000 was appointed Full Professor at the Institute of Ophthalmology. During the last 15 years he has been a member of the Institute Board of Management and for the last 8 years has been Head of the Department of Cell Biology.
The Greenwood laboratory's primary focus is the role the vasculature plays in the pathogenesis of diseases of the retina and brain. His work spans the spectrum from fundamental research through to clinical trials. Research into the role the vascular endothelium plays in the pathogenesis of retinal and brain inflammation is a core component of the laboratory. Such work has been at the forefront of identifying and characterising novel endothelial cell mechanisms that facilitate the recruitment of leukocytes to the retina and brain, a critical step in the pathogenesis of diseases such as posterior uveitis and multiple sclerosis. This work established the principle of outside-in signalling in CNS endothelial cells that support leukocyte transvascular migration and has influenced the decision to trial statin therapy for the treatment neuroinflammatory disease. More recently a major emphasis has been to investigate the biology underpinning vascular dysfunction in diseases such as diabetic retinopathy and wet age-related macular degeneration (AMD) and to discover new therapeutic targets. This work has resulted in the identification and characterisation of a novel pro-angiogenic factor called leucine-rich alpha-2-glycoprotein 1 (LRG1) and has led to the development of a therapeutic antibody targeting this protein. In 2018 this therapy will enter into clinical trials for the treatment of wet AMD. This work has been conducted in close collaboration with Professor Stephen Moss at the UCL Institute of Ophthalmology.

SIS

11:00 - 12:30 | HERMES

IM - OCT in inflammatory ocular diseases: beneath and beyond the retina

Optical coherence tomography (OCT) has revolutionized the understanding and management of different ophthalmological diseases, including ocular inflammation. Although the retina has been the subject of the most intense investigation, others ocular structures can also been analyzed by this elegant technique. Indeed, very early, OCT was used to study the cornea and the optic disk. More recently, recent methodological developments have given access to the choroid. The aim of this SIS is to provide an overview of the information that can be provided by OCT in analyzing ocular tissues distinct from the retina, in the context of inflammatory diseases.

WILLERMAIN F , NERI P

2311	11:00	From time domain to high resolution and angio-OCT: an historical perspective *NERI P , Mariotti C , Pirani V , Bisceglia P , Giovannini A - Agugliano*
2312	11:22	Anterior segment OCT in corneal diseases and surgery *NUBILE M , Calienno R , Salgari N , De Nicola C , Lappa A , Mastropasqua A - Chieti*
2313	11:44	OCT as a Novel useful tool in corneal transplantation *THURET G , Gabison E , Guindolet D , Lepine T , Rolland J , Gain P - Saint Etienne*
2314	12:06	Usefulness of OCT for imaging the choroid, the vitreous and the optic nerve during uveitis *DENNISTON A - Birmingham*

SIS

11:00 - 12:30 | RHODES 1

G - Mathematical modelling in glaucoma

Glaucomatous optic neuropathies (GON) share as a hallmark a progressive loss of RGCs and their axons with the presence of visual field defects, structural and molecular changes in the optic nerve head and other cellular responses throughout the retina. The advancement of image analysis technologies has allowed a more precise and objective study of the cellular and morphological changes associated with GON. The Special Interest Symposium will present recent studies focussing on mathematical and automatic methods to identify and quantify cellular and structural changes that appear on the retinal layers and on the optic nerve head following various types of retinal or optic nerve injury glaucoma models. The SIS will provide ample opportunity for interaction among scientists attending the conferences.

VIDAL-SANZ M , CORDEIRO MF

2321	11:00	Tridimensional studies on the adult rat optic nerve head *PAZOS M , Yang H , Gardiner S , Cepurna W , Elaine J , Morrison J , Burgoyne C - Barcelona*
2322	11:22	Counting microglial cells in the adult rodent retina *GALLEGO B I , De Gracia P , Ramirez A I , De Hoz R , Salazar J J , Rojas B , Trivino A , Ramirez J M - Madrid*
2323	11:44	Algorithms looking for patterns of cell loss in glaucoma models *DAVIS B - London*
2324	12:06	Counting retinal neurons in the adult rat retina *VIDAL-SANZ M , Jiménez-López M , Nadal-Nicolás F M , Ortín-Martínez A , Valiente-Soriano F J , Rovere G , Salinas-Navarro M , Avilés-Trigueros M , Agudo-Barriuso M , Villegas-Pérez M P - Murcia*

FP

11:00 - 12:30 | RHODES 2

RV - FP session - Diabetes

SOUBRANE G , DE LAEY JJ

2331		11:00	Alterations of retinal vessel size after single injection of intravitreal anti-VEGF for diabetic macular edema *AKPOLAT C , Kurt M , Cekic O - Istanbul*
2332		11:12	Upregulated expression of heparanase in the vitreous of patients with proliferative diabetic retinopathy originates from activated endothelial cells and leukocytes *ABU EL ASRAR A , Nawaz M I , Mohammad G , Van den Eynde K , Siddiquei M M , Mousa A , De Hertogh G , Geboes K , Opdenakker G - Riyadh*
2333		11:24	In vivo measurement of increased vascular permeability after STZ induction of diabetes in rats by fluorescence angiography using the Micron IV *ALLEN C , Bates D - Nottingham*
2334		11:36	Choroidal thickness in diabetic patients without diabetic retinopathy *PINTO PROENCA R , Vicente A , Oliveira Santos B , Cunha J P , Alves M , Papoila A L , Abegão Pinto L , Tavares Ferreira J - Lisbon*
2335	*rf*	11:48	Tomographic analysis of the retinal layers in diabetic macular edema treated with dexamethasone intravitreal implant *MEDEIROS PINTO J , Prates Canelas J , Rosa R , Coelho C , Vaz-Pereira S - Lisbon*
2336	*rf*	11:54	Iluvien monotherapy for diabetic macular oedema in vitrectomised and non-vitrectomised eyes: one year data *HAWRAMI A , Laviers H , Patra S , Zambarakji H - London*
2337	* *rf*	12:00	Deep learning approach for diabetic retinopathy screening *COLAS E , Besse A , Orgogozo A , Schmauch B , Meric N , Besse E - Paris*
2338	*rf*	12:06	Diabetic maculopathy screening in England; are we seeing too much? *BEGUM S , Macgregor C , Meredith P , Cansfield J , Meredith S - Portsmouth*

C

11:00 - 12:30 | RHODES 3

PO/RV - Mistakes in the diagnosis of fundus tumors

Intermediate

This course will describe the diagnosis and management of fundus tumors insisting on the main difficulties: tumors developing in children, problems with the practical attitude in front of a suspicious choroidal naevus, difficulties in the diagnosis of achromic tumors,special problem encountered in the diagnosis of intraocular lymphomas and and fo all these difficult cases the indications and results of the different imaging tools.

DESJARDINS L , ZOGRAFOS L

2341	11:00	Mistakes in the diagnosis of children intraocular tumors *CASSOUX N - Paris*
2342	11:18	Suspicious choroidal naevi: when to observe , when to treat *KIVELÄ T - Helsinki*
2343	11:36	Difficulties in the diagnosis of achromic fundus lesions and hemorragic lesions *DESJARDINS L - Paris*
2344	11:54	Problems in the diagnosis of intraocular lymphoma *CASSOUX N - Paris*
2345	12:12	Indications and interpretation of various imaging techniques *ZOGRAFOS L - Lausanne*

FP

11:00 - 12:30 | RHODES 4

LC - FP session - Lens and cataract

ZHANG K , MAKLEY L

2351		11:00	The αA-crystallin gene expression in differentiating lens fiber cells, FGF signaling, and transcriptional factories *CVEKL A , Limi S , Zhao Y , McGreal R , Xie Q , Zheng D - Bronx*
2352		11:12	Effects of histone acetylation on superoxide dismutase 1 gene expression in the pathogenesis of senile cataract *QIU X , Rong X , Jiang Y , Li D , Lu Y - Shanghai*
2353		11:24	Evolution of cataract surgery. past, present and future *BARRAQUER J - Barcelona*
2354		11:36	Genetic and phenotypic traits of staphylococcus epidermidis strains causing post-cataract endophthalmitis compared to commensal conjunctival flora *CHIQUET C , Aptel F , Musson C , Boisset S , Maurin M - Grenoble*

SIS

11:00 - 12:30 | GALLIENI 1+2

MBGE/NSPH - Mitochondrial optic neuropathies - disease mechanisms and therapies

Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a clinical key feature. The commonest causes world-wide is mutation in mitochondrial DNA (causing Leber's Hereditary Optic Neuropathy) and OPA1 mutations (causing Autosomal Dominant Optic Atrophy: ADOA). 60-80% of patients with autosomal dominant optic atrophy have mutations in the OPA1 gene. Inherited optic neuropathy is an 'orphan' disease. However, the disease prevalence is not so low (1: 20,000 to 35,000), and it is estimated that there are 5000 to 8000 distinct rare diseases, affecting 6-8% of the population of the European Union (27-36 million people). Recent trials of the drug idebenone, a co-enzyme Q10 analogue, in patients with the mitochondrial optic neuropathy, Leber's hereditary optic neuropathy, have shown the first glimmer of hope for the treatment of this group of patients. At this exciting time this SIS will focus on disease mechanisms and potential avenues towards therapy.

VOTRUBA M , YU-WAI-MAN P

2361		11:00	The genetic pathophysiology of dominant optic atrophy *LENAERS G , Charif M , Amati-Bonneau P , Chao de la Barca J , Procaccio V , Gerber S , Kaplan J , Roubertie A , Meunier I , Reynier P , Rozet J M , Hamel C , Bonneau D - Montpellier*
2362		11:18	Looking for a sensitive biomarker for genetically determined neurodegenerative diseases through the window of the eye *MARTINUZZI A , Vavla M , Capello G , Papayannis A , Petacchi E , Paparella G , Privato F , Prosdocimo G - Treviso*
2363		11:36	OCT angiography in mitochondrial optic neuropathies *BARBONI P , Balducci N - Bologna*
2364	*	11:54	Perturbed mitochondrial homeostasis in LHON: a new target for rescue strategy *CARELLI V - Bologna*
2365	*	12:12	Personalised therapies for mitochondrial optic neuropathies - myth or reality? *YU-WAI-MAN P - Newcastle upon Tyne*

SIS

11:00 - 12:30 | GALLIENI 4

ACB/COS - How I fell in love with scleral lenses - the attractive lens paradox

Scleral lenses represent a paradox in contact lens care: Even though they offer a great deal of advantages for patient and doctor in a so many scenarios of ocular surface dysfunction and disease - they are only used in a minority of cases. This may be due to the fact that Sclerals seem to represent the historic type of a large rigid ´foreign body´ that rests on the sclera and vaults the cornea. However, modern lens materials & designs nowadays make Sclerals an easy to use and versatile tool for daily practise with ideal wearing comfort and medical safety in contrast to the vast majority of (mainly soft) cosmetic contact lenses that can often give rise to problems. Sclerals are a highly underestimated medical tool. Their tear-fluid filled lake over the cornea makes them an ideal tool for optical restoration of irregular corneas, particularly in keratokonus, for the prevention of further wounding, for the restoration of ocular surface integrity in dry eye disease of different type and as a measure to improve or even heal corneal recurrent erosions, ulcers, opacities and scars without the need to undergo surgery or even keratoplasty. Long term experience of ophthalmologists from around the world will be introduced in this SIS.

KNOP E , KNOP N

2371		11:00	The ocular surface anatomy under cover - its interaction with a scleral lens *KNOP E , Knop N - Berlin*
2372		11:18	Keratokonus - the killing application for most contact lenses is the prototypical job for sclerals *NAU C , Schornack M - Minnesota*
2373		11:36	It´s not just keratokonus - some general fitting techniques for scleral lenses in so many scenarios *CARRASQUILLO K G - Boston*
2374		11:54	Moderate to severe dry eye - a promising indication for scleral lenses *DOAN S , Delcampe A - Paris*
2375	*	12:12	Are scleral lenses safe for the meibomian gland? *MEKKI M B , Yahiaoui S , Titah O , Belaoudmou R , Taibi A , Bouguerfa R - Algiers*

FP

11:00 - 12:30 | GALLIENI 5

PBP - FP session - Oxygen delivery and regulation of vascular tone

OSBORNE N , GARHÖFER G

2381		11:00	Ca2+ activity during ATP-induced tone changes in porcine retinal arterioles in vitro spreads along the processes of perivascular cells *KUDRYAVTSEVA O , Bek T - Aarhus*
2382		11:12	Vasodilation by cell membrane permeable but not impermeable carbonic anhydrase inhibitors of precontracted retinal arteries *EYSTEINSSON T , Hardarson A O , Carta F , Supuran C T - Reykjavik*
2383	*	11:24	Automatisation and improved repeatability of retinal oximetry *HARDARSON S , Karlsson R A , Olafsdottir O B , Eliasdottir T , Bek T , Stefánsson E - Reykjavik*
2384		11:36	Correlation between retinal and mixed venous oxygen saturation *VAN KEER K , Abegão Pinto L , Stalmans I , Vandewalle E - Leuven*
2385		11:48	The effect of systemic tamsulosin hydrochloride on choroidal thickness and pupil diameter sizes *DOGAN M , Kutluksaman B , Keles I , Halat A O - Afyonkarahisar*
2386	*rf*	12:00	The assessment of Ocular Blood Flow with Laser Speckle Flowgraphy in healthy Caucasian *WOZNIAK P A , Luft N , Aschinger G , Fondi K , Bata A M , Witkowska K J , Schmidl D , Werkmeister R M , Bolz M , Garhöfer G , Schmetterer L - Vienna*
2387	* *rf*	12:06	Quantitative assessment of retinal permeability in the diabetic Akimba mouse: validation of a promising animal model for diabetic retinopathy *HU TT , Vanheukelom V , De Vriese A , Feyen J H M - Heverlee*

Thursday, Oct 6 - Lunchtime session

CIS

12:40 - 13:40 | RHODES 1

Leber's hereditary optic neuropathy (LHON): latest advances in diagnosis, staging and patient management

KLOPSTOCK T , CARELLI V

2421	12:40	Introduction *KLOPSTOCK T - Germany*
2422	12:45	Advances in identifying patients with LHON: Early diagnosis *LAGREZE W D - Germany*
2423	12:55	Advances in understanding of the disease: Pathogenic mechanisms for neuronal degeneration *TIRANTI V - Italy*
2424	13:05	Advances in understanding of the disease: Clinical staging *CARELLI V - Italy*
2425	13:15	Advances in patient care: Raxone a new treatment option for patients with LHON *KLOPSTOCK T - Germany*
2426	13:35	Co-Chairman's summary and Q&A *CARELLI V - Italy*

CIS

12:40 - 13:40 | RHODES 2

Demodex: innocent or guilty in blepharitis?

JAMES TE

	12:40	Introduction
2431	12:45	Demodex background and epidemiology aspects *MERAYO-LLOVES J - Spain*
2432	13:00	Demodex: ocular implications *KAYA S - Austria*
2433	13:15	Management of Demodex in ophthalmology *JAMES TE - United Kingdom*
	13:15	Conclusion

KN

13:50 - 14:20 | HERMES

Keynote Lecture by Shigeru KINOSHITA

Introduction by Thomas FUCHSLUGER

2511

Medical science and clinical research in corneal regenerative medicine

Shigeru KINOSHITA S - Kyoto

Summary:

It is important for clinician scientists to acquire the advanced knowledge and novel technology needed to create completely new areas of translational research, ultimately aimed at application in the clinical setting. For instance, devastating ocular surface disorders such as Stevens-Johnson syndrome are very difficult to treat properly. Today, thanks to recent advancements in corneal biology and immunology, the state-of-the-art corneal regenerative medicine such as autologous cultivated oral mucosal epithelial transplantation is applied to treat and, in general, well restore ocular surfaces devastated by disease. A similar type of translational research, based on the basic understanding and clinical application of corneal endothelial cell biology, is being used to develop the novel therapy of 'cultured corneal endothelial cell injection' into the anterior chamber for corneal endothelial dysfunction such as Fuchs endothelial corneal dystrophy. For this purpose, non-proliferative corneal endothelial cells from donated corneas can be induced to proliferate, without inducing cell state transition (CST). In clinical research started in December 2013, all the cases performed this procedure have already shown promising results. It is our hope that ophthalmology-related translational research, such as that described above, will receive official governmental approval based on accumulated data of the safety and efficacy of the procedures.

Award presentation of the EVER Certificate of Honour

Biography Shigeru KINOSHITA:

Dr. Shigeru Kinoshita, a clinician scientist, graduated from Osaka University Medical School in 1974, and has served as the Professor and Chair of Ophthalmology at Kyoto Prefectural University of Medicine since 1992. Because of his stepping down from the Chair of Ophthalmology in March 2015, He was elected the Professor and Chair of Frontier Medical Science and Technology for Ophthalmology at Kyoto Prefectural University of Medicine in April 2015. And, he has been continuously working as a distinguished clinician scientist.
In the early 1980s at Harvard Medical School, he, in collaboration with Dr. Richard A. Thoft, established the concept of centripetal movement of corneal epithelium, and his groundbreaking work has shed new light on the importance of limbal epithelium. His series of findings has had an enormous impact on this subject and has afforded much insight, ultimately contributing to the development of the corneal stem cell theory set forth by Tuen-Tien Sun. Based on these concepts, Dr. Kinoshita developed a new surgical procedure for in vivo corneal epithelial transplantation that has led to epithelial stem cell transplantation for ocular surface rehabilitation. Over the past 30 years, his primary interest has been focused on the translational research of new therapeutic modalities for severe corneal diseases. Following this path, his group has recently established the system of cultivated mucosal epithelial stem cell transplantation for severe ocular surface disorders such as Stevens-Johnson syndrome and chemical injury, and cultivated corneal endothelial cell transplantation for bullous keratopathy. His group also proved the clinical efficacy of Rho-associated protein kinase (ROCK)-inhibitor topical application for partial endothelial dysfunction, aiming at the development of novel therapies for corneal endothelial dysfunction.
Kinoshita is a recipient of the 1999 Alcon Research Institute Award, the 2008 Castroviejo Medal Lecturer of the Cornea Society, the 2009 ARVO Gold Fellow, the 2010 Claes H. Dohlman Conference Address of the TFOS, the 2010 Meibom Lecturer in Germany the Doyne Memorial Lecturer of the 2011 Oxford Ophthalmological Congress in United Kingdam, the 2011 Elsemay Bjorn Lecture in Finland, Schepens Eye Research Institute Almunus Awardee 2011, the Peter Herberg Lecture at IMCLC2012, the Richard Lindstrom Lecture, CLAO, ASCRS 2014, Charles D. Kelman Inovator Award, ASCRS 2015, and the Friedenwald Award Lecturer at the ARVO 2016. He served as an ARVO Program Committee Member in the Cornea Section between 1996 and 1999, the ARVO Trustee of the Cornea Section between 2006 and 2011, and the ARVO Vice President in 2010-2011.

SIS

14:30 - 16:00 | HERMES

IM/RV - Challenges and controversies in ophthalmology: When the patient overlap between different subspecialties

The evolution of tertiary care ophthalmology is clearly towards the development of subspecialist with a very specific domain of competence. However, in several diseases the clinical presentation requires an experience in multiple subspecialties. The aim of this SIS is, based on clinical cases, to join different sections to understand how they differently approach the same disease.

CASPERS L , WILLERMAIN F

2611		14:30	Controversies between retinal dystrophies and uveitis - the point of view of the retina specialist. Does electrophysiology help? *LEROY B , Holder G - Ghent*
2612		14:45	Controversies between retinal dystrophies and uveitis - the point of view of the uveitis specialist. Does retinal antibody detection help? *WILLERMAIN F , Draganova D , Leroy B P , Caspers L , Postelmans L , Corazza F - Bruxelles*
2613		15:00	Controversies between lymphoma and uveitis - the point of view of the ophthalmologist *TOUITOU V - Paris*
2614		15:15	Controversies between lymphoma and uveitis - the point of view of the neuro-oncologist *TOUITOU V , HOUILLIER C - Paris*
2615		15:30	Controversies between how to handle uveitis and glaucoma. The point of view of the uveitis specialist *KESTELYN P - Gent*
2616	*	15:45	Controversies between how to handle uveitis and glaucoma. The point of view of the glaucoma specialist *BRON A - Dijon*

SIS

14:30 - 16:00 | RHODES 1

G/PBP - OCT spectralis in neurodegeneration - Young investigator presentations

Experts from different fields will discuss the use of the spectralis in neurodegeneration including: Glaucoma, Alzheimer's, Down's, Parkinson's, Multiple Sclerosis

CORDEIRO MF , NORMANDO EM

2621		14:30	OCT in AD *NORMANDO E M , Crawley L , Ahmed F , Bloom P , Cordeiro M F - London*
2622		14:52	Retinal structure in Down's syndrome; potential markers of Alzheimer's disease *WALPERT M , Normando E M , Cordeiro M F , Holland A - Cambridge*
2623		15:14	Fluorescence lifetime imaging *DYSLI C - Bern*
2624		15:36	Auto fluorescence *HERMANN P - Bonn*

SIS

14:30 - 16:00 | RHODES 2

NSPH - Update in graves' orbitopathy

Graves' Orbitopathy is one of the most frequent inflammatory disorders of the orbit, but still with a puzzling pathogenesis.
Diagnostic evaluation and management are also challenging.

New diagnostic approach, with a comprehensive differential diagnosis will be presented. The updated EUGOGO(European Group of Graves' Orbitopathy) guidelines and medical management as the possibility of new molecules for the immunosuppression therapy will be discussed.
Various pathogenesis hypotheses and their possible consequence on the GO management will also be considered.

BOSCHI A , BALDESCHI L

2631	14:30	Update in Graves' Orbitopathy *LUDGATE M - Cardiff*
2632	14:52	Differential Diagnosis of Graves' Orbitopathy *BALDESCHI L - Bruxelles*
2633	15:14	Euthyroid Graves' Orbitopathy *BOSCHI A - Bruxelles*
2634	15:36	Update in medical management of Graves' orbitopathy *SALVI M - Milan*

C

14:30 - 16:00 | RHODES 3

PBP/RV - ABC in retina structure and function

Beginner

An understanding of the anatomy and physiology of the retina are essential in order to help in the diagnoses and treatment of various types of retinal diseases. Generally, only a limited amount of information is available in ophthalmic textbooks with the reader being unaware of more recent advances. The aim of this course is therefore to provide some more in-depth information on retinal structure and function to hopefully facilitate in an understanding in, for example, imaging diagnostic technologies like OCT and adaptive optics. Moreover, the newer available methods that include gene and stem cell treatments are aimed at preserving specific retinal cell-types and this requires knowledge related to the functional and morphological relationship between neurons, glial cells and the retinal vascular. In addition, an understanding of the relationship between retinal physiology and circadian rhythms cannot be ignored. The course should benefit clinicians, basic scientists and physiologists and will concentrate on retinal glial cells, the important relationship between photoreceptors and retinal pigment epithelial cells, the significance of ganglion melanopsin cells and the unique characteristics of the ON/OFF pathway of the retina.

GRZYBOWSKI A , OSBORNE N

2641	14:30	General structure and function of the retina *GRZYBOWSKI A - Olsztyn*
2642	14:48	Retinal vasculature structure and function *SCHMETTERER L - Vienna*
2643	15:06	The RPE/photoreceptor complex *OSBORNE N - Oxford*
2644	15:24	Retinal glial cells *OSBORNE N - Oxford*
2645	15:42	The ON/OFF system pathway of the retina *CASTELO-BRANCO M - Coimbra*

C

14:30 - 16:00 | RHODES 4

PO - Challenges in management of orbital tumors

Intermediate

The purpose of this course is to emphasize the diagnostic and surgical challenges in orbital tumors. Given the variety of structures confined to orbit, orbital tumors constitute a wide spectrum of lesions which pose numerous challenges for the clinician in terms of accurate diagnosis and management. A systematic approach is necessary to understand the pre-operative evaluation, classification, surgical planning and management of orbital tumors. In this course we will provide a general overview of diagnostic challenges including clinical features, imaging characteristics, pathological evaluation and surgical challenges in orbital tumors.

TUNC M

2651	11:30	Clinical evaluation in orbital tumors *MOURIAUX F - Rennes*
2652	11:52	The art of orbital imaging *TUNC M - Ankara*
2653	12:14	Orbital pathology: Differential diagnostic challenges *HEEGAARD S - Copenhagen*
2654	12:36	Surgical management in orbital tumors *BRISCOE D - Afula*

C

14:30 - 16:00 | GALLIENI 1+2

NSPH - Update in clinical features and genetics in microphthalmia

Advanced

Microphthalmia is a rare and panocular disease. This rare ocular disorder can occur as unilateral or bilateral. Anophthalmia is at the extreme of the malformative manifestations. Microphthalmia is a developmental and genetic ocular disease. Axial length is reduced with severe hyperopia and ocular globe anomalies are common. Genetic components are exposed with update of new genes. Syndromic manifestations in microphthalmia can be associated. Nanophthalmos is a specific form of microphthalmia and ocular complications must be known and anticipated. Exploration, imaging, medical and surgical care are specific and described to optimize the treatment of ocular complications.

BREMOND-GIGNAC D , ATILLA H

2661	14:30	Genetics in microphthalmia *CALVAS P , Davis E , Ragge N , Fares-Taïe L , Srour M , Michaud J , Kaplan J , Rozet J M , Chassaing N - Toulouse*
2662	14:52	Nanophthalmos clinical features and specific outcome *BREMOND-GIGNAC D - Paris*
2663	15:14	Optical coherence tomography findings of retinal folds in nanophthalmos *ATILLA H - Ankara*
2664	15:36	Specific gene in microphthalmia *ROZET J M , Fares-Taïe L , Chassaing N , Gerber S , Kaplan J , Ragge N , Calvas P - Paris*

FP

14:30 - 16:00 | GALLIENI 4

COS - FP session - Ocular surface diseases update

LAZREG S , GICQUEL JJ

2671		14:30	Effectiveness of platelet-rich plasma treatment in patients with chronic corneal erosions, associated with Herpetic keratitis *LOSHKAREVA A , Maychuk D - Moscow*
2672		14:42	Ocular surface involvement on GVHD patients *LAZREG S - Dar el Beida*
2673		14:54	Communication between the researcher and the researched. Designing an application based study regarding effects of air pollution on ocular surface diseases *CZAK W , Nowakowski J , Mulak M , Laba A , Misiuk - Hojlo M - Wroclaw*
2674		15:06	Correlations Fleischer deposits with topographic parameters at different deformations of the cornea *ANISIMOV S , Anisimova S , Mistrukov A - Moscow*
2675	*rf*	15:18	Severe ocular manifestations of rosacea in adult *HASSAIRI A , Limaiem R , Kortli M , Maamouri R , El Matri L - Tunis*
2676	*rf*	15:24	Pollen Count Compared with Severity of Symptoms and Signs of Dry Eye Disease in Norway *EIDET J R , Tashbayev B , Chen X , Ræder S , Badian R , Utheim Ø , Fostad I G , Dartt D A , Utheim T P - Oslo*
2677	* *rf*	15:30	Surface chemistry of the interactions of cationic nanoemulsions with human meibum films *DAULL P , Yokoi N , Nencheva Y , Georgiev G A - Evry*

FP

14:30 - 16:00 | GALLIENI 5

RV - FP session - Imaging

DE LAEY JJ , STANGOS A

2681		14:30	Normal values for fundus perimetry with the MAIA microperimeter and short-term repeatability evaluation *BAUDIN F , Assad G , Meillon C , Koehrer P , Bron A , Creuzot C - Dijon*
2682		14:42	High resolution adaptive optics retinal image analysis in early-stage central areolar choroidal dystrophy with a PRPH2 mutation *GOCHO K , Itoh N , Akeo K , Kameya S , Hayashi T , Takahashi H - Inzai*
2683	*	14:54	Static and dynamic retinal vessel analyses in patients with stroke as compared to healthy control subjects *DE BOEVER P , Palkovits S , Pertl L , Fazekas F , Kneihsl M , Trozic I , Goswami N , Weger M - Mol*
2684		15:06	Stereo OCT angiography in macular diseases *MAUGET-FAYSSE M , Wolff B , De Bat F , Vasseur V , Alonso A S - Paris*
2685		15:18	Hypoxia and retinal blood flow changes: a study using OCT-Angiography *CORDEIRO SOUSA D , Moreira S , Leal I , Dionísio P , Abegão Pinto L , Marques-Neves C - Lisbon*
2686	*rf*	15:30	Static retinal vessel analysis in routine optometric practice *FRENCH C , Heitmar R - Birmingham*
2687	*rf*	15:36	Trial study to automatically distinguish small haemorrhages in early diabetic retinopathy from image artefacts *SUZUKI N , Yamane K - Numazu*

POS

16:00 - 17:00 | POSTER AREA

EOVS: Electrophysiology, physiological Optics, Vision Sciences

T001 - T013

LEROY B , HOLDER G

T001		Normal Values for Amplitude of Accommodation among a Population of High School students in Iran *YEKTA A A , Hashemi H , Khabazkhoob M , Forouzesh S , Ostadimoghaddam H , Heravian J , Azimi A , Nabovati P , Yazdani N , Yekta R - Mahhad*
T002		Aberrations, accommodation and pseudoaccomodation in myopia and hyperopia *TARUTTA E , Harutyunyan S , Khandzhyan A , Khodzhabekyan N - Moscow*
T004		Difference between manifest and cycloplegic refraction in healthy non-presbyopic patients *DEL BUEY M A , Lanchares E , Pinilla I , Almenara C , Perez I , Minguez E , Cristobal J A - Zaragoza*
T005		The Impact of efferent oculomotor signals on size and distance perception *KRASTEL H , Streuer A , Magerl W , Kubarko A , Jonas J B - Neckargemünd*
T006		Early hydroxychloroquine retinal toxicity enhanced by multifocal electroretinogram and laser flare-cell meter *CELLINI M , Sebastiani S , Campos E - Bologna*
T007	*rf*	Analysis of macular sensitivity using multifocal electroretinogram and microperimetry in Central Serous Chorioretinopathy patients after half-dose photodynamic therapy *ROCHA DE SOUSA A , Rosinha P , Rodrigues-Araújo J , Alves-Faria P , Costa A , Falcão-Reis F , Penas S - Porto*
T008		Combination of global electroretinogram and sd-oct in the etiology of infantile nystagmus *BOULADI M , Bouraoui R , Limaiem R , Chaker N , Mghaieth F , El Matri L - Tunis*
T009		Onset-offset visual evoked potentials in the diagnosis of ocular albinism in infantile nystagmus *BOULADI M , Bouraoui R , Limaiem R , Chaker N , Mghaieth F , El Matri L - Tunis*
T010		Are Currently Available Tests Satisfactory for Color Vision Assessment? *ISIK M , Ozcerit A T , Erdurmus M , Inam O - Sakarya*
T011		The Effect of Sports Participation on Quality of Life in Subjects with Low Vision *ILHAN B , IDIL A , Ilhan I , Erkan Turan K - Ankara*
T012		Unilateral Carcinoma-Associated Retinopathy: Diagnosis, Serology and Treatment *ROELS D , Ueno S , Kondo M , Leroy B P - Ghent*
T013	*rf*	Systematic Assessment of Clinical Methods to Diagnose and Monitor Diabetic Retinal Neuropathy *JENKINS K S , Rowan A , Layton C - Brisbane*

POS

16:00 - 17:00 | POSTER AREA

G: Glaucoma

T014 - T064

PAZOS M , ABEGAO PINTO L

T014		Long-term results of up to 6 years of mitomycin-c augmented non-penetrating deep sclerectomy for pseudoexfoliation glaucoma *YAZGAN S , Ates H , Guven Yilmaz S , Celik T - Zonguldak*
T015		Filtering Blebs After XEN Implantation and Trabeculectomy: A Clinical and In Vivo Confocal Microscopy Study *CARDIGOS J , Crisostomo S , Costa L , Anjos R , Vieira L , Cardoso M , Reina M , Gomes T - Lisbon*
T016		Ab Interno Collagen Stent implantation as a treatment option for open angle glaucoma *CRISOSTOMO S , Cardigos J , Costa L M , Basílio A L , Anjos R , Cardoso M , Gomes T - Lisbon*
T017		Trends in glaucoma surgical procedures in Portugal - a national database report 2000-2014 *BARBOSA BREDA J , Gonçalves-Pinho M , Vasco Santos J , Rocha Sousa A , Freitas A - Porto*
T018	*rf*	Incidence and risk factors of elevated intraocular pressure following deep anterior lamellar keratoplasty *HUANG O , Mehta J , Htoon H , Tan D , Wong T - Singapore*
T019		New drainage construction in the surgical treatment of glaucoma *SULEIMAN E , Kiseleva O , Zhuravleva A - Moscow*
T020		EyeOP1 as a novel non-invasive surgical treatment of glaucoma: an Italian multicenter study *GIANNACCARE G , Bagnis A , Gizzi C , Vagge A , Fresina M , Del Noce C , Sebastiani S , Dormi A , Traverso C E , Campos E - Bologna*
T021		Retrospective review of pressure reducing effect of iStent and Trabectome procedures combined with cataract surgery *TOTH M , Bazeer S , Gazzard G - London*
T022		Canaloplasty with Stegmann's Canal Expander® for Open-angle Glaucoma *STANGOS A , Mameletzi E , Sunaric Megevand G - Geneva*
T023		Ultrasound evaluation of Ahmed Glaucoma Valve: IOP versus tube patency *BONO V , Zeppa L , Costagliola C , Zeppa L - Avellino*
T024		Macroscopic analysis of filtering bleb functionality after XEN Gel Stent implantation with Anterior Segment Optical Coherence Tomography *COSTA L , Cardigos J , Crisostomo S , Anjos R , Sa Cardoso M , Gomes T - Lisbon*
T025		Trabeculectomy: long term visual field stability *BOBAT H , Lockwood A , Kirwan J F - Portsmouth*
T026		Augmentation of corneal graft tissue with UV-riboflavin crosslinking: a pilot study in glaucoma drainage device patients *STONE D , Ahmad S , Craven R , Owaidhah O - Riyadh*
T027		Case-finding for angle closure: the diagnostic value of simple tests for estimating limbal and central anterior chamber depth *DABASIA P , Murdoch I , Edgar D , LAWRENSON J - London*
T028		Integrated visual field and relative risk for quality of life loss *MUNOZ M , Pujol O , Mora C , Pastor L , Gudiña S , Maull R , Vega Z , Morilla A , Anton A - Barcelona*

POS

16:00 - 17:00 | POSTER AREA

G: Glaucoma

T014 - T064

T029	* *rf*	Ultrasound treatment in patients with Primary Open-Angle Glaucoma with a second generation probe: Results of a Multicenter Clinical Trial *APTEL F , Rouland J F , Stalmans I , Denis P - Meylan*
T030		Transmission electron microscopy study of the collagens of the trabecular meshwork in glaucoma patients *RAMIREZ A I , García-Antón M , Rojas B , Salazar J J , De Hoz R , Triviño A , Escribano J , García-Feijoo J , Ramírez J M - Madrid*
T031	*rf*	A link between diabetes mellitus and glaucoma — Danish Nationwide Study *HORWITZ A , Petrovski B E , Petrovski G , Torp-Pedersen C , Kolko M - Copenhagen*
T032		Hemodynamic changes in eyes with early primary open-angle glaucoma measured by transpalpebral rheoophthalmography *KLEYMAN A , Kiseleva O , Iomdina E , Bessmertny A , Luzhnov P , Shamaev D - Moscow*
T033	* *rf*	Primary Open Angle Glaucoma treated by High Intensity Focused Ultrasound (HIFU). Results at 18 months of a prospective pilot study on patients treated with the 2nd generation probe *ROULAND J F , Aptel F - Lille*
T034	*	Efficacy and patient tolerability of preservative-free latanoprost compared with preservative prostaglandin analogs in patients with ocular hypertension or glaucoma *EL AMEEN A , Vandermeer G , Pisella P J - Tours*
T035		Why risking the satisfaction and the compliance of your newly diagnosed glaucoma patient? The PASSY survey. *MUNOZ - NEGRETE F J , Erb C , Stalmans I , Lemij H - Madrid*
T036	*rf*	High-intensity focused ultrasound cyclocoagulation: a 6-month study *VANDEWALLE E , Somers A , Vermorgen K , Stalmans I - Leuven*
T037		Introducing and measuring cornea and sclera deformability parameters on the basis of Schiøtz tonometry: mathematical modeling and clinical evaluation in Primary Open Angle Glaucoma (POAG) *IOMDINA E N , Lyubimov G , Moiseeva I , Stein A , Kiseleva O , Archakov A - Moscow*
T038		5-year Incidence of Lubricant Dependence in Medically and Surgically Treated Glaucoma Patients *IYER J , Lim F , Yang Z , Tong L , Wong T - Singapore*
T039		Effect of different lightning conditions on daily living activities of glaucoma patients *Zenouda A , Lombardi M , Gutman E , Brasnu E , Hamard P , Sahel J A , Baudouin C , LABBE A - Paris*
T040		Follow-up of patients treated by prostaglandins eyedrops. Preliminary results from the FREE survey *GRABSKA-LIBEREK I - Warszawa*
T041		A descriptive subgroup analysis of within hospital glaucoma referral in a tertiary center in Portugal *LEAL I , Cordeiro Sousa D , Marques-Neves C , Abegao Pinto L - Lisbon*
T042	*rf*	A comparison of visual field testing with a new automated perimeter, the Compass visual field analyser, and the Humphrey visual field analyser *FENOLLAND J R , Bonnel S , Rosenberg R , Sendon D , Ghazal W , Giraud J M , Renard J P - Issy les Moulineaux*

Thursday, Oct 6 - Poster session 1

POS

16:00 - 17:00 | POSTER AREA

G: Glaucoma

T014 - T064

T043		Efficacy & safety comparison between Cosopt & Xolamol : Branded & generic fixed combination of 2% Dorzolamide / 0.5% Timolol *ALI ALJASIM L , Edward D , Khandekar R - Riyadh*
T044		Early & delayed effect of using steroid following SLT, randomised controlled trial *ALI ALJASIM L , Owaidhah O - Riyadh*
T045		Use of glaucoma medications in Portugal: a cross-sectional nationwide study *CORDEIRO SOUSA D , Leal I , Nascimento N , Abegão Pinto L - Lisbon*
T046		Ultrafiltration rate in hemodialysis does not affect mean ocular perfusion pressure or intraocular pressure in end-stage renal disease *LEAL I , Cordeiro Sousa D , Couceiro R , Bigotte Vieira M , Noélia L , Resina C , Neves F , Gomes da Costa A , Pinto F , Marques-Neves C , Proença H - Lisbon*
T047		Dexamethasone induced glaucoma as part of chemotherapy for lymphoblastic lymphoma and colorectal cancer *LOCKWOOD A , Mitchell A , Lewis K , Papadopoulos M , Gray J , May K - London*
T048		Müller cells increase survival of retinal ganglion cells - a coculture model of primary retinal ganglion cells and primary Müller cells *TOFT-KEHLER A K , Skytt D , Brændstrup C , Gurubaran I , Kolko M - Copenhagen*
T049	*rf*	Quantification of green fluorescent protein expression in mouse retinal ganglion cells following intravitreal injection of recombinant adeno-associated virus *KHATIB T , Osborne A , Widdowson P , Martin K - Cambridge*
T050		Age related changes in axon guidance cues in the optic chiasm *GOMES ALVES DA CONCEICAO R , Barber A C , Martin K R - Cambridge*
T051		Increased intraocular pressure causes deficiency in the level of ELAVL1/HuR cytoplasmic fraction in the retina *SMEDOWSKI A , Trzeciecka A , Podracka L , Pietrucha-Dutczak M , Lewin-Kowalik J , Akhtar S , Kaarniranta K , Amadio M - Katowice*
T052		The predegenerated nerves extract enhances the endogenous neuroprotective system of Retinal Ganglion Cells by modulating of BDNF expression in rat glaucoma model *PIETRUCHA-DUTCZAK M , Smedowski A , Lewin-Kowalik J - Katowice*
T053		Association of polymorphic variants of miRNA processing genes DGCR8 and XPO5 with primary open-angle glaucoma risk in a Polish population *SZAFLIK J P , Molasy M , Walczak A , Przybylowska-Sygut K , Szymanek K , Szaflik M , Szaflik J , Majsterek I - Warszawa*
T054		Neuroprotective effects of EPA and DHA fatty acids in the DBA/2J hereditary glaucoma mouse model *KALOGEROU M , Prokopiou K , Kolovos P , Malas S , Papagregoriou G , Deltas C , Georgiou T - Larnaca*
T055		The vitreopapillary interface in healthy and glaucoma –The VPI study *WILLEKENS K , Pinto L A , Vandewalle E , Stalmans P , Stalmans I - Leuven*
T056		Longitudinal changes in retinal nerve fiber layer thickness in a healthy caucasian population *POPA CHERECHEANU A , Barac C , Miu J , Roncea T , Nicolae A , Duta S , Pirvulescu R - Bucharest*

POS

16:00 - 17:00 | POSTER AREA

G: Glaucoma

T014 - T064

T057	*rf*	A vascular comparison between primary open-angle glaucoma and normal-tension glaucoma *VAN KEER K , Abegão Pinto L , Barbosa Breda J , Willekens K , Vandewalle E , Stalmans I - Leuven*
T058		Factors determining the prelaminar tissue thickness in glaucoma *REBOLLEDA G , Diez Alvarez L , Casas LLera P , Cabarga C , De Juan V , Muñoz-Negrete F J - Madrid*
T059		Lamina cribrosa displacement after trabeculectomy in pseudoexfoliation and primary open angle glaucoma *KADZIAUSKIENE A , Strelkauskaite E , Asoklis R , Lesinskas E , Schmetterer L - Vilnius*
T060		Anterior segment parameters measured by ultrasound biomicroscopy in the subtypes of angle-closure *KIM Y Y , Yoo C , Cho S Y , Lee T E - Seoul*
T061		Comparison of the pattern of peripapillary retinal nerve fiber layer damage between open-angle glaucoma and anterior ischemic optic neuropathy *HEO D W , Kim K N , Lee Y H , Kim C S - Daejeon*
T062		Clinical precision for follow-up of glaucoma with PIMD-2 Pi *SANDBERG MELIN C , Malmberg F , Söderberg P - Uppsala*
T063		Choroid thickened after non-penetrating deep sclerectomy *REBOLLEDA G , De Juan V , Moreno-Montañés J , Muñoz-Negrete F J - Madrid*
T064		Macular ganglion cell layer abnormalities in Spectral Domain(SD)- OCT outside glaucomatous neuropathy *MENDES M , El Chehab H , Bouteleux V , Agard E , Russo A , Dot C - Lyon*

POS

16:00 - 17:00 | POSTER AREA

MBGE - Molecular Biology/Genetics/Epidemiology

T065 - T084

GEORGIADIS T , MOHAN R

T065		From perfect visual function to “legally” blind in one year: New mutations in progressive cone dystrophy *SOUSA NEVES F , Braga J , Loureiro M , Arede C , Sequeira J , Varandas R - Vila Nova de Gaia*
T066		Patterned macular dystrophy as the first sign of maternally-inherited diabetes and deafness (MIDD) *ESTEBAN O , Ascaso J , Peiro B , Martinez M , Almenara C , Perez I - Zaragoza*
T067		Stargardt disease phenotype-genotype correlation – first results of a Lithuanian cohort study *STRUPAITE R , Cimbalistiene L , Ambrozaityte L , Utkus A , Asoklis R - Vilnius*
T068		A Novel Homozygous c.1154+3_1151+6delAAGT mutation in CERKL Causes Autosomal Recessive Retinitis Pigmentosa with a Special Phenotype in a Consanguineous Tunisian Family *EL MATRI L , Falfoul Y , Habibi I , Turki A , Maamouri R , El Matri K , Chebil A - Tunis*
T069		Oguchi disease due to a novel mutation in the GRK1 gene *DE ZAEYTIJD J , Zeitz C , Leroy B P - Ghent*
T070		Pseudodominance in a Czech family with Usher syndrome type II *KOUSAL B , Dudakova L , Skalicka P , Bujakowska K , Liskova P - Praha*
T071		OPA1 analysis in an international series of probands with bilateral optic atrophy *LISKOVA P , Tesarova M , Dudakova L , Stepanka S , Kolarova H , Honzik T , Seto S , Votruba M - Prague*
T072		Two novel KERA mutations causing cornea plana in a Czech family and associated phenotypes *SKALICKA P , Dudakova L , Liskova P - Prague*
T073		Metallothionein polymorphisms in a Northern Spanish population with Age-Related Macular Degeneration (AMD) *GARCIA M , Alvarez L , Fernandez A , Gonzalez-Iglesias H , Escribano J , Fernandez-Vega B , Fernandez-Vega A , Villota E , Fernandez-Vega L , Coca-Prados M - Oviedo*
T074		Classification and heritability of macular pigment spatial profile phenotypes using two-wavelength fundus autofluorescence *HUNTJENS B , Ctori I , Mahroo O , Williams K , Hammond C - London*
T075		The zinc-metallothionein redox system in human retina and RPE *ALVAREZ L , García M , Rodríguez S M , Fernández B , Pereiro R , Sanz-Medel A , Coca-Prados M , González-Iglesias H - Oviedo*
T076		Retinal function and morphology in Mitf mutant mice *GARCIA LLORCA A , Gudmundsdóttir Aspelund S , Ogmundsdóttir M H , Steingrimsson E , Eysteinsson T - Reykjavík*
T077		The role of LRG1 in vessel normalization *SEPETIS A , O'Connor M , Dowsett L , Hoeh A , Gourlaouen M , Moss S , Greenwood J - London*
T078	*	Validation of the STARS risk assessment tool for age-related macular degeneration in an Algerian population *DELCOURT C , Lazreg S , Sanchez A , Bandello F , Nouri M T - Bordeaux*
T079		Variations in normative foveal morphology SD-OCT data: A study of White, South Asian and Black ethnicities *CTORI I , Huntjens B - London*

POS

16:00 - 17:00 | POSTER AREA

MBGE - Molecular Biology/Genetics/Epidemiology

T065 - T084

T080		Diabetic retinopathy and hearing loss; Results from Korean National Health and Nutrition Survey (KHANES V) (2010-2012) *SHIN Y U , Cho H , Lim H W , Seong M , Kang M H , Hong E H , Chung J H - Guri*
T081		The German AugUR study: a population-based prospective study to investigate chronic diseases in the elderly with focus on age-related macular degeneration (AMD) *BRANDLL C , Stark K J , Olden M , Zimmermann M E , Schelter S C , Loss J , Kronenberg F , Helbig H , Weber B H , Heid I M - Regensburg*
T082		Spectrum and outcomes of open globe injuries presenting to a tertiary Eye Centre in Singapore *GOH M J , Chaung J , Koh V , Sundar G - Singapore*
T083	*	Wooden projectile caused eye injuries in Finland - Helsinki eye trauma study *HAAVISTO A K , Sahraravand A , Leivo T , Holopainen J - Helsinki*
T084		The prevalence of refractive errors among underserved rural areas in Iran *YEKTA A A , Hashemi H , Khabazkhoob M , Ostadimoghaddam H , Malekifar A , Nabovati P - Mahhad*

Thursday, Oct 6 - Poster session 1

16:00 - 17:00 | POSTER AREA

PBP - Physiology/Biochemistry/Pharmacology

T085 - T108

OSBORNE N , HARDARSON S

T085 Hyperhomocysteinemia caused chorioretinal vasculopathy in an animal model
LEE Y J , Ke C Y , Lin P K - New Taipei City

T086 Changes in choroidal thickness and mean ocular perfusion pressure with hemodialysis
CORDEIRO SOUSA D , Leal I , Couceiro R , Bigotte Vieira M , Lopez N , Resina C , Neves F , Gomes da Costa A , Pinto F , Marques-Neves C , Proença H - Lisbon

T087 Functional end-arterial circulation of the choroid assessed by using fat embolism and electric circuit simulation
LEE J E , Ahn K S , Park G H , Kim H J , Kim H W , Chung I Y , Byon I S , Park S W - Busan

T088 Assessment of chorioretinal blood flow and vessel diameter by laser speckle flowgraphy in three animal models
WEI X , Barathi A , Sai B B , Balne P K , Khandelwal N , Agrawal R - Singapore

T089 Retinal vessel parameters in obstuctive sleep apnea
HEITMAR R , Turnbull C , Blann A , Stradling J - Birmingham

T090 Visualizing retinal vessel dynamics of young type 1 diabetic patients using self-organizing map
HAIKONEN S , Kytö J , Kämäräinen J K , Kauppi J P , Huttunen H , Groop P H , Summanen P - Helsinki

T091 Coats' syndrome is associated with reduced pressure autoregulation in retinal arterioles
HERBORG A , Bek T , Petersen L - Aarhus C

T092 *rf* The assessment of Ocular Blood Flow with Laser Speckle Flowgraphy in healthy Caucasian
WOZNIAK P A , Luft N , Aschinger G , Fondi K , Bata A M , Witkowska K J , Schmidl D , Werkmeister R M , Bolz M , Garhöfer G , Schmetterer L - Vienna

T093 * *rf* Quantitative assessment of retinal permeability in the diabetic Akimba mouse: validation of a promising animal model for diabetic retinopathy
HU TT , Vanheukelom V , De Vriese A , Feyen J H M - Heverlee

T094 The venous oxygen saturation predicts the visual prognosis after anti-VEGF treatment of central retinal vein occlusion
JEPPESEN S K , Bek T - Aarhus C

T095 Retinal venous oxygen saturation in healthy, atrophic and retinal vascular diseases
OLAFSDOTTIR O B , Hardarson S , Vandewalle E , Pinto L A , Eysteinsson T , Eliasdottir T , Gottfredsdottir M S , Van Keer K , Bek T , Stalmans I , Stefánsson E - Reykjavik

T096 Differential hypoxic response of human choroidal and retinal endothelial cells proposes tissue heterogeneity of ocular angiogenesis
MAMMADZADA P , Gudmundsson J , Kvanta A , Andre H - Stockholm

T097 Vessel Diameter Study: Intravitreal Versus Posterior Subtenon Triamcinolone Acetonide Injection For Diabetic Macular Edema
AKPOLAT C , Kurt M , Cekic O - Istanbul

T098 The preventive effects of the rhodiola rosea on ischemia-reperfusion injury in the RAT retina
Kükner A S , ERDURMUS M , Terzi E H , Fırat T , Kın Tekçe B , Cetinkaya A , Soydan A , Kükner A - Ankara

T099 Experimental study of intraocular temperature distribution in the rabbit under various environmental conditions
Anatychuk L , Pasyechnikova N , ZADOROZHNYY O , Kobylianskyi R , Nazaretyan R , Myrnenko V - Odessa

POS

16:00 - 17:00 | POSTER AREA

PBP - Physiology/Biochemistry/Pharmacology

T085 - T108

T100		The Anti-angiogenic Effects of Gold Nanoparticles on Experimental Choroidal Neovascularization in Mice *KANG S , Rho C R , Cho W K , Roh Y J - Daejeon*
T101		RESVEGA in exudative age-related macular degeneration *KUBICZ A - Wrocław*
T102	*rf*	Variation of accommodative process and anterior chamber parameters in diabetic patients *COSTA L , Passos I , Pires G , Proença R , Amado D , Ferreira J - Lisbon*
T103	*rf*	In the search of biomarkers for thyroid associated orbitopathy (TAO) *Kishazi E , Dor M , Eperon S , Gracià M D L A , Fouda C , Oberic A , Hamédani M , TURCK N - Geneva*
T104	*	Mechanisms of ocriplasmin uptake by retinal cells *CANDI A , Fonteyn L , Porcu M , Barbeaux P , Feyen J H , Hu T T - Heverlee*
T105		Light-induced oxidative stress production in the rod outer segments *PANFOLI I , Calzia D , Heinig N , Schumann U , Degan P , Traverso C E , Funk R H W , Roehlecke C - Genova*
T106		Upregulated expression of proteolytic enzymes in the cultured retinal pigment epithelial cells of minipig transgenic for the human mutated huntingtin *ARDAN T , Kocurova G , Hrnciarova E , Motlik J - Libechov*
T107		The effect of systemic alfuzosin hydrochloride on choroidal thickness and pupil diameter sizes *DOGAN M , Kutluksaman B , Karalar M - Afyonkarahisar*
T108		A 5-minute time interval between two different dilating eyedrops increases their combined effect *SAGUET P , Charlot F , Mouriaux F , Lux A L , Beraud G , Denion E - Caen*

SOC

16:00 - 17:00 | POSTER AREA

Meet the Experts

In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a 45 minute session called "Meet the Experts". This will be a table of 6-8 "guests" at a table headed by one of the EVER speakers. The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.

Thursday, Oct 6 - Second afternoon session

SIS

17:00 - 18:30 | HERMES

RV - Controversies in vitreoretinal practice

This symposium will provide three relevant issues in Vitreoretinal practice: the potential treatment options for symptomatic vitreous opacities, the prophylactic use of antibiotics in intravitreal injections, and finally, the current preferred therapeutic approach for the management of age-related macular degeneration (AMD) and diabetic retinopathy. The speakers will analyze these topics, presenting and discussing both pro and con positions.

GRZYBOWSKI A , ASCASO F

2711		17:00	Vitrectomy for vitreous floaters *ASCASO F - Zaragoza*
2712	*	17:18	Laser for vitreous floaters *TASSIGNON M J - Edegem*
2713		17:36	Antibiotics in intravitreal injections *GRZYBOWSKI A - Olsztyn*
2714		17:54	Treat & Extend vs PRN in AMD *PRUENTE C - Binningen*
2715		18:12	Treat and Extend vs PRN in Diabetic retinopathy *POURNARAS C - Genève*

SIS

17:00 - 18:30 | RHODES 1

G - Laser - the force reawakens. New concepts in established technology

Laser treatments are important and effective in the modern management of glaucoma. In this session we will explore recent advances in inflow and outflow laser treatment options. Has Selective Laser Trabeculoplasty delivered the pressure lowering it promised with a new generation of medication free patients?
Does diode laser have a role in the antiVEGF era of rubeotic glaucoma management? How can YAG laser assist glaucoma drainage devices?
This session will address all forms of laser treatments in glaucoma in an effort to maximise patient outcome and enhance your clinical practice

CRAWLEY L , BLOOM P

2721	*	17:00	Laser Trabeculoplasty Is the glaucoma fraternity completely convinced? *GAZZARD G - London*
2722		17:22	Inside out Diode laser for rubeotic glaucoma in the anti VEGF era *AHMED F - London*
2723		17:44	Yag laser glaucoma treatments; iridotomies and beyond *CRAWLEY L - London*
2724	*	18:06	Endoscopic laser- a direct view on the direct view *BLOOM P - London*

C

17:00 - 18:30 | RHODES 2

G - YOS for EVER - Young Ophthalmologist/Scientist

Beginner

EVER 2016 will introduce a new symposium entitled YOS for EVER. YOS is a well-recognized acronym for "young ophthalmologist" and as not only ophthalmologists attend EVER, YOS stands for "young ophthalmologist/scientist". YOS for EVER represents the trainee and young specialist group within EVER. This is a networking assembly of students, residents, post-docs and junior scientists to focus on objectives and goals relevant to the early stages of career development. Such topics include board examinations, information exchange, research and/or educational programs, fellowship and job opportunities. The 2016 inaugural symposium will be organized by Gauti Jóhannesson, a young ophthalmologist/scientist and member of the organization committee for YOS sessions at the Nordic Ophthalmologic Congress. All interested parties are encouraged to attend as guidelines and objectives and representatives for this new subgroup will be discussed at this first meeting. Immediately following the symposium, there will be a reception with light food and beverages for those attending this session.

JOHANNESSON G

2731	*	17:00	Presentation skills for oral presentations *JOHANNESSON G - Umeå*
2732		17:22	How to fast track your research career *BECHRAKIS N E - Innsbruck*
2733		17:44	Tricks for the spotlight - handling media *SOMNER J - Cambridge*
2734		18:06	How to succeed with grant applications? *DANIELSON P - Umeå*

SIS

17:00 - 18:30 | RHODES 3

NSPH - Hot topic in ocular surface in children

Manifestations of ocular surface in children may be severe causing visual impairment. Vernal keratoconjunctivitis, Atopic Keratoconjunctivitis, severe dry eye manifestations of systemic pathology are rare diseases. Physiopathology of these diseases is reviewed and developed. Severe ocular surface disease in children is a challenge. Understanding and treatment is the key point. The pathogenesis remains unclear and classical tear substitute or antiallergic therapy often unsuccessful. An overview of the innovating new molecules, diagnosis and treatment are summarized. Furthermore molecules' action can explain how the disease can be improved.

BREMOND-GIGNAC D , ATILLA H

2741		17:00	Topical cyclosporine-A in dry eye associated with chronic graft versus host disease *ATILLA H - Ankara*
2742		17:22	Severe clinical features in Vernal Keratoconjunctivitis *LAZREG S - Dar el Beida*
2743		17:44	Atopic Keratoconjunctivitis in children *CHIAMBARETTA F - Clermont Ferrand*
2744		18:06	Topical cyclosporine-A in Vernal Keratoconjunctivitis, when how and how long *BREMOND-GIGNAC D - Paris*

Thursday, Oct 6 - Second afternoon session

FP

17:00 - 18:30 | RHODES 4

PO - FP session - PO

MOURIAUX F , MOULIN A

2751	*rf*	17:00	The role of anterior segment optical coherence tomography (AS-OCT) and ultrasound biomicroscopy (UBM) in conjunctival nevi *LAUWERS N , Janssens K , Mertens M , De Keizer R J W , De Groot V - Edegem*
2752		17:06	Loss of 5 hydroxymethylcytosine in conjunctival melanoma *MOULIN A , Caseiro P , Schalenbourg A , Zografos L , Kaya G - Lausanne*
2753		17:18	Outcomes after surgical resection of lower eyelid tumors and reconstruction using a septal chondromucosal graft and an upper eyelid skin flap *LEMAITRE S , Levy-Gabriel C , Couturaud B , Gardrat S , Cassoux N , Desjardins L - Paris*
2754		17:30	Cyberknife treatment in adenoid cystic carcinoma of the lacrimal gland *TUNC M , Guney Y - Ankara*
2755		17:42	4 Gy radiotherapy in 6 patients with orbit marginal zone lymphoma: A small case series *GRAEFF E - Basel*
2756	*rf*	17:54	Sequential bilateral optic nerve infiltration as the sole manifestation of relapsed T-cell lymphoblastic lymphoma: a case report *KHAYAT H , ALSULAMI R , Alsobhi E , Alqahtani A , Alkahtani A , Alzahrani S - Jeddah*
2757	*rf*	18:00	Clinical and instrumental diagnostics in patients with orbital metastasis *SAAKYAN S - Moscow*
2758	*rf*	18:06	Grading iris color of post-mortem human eyes *MADIGAN M , Cionaca V , Sitiwin E , Ton H T - Sydney*

SIS

17:00 - 18:30 | GALLIENI 1+2

MBGE/NSPH - Syndromic retinopathies

Syndromic retinopathies are complex disorders in which the retinal involvement is of is one of the key features of the disease also affecting other organs and tissues. The special interest symposium will provide an overview of the molecular genetic mechanisms underlying inherited syndromic retinopathies, advances in the field of genetic testing and present selected distinct clinical entities manifestating in children.

LISKOVA P

2761	17:00	Using iPS cells to uncover cilia protein function and model disease *SCHWARZ N - London*
2762	17:22	Searching for the molecular causes of syndromic inherited retinal degenerations *BUJAKOWSKA K - BostonMA*
2763	17:44	Syndromic paediatric vitreoretinopathies *HENDERSON R - London*
2764	18:06	Molecular genetic basis of Usher syndrome in the Czech population *LISKOVA P , Kousal B , Bujakowska K , Dudakova L - Prague*

SIS

17:00 - 18:30 | GALLIENI 4

ACB - Tear proteome, inflammation and wound healing

Ocular surfaces are delicate structures of the anterior segment of the eye protected, nourished and lubricated by tear fluid. Composition of the tear film is in essential role in the health of the anterior segment of the eye. The system has it's own regulatory mechanisms. Ocular surfaces are exposed environmental factors, topical ophthalmic drugs and affected by various ocular and systemic diseases. Inflammation and wound healing are vital processes involved in the defense mechanisms of the human body and pathogenesis of many eye diseases. It is also one of the most important factors in many ocular surgeries e.g. corneal, refractive and glaucoma surgery. It consists of many overlapping processes like inflammation, fibroblast activation, ECM production and remodeling of the ECM and there are many mechanisms and mediators involved in it. Tear proteomics is a powerful tool to diagnose and detect mechanisms and drugable targets of the ophthalmic and systemic diseases. SIS is focusing in the proteomics and biomarkers of the tears and anterior surface of the eye in relation these diseases.

UUSITALO H , BEUERMAN R

2771		17:00	Inflammation The good and the bad *CALONGE M , Herreras J M , Stern M E - Valladolid*
2772		17:22	Quantifying Inflammation as a common component of eye disease *BEUERMAN R - Singapore*
2773	*	17:44	Tear lipids in corneal stress and inflammation *HOLOPAINEN J - Helsinki*
2774		18:06	Tear fluid biomarkers, conjunctival inflammation in glaucoma *UUSITALO H - Tampere*

SIS

17:00 - 18:30 | GALLIENI 5

LC - Non-surgical cataract treatment

At present, cataract can only be treated with surgical removal of the non-transparent lens. There are no effective prophylactic or therapeutic treatments despite the many attempts to find a non-surgical cure for cataract. In this symposium we will receive an introduction on lens and eye transparency and non-transparency, in order to better understand the various types of cataract measures and end-points used by the other speakers. We will hear about pharmacological and photochemical interventions intended to reverse or decrease the degree of cataract or cataract-related parameters in various models.

LOFGREN S , BARRAQUER RI

2781		17:00	Transparency of the lens and the eye *PRIETO P - Murcia*
2782		17:15	Effects of a thiol antioxidant in various cataract models *ERCAL N , Maddirala Y , Carey J , Tobwala S - Rolla*
2783		17:33	Lanosterol reversal of protein aggregation in cataract *ZHANG K , Zhao L , Zhu J , Hou R , Wang S , Yan Y - La Jolla*
2784		17:51	Photochemical reversal of cataract *KESSEL L - Glostrup*
2785	*	18:09	Pharmacological restoration of transparency in cataract *MAKLEY L , Andley U , Gestwicki J - San Francisco*

SIS

18:30 - 19:30 | RHODES 2

Evening symposium: Modern understanding of dry eye

SULLIVAN DA

2831	18:30	The last key highlights on dry eye *SULLIVAN DA - United States*
2832	18:45	Interrelationship between dry eye and MGD *LAZREG S - Algeria*
2833	19:00	Is dry eye more about the ocular surface than the tear film? *MESSMER EM - Germany*
2834	19:15	How are ocular surface cells protected in stressful situations? *CHIAMBARETTA F - France*

EVER 2016
Friday, Oct 7

SIS

8:30 - 10:00 | HERMES

RV - Confrontation of OCT-angiography and fluoresceine angiography

OCT angiography became an emerging imaging modality particularly useful for the diagnosis and management the retinal vascular pathologies.
It is particularly useful for the investigations of various macular ischemic microangiopathies as well as for the diagnosis and management of age related macular degeneration.
The aim this SIS is to bring together experts in order to clarify confrontation aspects of OCT-Angiography and fluorescein angiography in those macular pathologies.

POURNARAS C , ZOGRAFOS L

3111		8:30	OCT-A physics, instruments and limits of clinical application *COSCAS F - Creteil*
3112	*	8:42	OCT-A in neovascular age related macular degeneration *LUMBROSO B - Rome*
3113		8:54	OCT angiography in Retinal Angiomatous Proliferation *SOUBRANE G - Paris*
3114	*	9:06	Diabetic maculopathy: Confrontation of FA and OCT-A findings *COSCAS G , Lupidi M , Fiore T , Cagini C , Coscas F - Creteil*
3115		9:18	OCT-A and FA findings in ocular Drepanocytosis *AMBRESIN A - Lausanne*
3116		9:30	OCT-A versus FA guided focal laser, in macular ischemic microangiopathies *POURNARAS C - Genève*
3117		9:42	OCT-A and FA in irradiation induced microangiopathy *ZOGRAFOS L - Lausanne*

SIS

8:30 - 10:00 | RHODES 1

G - New technologies in glaucoma surgery

The surgical field of glaucoma is rapidly changing with the introduction of new devices and techniques. Is this the end for the good old trabeculectomy? First, an overview will be provided of new techniques like the Xen gelstent implant, the ultrasound cyclocoagulation and the iStent. Secondly, difficult cases will be presented and the panel will discuss the different treatment options and guide us through the mazes of the labyrinth of glaucoma treatment nowadays.

VANDEWALLE E , STALMANS I

3121	*	8:30	The role for the Xen gel stent implant in glaucoma treatment *STALMANS I - Leuven*
3122	*	8:48	High-intensity focused ultrasound treatment for open angle glaucoma *APTEL F - Meylan*
3123	*	9:06	Results for the Synergy trial: use of iStent in open angle glaucoma *GARCIA-FEIJOO J , Voskanyan L , Martinez de la Casa J M - Madrid*
3124		9:24	How to tackle these difficult cases *ABEGAO PINTO L - Lisbon*
3125		9:42	How to tackle these difficult cases *VANDEWALLE E - Leuven*

SIS

8:30 - 10:00 | RHODES 2

COS - Nanotechnology in ophthalmology

This SIS highlights nanotechnological approaches for therapies in cornea, retina and glaucoma.

KOMPELLA UB , GRIFFITH M

3131	8:30	Nanoparticles for ocular surface drug and gene delivery *KOMPELLA U B - Aurora*
3132	8:48	Magnetized nanoparticles for transfection of the corneal endothelium *FUCHSLUGER T , Mykhailyk O , Christian P , Singer B , Czugala M - Erlangen*
3133	9:06	Layer-by-layer coated nanoparticles for glaucoma therapy: Focusing on the transport and cellular uptake in the trabecular meshwork *BREUNIG M , Guter M , Babl S , Liebl R - Regensburg*
3134	9:24	Recent progress in microrobots for ophthalmic therapies *ULLRICH F , Nelson B J - Zürich*
3135	9:42	Collagen biomaterials for cornea regeneration - how does it work *GRIFFITH M , Reddy J , Liszka A , Lewis P N , Hayes S , Meek K M - Linköping*

SIS

8:30 - 10:00 | RHODES 3

PO - Conjunctival tumors

Conjunctival neoplasms are rare tumours of benign or malignant nature, which are 1) often misdiagnosed; 2) associated with severe ocular morbidity when diagnosed too late and/or treated incorrectly; and c) associated with increasing mortality in some areas of the globe. Their diagnosis and treatment can be difficult requiring a multimodality approach. There has been much progress in our understanding of the pathogenesis of these tumours in recent years. In addition, major advances have occurred in treatment with the introduction of topical chemotherapy, adjunctive radiotherapy and microsurgical developments. This symposium will provide an overview of latest understanding of the epidemiology, pathology, imaging, TNM/AJCC clinical staging and treatment of these tumours. It will highlight the use of novel cell lines that will hopefully advance our understanding of some conjunctival malignancies. Finally, it will provide the opportunity for a panel discussion where specific clinical problems can be addressed.

COUPLAND S , CAUJOLLE JP

3141	8:30	Overview of the epidemiology and pathology of conjunctival tumours *LOEFFLER K U - Bonn*
3142	8:48	Diagnostic modalities of conjunctival tumours *BLASI M A - L'Aquila*
3143	9:06	Treatment of conjunctival tumours *CAUJOLLE J P - Nice*
3144	9:24	Cell lines of conjunctival tumours and their potential use in research *JAGER M J , Cao J - Leiden*
3145	9:42	Update on the 8th Edition TNM staging system for conjunctival tumours *COUPLAND S - Liverpool*

8:30 - 10:00 | RHODES 4

EUPO session 1 - Neuro-ophthalmology

Common Optic Neuropathies in Adults: Diagnosis, Treatment and Prognosis

EUPO Programme, see pages 134-135.

8:30 - 10:00 | GALLIENI 1+2

LC - Ocular damage from ambient optical radiation

The first speaker provides an overview of the ambient exposure of ocular tissues to optical radiation. The second speaker will review out current knowledge on the association between sun exposure and cataract. The third speaker will review the evidence for apoptosis as a damage mechanism in ultraviolet radiation damage to the lens. The forth speaker will review the possibility that near-infrared radiation exposure from remote- controls and sensors contributes to cataract formation. Finally, the fifth speaker will provide an update on the possible threat to the retina caused by the ongoing conversion from incandescent sources to LED-sources for illumination.

SODERBERG P , WEGENER A

3161	8:30	Ambient exposure of the ocular tissues to optical radiation *SODERBERG P , Yu Z , Talebizadeh N , Malmqist L , Sandberg Melin C , Galichanin K - Uppsala*
3162	8:48	Update on epidemiological evidence for an association between sun exposure and cataract *WEGENER A , Meyer L - Bonn*
3163	9:06	Evidence for apoptosis in the lens after in vivo exposure to ultraviolet radiation *TALEBIZADEH N , Yu Z , Kronschläger M , Galichanin K , Söderberg P - Uppsala*
3164	9:24	Is the increasing exposure of the eye to near-infrared radiation from remote controls and sensing a threat to the lens? *YU Z , Schulmeister K , Talebizadeh N , Kronschläger M , Söderberg P - Uppsala*
3165	9:42	Is conversion of indoor illumination to LED-sources a threat to the retina? *BEHAR-COHEN F - Paris*

SIS

8:30 - 10:00 | GALLIENI 4

ACB - Stem cells and cell therapy advances in ophthalmology

The anatomical and biological properties of stem cells in the eye have been the topic of indepth research over the last few decades. Enormous advances in the cell and tissue isolation and cultivation techniques, as well as molecular characterization of the different cell populations have been achieved, next to the major advances made in the bioscaffolds' engineering for cell delivery and treatment of eye diseases. Advances in the cell and gene therapy have reached culmination with the human cornea being at the top and holding great promise in treating eye disorders. The eye is indeed a golden mine for stem cells. This session will include lectures from European experts in the field with high international recognition and large collaborative networks.

PETROVSKI G , MOE M

3171		8:30	Challenges in the clinical applications of cornea limbal stem cells *FERRARI S - Venice*
3172	*	8:52	Regulating gene expression towards solving ocular surface diseases *MOORE T , Atkinson S , Maurizi E , Schiroli D , Mairs L , Christie K , McLean I , Allen E , Pedrioli D L , Moore J , Nesbit A - Coleraine*
3173		9:14	Advances in corneal endothelium engeeing for future transplantation applications *SHAHDADFAR A - Oslo*
3174		9:36	The future of stem cell and cell therapy in ophthalmology *Ferrari S , Moore T , Shahdadfar A , PETROVSKI G - Szeged*

SIS

8:30 - 10:00 | GALLIENI 5

MBGE - Grand rounds in ophthalmic genetics

This SIS will provide a forum to discuss clinical and molecular cases with peers and leaders from the field of ophthalmic genetics. The format is simple and is comparable to that of the Grand Rounds in departments of ophthalmology around the World. Both SIS organisers will be present, together with other leaders in the field of ophthalmic genetics.
Because of the format of the SIS, there will be no formal speakers set in stone from the outset, as all EVER participants will be free to submit cases during the meeting prior to this session. As such, the format will be similar to the FAN Club meeting. Nevertheless, we have indicated speakers who have declared their interest in presenting.

LEROY B , HAMEL C

3181	8:30	Cases *AUDO I - Paris*
3182	8:48	Cases *HAMEL C - Montpellier*
3183	9:06	Cases *LISKOVA P - Prague*
3184	9:24	Cases *HOLDER G - London*
3185	9:42	Cases *LEROY B - Ghent*

KN

10:10 - 10:40 | HERMES

Keynote Lecture by Marcela VOTRUBA

Introduction by Bart LEROY

3211

OPA1 gene and mitochondrial optic neuropathy: disease mechanisms and potential therapies

Marcela VOTRUBA - Cardiff

Summary:

Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a key clinical feature. The commonest causes world-wide are mutation in mitochondrial DNA (causing Leber's Hereditary Optic Neuropathy) and mutation in the nuclear gene, OPA1 (causing Autosomal Dominant Optic Atrophy: ADOA). 60-75% of patients with autosomal dominant optic atrophy have mutations in the OPA1 gene. The OPA1 protein is targeted to the mitochondria and is involved in regulation of mitochondrial fusion. A better understanding of mitochondrial function, including dynamics, is revealing that functional and structural changes in mitochondrial morphology are important factors in diseases of ageing in the eye and visual system. Key proteins have been discovered which control the balance of mitochondrial fusion and fission and have a range of other functions, such as controlling maintenance of mitochondrial DNA, cell death, autophagy, mitochondrial metabolism and redox signalling. A decline in mitochondrial function plays a role in the ageing process and increases the incidence of age-related disorders. Mitochondrial optic neuropathies are 'orphan' diseases but with the advent of recent trials of novel therapies in patients with the mitochondrial optic neuropathy, Leber's hereditary optic neuropathy, there is the first glimmer of hope for the treatment of this group of patients.

Award presentation of the EVER Certificate of Honour

Biography Marcela VOTRUBA:

Marcela Votruba is a Professor in Ophthalmology at Cardiff University and a Consultant in Ophthalmology at The University Hospital of Wales. She was awarded an Open Scholarship to The Queen's College, Oxford (1981-1984) to read Physiological Sciences and obtained her BM BCh at Green College, Oxford (1987). After Primary FRCS (1989) she trained in ophthalmology at The Royal London Hospital, St Bartholomew's Hospital, London, Bristol Eye Hospital and Moorfields Eye Hospital, London. She obtained a PhD (1999) at UCL in ophthalmic genetics, supervised by Professor Shomi Bhattacharya and Professor Tony Moore, using linkage analysis and positional cloning to identify the OPA1 gene, causing dominant optic atrophy. She has held Wellcome Trust and MRC Clinician Scientist Fellowships and is a former Consultant at Moorfields Eye Hospital and a Visiting Research Scholar at the National Eye Institute, National Institutes of Health, USA.
Her research focuses on ophthalmic genetics and mitochondrial diseases. She is particularly interested in the role of mitochondria in optic neuropathy and retinal degeneration. Her Mitochondria & Vision Lab in The Cardiff School of Optometry & Vision Institute focuses on in vitro and in vivo approaches to modelling mitochondrial dysfunction leading to retinal ganglion cell loss and on genes and proteins involved in the regulation of mitochondrial morphology, with a strong emerging interest in novel therapies. She runs a genetic eye disease clinic and a retinal clinic at the Cardiff Eye Unit, University Hospital, Wales. Since 2014 she has been the Head of the School of Optometry & Vision Sciences at Cardiff University, Wales, UK.

Friday, Oct 7 - Second morning session

JM

11:00 - 12:30 | HERMES

ARVO@EVER - Animals in ocular oncology

ARVO

COUPLAND S

3311		11:00	Introduction and overview on animal models used in ocular oncology *JAGER M J - Leiden*
3312		11:12	Use of the chick embryo model in uveal melanoma *KALIRAI H - Liverpool*
3313		11:24	Uveal melanoma patient-derived xenografts *DECAUDIN D - Paris*
3314		11:36	Use of the zebrafish model in uveal melanoma *MIONE M - Karlsruhe*
3315		11:48	Orthopedic xenograft mice model of retinoblastoma *CASSOUX N - Paris*
3316		12:00	Intraocular lymphoma models *FRENKEL S - Jerusalem*
3317		12:12	Summary and future directions *COUPLAND S - Liverpool*

FP

11:00 - 12:30 | RHODES 1

RV - FP session - AMD & miscellaneous

SOUBRANE G , LEYS A

3321		11:00	The immunohistochemical identification and localization of homocysteine in the human retina with the features of age related macular degeneration *OZIMEK M , Choragiewicz T , Junemann A , Rejdak R - Lublin*
3322		11:12	Treatment of neovascular age-related macular degeneration with anti-VEGF agents: predictive factors of long-term visual outcomes *PEDROSA A C , Sousa T , Pinheiro-Costa J , Beato J , Falcão M , Falcão-Reis F , Carneiro A - Porto*
3323		11:24	Characterization, structural analysis, evolution of AMD drusenoid deposits "L", Lipid type and "P", Protein-cellular type, with multimodal imaging and morphology-structural software *GONZALEZ C - Toulouse*
3324		11:36	Optimization of storage of differentiated retinal pigment epithelial cells *KHAN A Z , Utheim T P , Reppe S , Sandvik L , Lyberg T , Roald B B H , Eidet J R - Oslo*
3325	*rf*	11:48	Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention *FRUSCHELLI M , Fazio S , Capozzoli M , Chimenti G , Hadjistilianou T , Sicuranza A , Aprile L , Puccetti L - Siena*
3326	*rf*	11:54	Frequency doubling technology perimetry and retinal fiber layer correlation in type 2dDiabetics without retinopathy *ALDAHAM S , Martín-Ridaura M D C , Puell M C - Madrid*
3327	*rf*	12:00	Correlation between choroidal and retinal thickness in diabetic patients without diabetic retinopathy *CARDIGOS J , Proenca R , Vicente A , Marques N , Cunha J P , Abegao Pinto L , Ferreira J - Lisbon*
3328	*rf*	12:06	SD-OCT for study of retinal layers segmentation in patients under Hydroxychloroquine treatment *COSTA L , Basílio A L , Proença R , Cunha J P , Vieira L , Flores R , Santos A - Lisbon*

FP

11:00 - 12:30 | RHODES 2

COS - FP session - Corneal transplantation from the lab to the OR

GICQUEL J , FUCHSLUGER T

3331	11:00	How to make better, safer and easier endothelial controls of long-term stored corneas with Specular Microscopy? *GARCIN T , Bernard A , Calyaka E , Herbepin P , Hor G , He Z , Gain P , Thuret G - Saint Etienne*
3332	11:12	Effect of biochemical cues on proliferation, phenotype and migration of human corneal stromal cells *FERNANDEZ-PEREZ J , Ahearne M - Dublin*
3333	11:24	Influence of material compliance on human corneal stromal cell behaviour *KELLY C , Ahearne M - Dublin*
3334	11:36	Involvement of abnormally-activated CD44+ cells migrating from the iris to the center of the cornea in Fuchs Endothelial Corneal Dystrophy *HE Z , Thuret G , Jun A S , Muraine M , Kallay L , Toubeau D , Pereira S , Bergandi F , Gain P - Saint-Etienne*
3335	11:48	Alterations in proliferative activity in the corneal endothelial periphery after transcorneal freezing *CORRELL M , Crouzet E , Cabrerizo J , Dornonville de la Cour M , Gain P , He Z , Heegaard S , Kiilgaard J , Thuret G - Glostrup*

SIS

11:00 - 12:30 | RHODES 3

PO - Controversies in posterior uveal melanoma

The management of malignant melanoma of the posterior uvea (ciliary body and choroid) is still controversial in some points. This controversy has evolved because the peculiar and often unpredictable behavior of this tumor is poorly understood. This SIS meeting discusses some of the controversial issues, with emphasis on the debate.

MOURIAUX F , CASSOUX N

3341	11:00	Fine needle aspiration biospy or not? *CASSOUX N - Paris*
3342 *	11:22	Endoresection or not? *BECHRAKIS N E - Innsbruck*
3343	11:44	Cytogenetic or molecular analysis for prognosis? *JAGER M J - Leiden*
3344	12:06	Follow-up : which one and for whom? *DAMATO B - San Francisco*

11:00 - 12:30 | RHODES 4

EUPO session 2 - Neuro-ophthalmology
Systematic Approach to the Ocular Motor System

EUPO Programme, see pages 134-135.

11:00 - 12:30 | GALLIENI 1+2

PO/IM - Cytology of atypical inflammation or tumors

Diagnostic challenges in unsolved cases of inflammation or masses in the vitreous, retina or choroid
An inflammation can obscure or mask a malignant process. Some tumors start very indolent and mimic uveitis and present in the immunology clinic. In these difficult presentations it is important to detect the atypical components and act quickly following the modern techniques to exclude or confirm malignancies. In this SIS the atypical presentations which are suspicious for malignancies will be highlighted. A retinal or choroidal lymphoma with vitreous seeding is a typical diagnostic challenge. An atypical flat choroidal melanoma can be obscured by bleeding or inflammation. Paraneoplastic processes can mimic real neoplasms or inflammation and their typical clinical aspect will be explained. For challenging cases a biopsy can be necessary. The technical aspects of vitreous biopsies, handling and will be explained, highlighting the newer techniques. Even in very small samples it is nowadays possible to perform genetic analysis to confirm the diagnosis and add prognostic factors

VAN GINDERDEUREN R , VAN CALSTER J

3361	11:00	Latest diagnostic possibilities in unsolved uveitis, suspicious for malignancy *NERI P , Arapi I , Pirani V , Giovannini A , Mariotti C - Agugliano*
3362	11:18	How to recognize a masquerade syndrome? What is the differential diagnosis? *VAN CALSTER J - Leuven*
3363	11:36	How to perform a vitreal, retinal or choroidal biopsy? What justifies an invasive technique? *VAN CALSTER J - Leuven*
3364	11:54	Innovative pathology techniques for small tissue samples or cytology of vitreous biopsies *VAN GINDERDEUREN R - Leuven*
3365	12:12	Applied genetic testing in ocular tumors *COUPLAND S - Liverpool*

FP

11:00 - 12:30 | GALLIENI 4

IM - FP session - Novelties in diagnosis and treatment in ocular immunology

BODAGHI B , WILLERMAIN F

3371		11:00	Diagnosis and management of cytomegalovirus anterior uveitis/endothelitis in immunocompetent patients in 2 European referral centers *ANTOUN J , Caspers L , Groot-Mijnes J , Motulsky E , Dam-van Loon N H T , Makhoul D , Willermain F , Judice Relvas L - Brussels*
3372		11:12	Presentation and management of cytomegalovirus retinitis in immunocompromised children *DENIER C , Robert M , Adjadj E , Michel S , Aymard P A , Bremond-Gignac D - Paris*
3373		11:24	Validation of an antiretinal antibody detection strategy for the diagnosis of autoimmune retinopathies *DRAGANOVA D , Debaugnies F , Postelmans L , Caspers L , Willermain F , Corazza F - Bruxelles*
3374	*	11:36	Evaluation of Tumor Necrosis Factor inhibitor therapy in Susac syndrome *BUELENS T , Ossewaarde-van Norel A , Nubourgh I , Glibert G , Kamgang Semeu P , Caspers L , Postelmans L , Willermain F - Brussels*
3375		11:48	In vitro evaluation of anti HSV-1 siRNAs and in vivo evaluation of electroporation to transfect siRNAs on murine cornea *ROUSSEAU A , Escriou V , Roy P , Poccardi N , Takissian J , Bigey P , Labetoulle M - Le Kremlin Bicêtre*

SIS

11:00 - 12:30 | GALLIENI 5

MBGE/LC - Radiation induced cataracts

Radiation cataracts are a field of recent interest, following accumulating evidence in the literature that the lens is more radiosensitive than previously thought. Indeed the International Commission for Radiation Protection recently revised its judgement regarding the threshold for lens effects and occupational dose limits, with the new recommendations now incorporated into the EU Basic Safety Standard. It is intended that this session will highlight research gaps including mechanistic needs, and how also other research fields could contribute to radiation cataract research. Speakers will examine recent developments in our mechanistic understanding of radiation cataract initiation and development, including evidence for low dose radiation effects. In addition, speakers will explore the radiation protection aspects and the need for collaborative 'molecular epidemiology' research to full answer the remaining questions as to how low dose ionising radiation exposure causes cataracts.

AINSBURY L , WEGENER A

3381	11:00	Investigating the effect of low dose ionising radiation on epithelial progenitor cell niches *QUINLAN R , Kalligeraki A , Pal R , Wu J J , Inagaki M , Tanaka H - Durham*
3382	11:30	Lifetime Study in mice: 24 months follow up after low doses of ionizing radiation with Scheimpflug imaging and OCT *DALKE C , Rößler U , Neff F , Greiter M , Gomolka M , Hornhardt S , Garrett L , Kunze S , Unger K , Rosemann M , Kempf S J , Azimzadeh O , Wurst W , Aubele M , Zitzelsberger H , Hölter S M , Tapio S , Hoeschen C , Kulka U , Atkinson M , Graw J - Neuherberg*
3383	12:00	Epidemiological needs to support lens mechanistic research *AUVINEN A - Tampere*

SIS

13:30 - 15:00 | HERMES

RV - Retinal detachment

Retinal detachment may occur in different conditions as in pseudophakic, myopic, diabetic eyes. Prevention of retinal detachment will firstly discussed. Then, the characteristics in each condition will be detailed in order to apply the best strategy for the management of our patients. Finally, retinal detachment associated with tumor cases will be discussed.

POURNARAS J , LE MER Y

3511	13:30	Prevention of retinal detachment *STANGOS A - Geneva*
3512	13:48	Pseudophakic retinal detachment *POURNARAS C - Genève*
3513	14:06	Myopic Retinal detachment *BERROD J P - Vandoeuvre les Nancy*
3514	14:24	Diabetic Retinal detachment *LE MER Y - Paris*
3515	14:42	Retinal detachment in ocular oncology *POURNARAS J A - La Conversion*

SIS

13:30 - 15:00 | RHODES 1

G - EVER Obergurgl optic nerve meeting symposium: the ageing optic nerve

The theme of the 5th Obergurgl Optic Nerve Meeting in Dec. 2015 was “The ageing optic nerve” (Organizers: Jonathan Crowston, Melbourne; Franz Grus, Mainz; Keith Martin, Cambridge). The program featured leading researchers from ophthalmology, neuroscience and related fields.
Speakers discussed the influence of oxidative stress, mitochondria, glia and autoimmunity on optic nerve health, as well as their ability to protect against degeneration or to slow it down. The emphasis was on ageing and its role in disease pathogenesis and treatment approaches.
The conference brought together clinicians and basic scientists from different fields and highlighted translational research providing a platform for networking and stimulating discussions.

GRUS F , CROWSTON J , MARTIN K

3521		13:30	Autophagy and ageing in the retina *BOYA P - Madrid*
3522		13:48	Repairing the ageing brain - neural ECM in regeneration and rehabilitation *KWOK J - Leeds*
3523	*	14:06	Gene transfer of E2F2 induces in situ regeneration of retinal pigment epithelium *LUHMANN U , Kampik D , Nishiguchi K , Basche M , Smith A J , Ali R R - Basel*
3524		14:24	Stem cells in reparing optic nerve damage *PEBAY A , Gill K , Needham K , Van Bergen N , Lim S , Hernandez D , Liang H , Kearns L , Hung S , Hewitt A , Mackey D , Trounce I , Wong R - Melbourne East*
3525		14:42	Retina proteomics provide new insights in glaucoma *FUNKE S , Perumal N , Schmelter C , Teister J , Markowitsch S , Beck S , Pfeiffer N , Grus F H -*

SIS

13:30 - 15:00 | RHODES 2

COS/RV - Emerging solutions in ophthalmology

This SIS cross-sectional thematizes cutting-edge developments to approach unmet needs in ophthalmology.

FUCHSLUGER T , STEFANSSON E

3531		13:30	Presence of proteinase inhibitor-9 and granzyme B in healthy and pathological human corneas *JIRSOVA K , Reinstein Merjava S , Chudickova M , Holan V - Prague*
3532		13:48	Transduction of corneal endothelial cells with AAV2 vectors *GRUENERT A - Erlangen*
3533		14:06	Agonistic β2 receptor autoantibodies in ocular hypertension and open-angle glaucoma *HOHBERGER B - Erlangen*
3534	*	14:24	Automated intravitreal injection system for the efficient treatment of AMD *ULLRICH F - Zürich*
3535		14:42	Ocular drug delivery with cyclodextrin nanoparticles: Anterior segment advantages and posterior segm *STEFANSSON E - Reykjavik*

SIS

13:30 - 15:00 | RHODES 3

PO - Topical and intravitreal pharmacotherapy in ocular oncology

In ocular oncology, a great variety of therapeutic agents are used for topical chemotherapy of the conjunctival as well as for intravitreal specific chemotherapy. In addition, numerous anti-VEGF drugs are administrated in order to prevent or to treat irradiation induced side effects. The aim of this SIS is to bring together experts in ocular oncology in order to present a comprehensive overview of this subject.

ZOGRAFOS L , DESJARDINS L

3541		13:30	Topical chemotherapy for pigmented and epithelial tumors of the conjunctiva *DESJARDINS L - Paris*
3542		13:45	Neovascular glaucoma. Prevention and treatment with intravitreal anti-VEGF's in ocular oncology *SCHALENBOURG A - Lausanne*
3543		14:00	Irradiation induced maculopathy. Pathogenesis and therapeutic approach with anti-VEGF's *ZOGRAFOS L - Lausanne*
3544	*	14:15	Intravitreal pharmacotherapy of CME related to conservative management of uveal melanomas *BECHRAKIS N E - Innsbruck*
3545		14:30	Intravitreal chemotherapy for intraocular lymphomas *CASSOUX N - Paris*
3546		14:45	Retinal toxicity following intra-vitreal injections of melphalan *MUNIER F , Gaillard M C , Stathopoulos C , Beck-Popovic M - Lausanne*

Friday, Oct 7 - First afternoon session

13:30 - 15:00 | RHODES 4

EUPO session 3 - Neuro-ophthalmology
Uncommon but Important Causes of Visual Loss

EUPO Programme, see pages 134-135.

13:30 - 15:00 | GALLIENI 1+2

EOVS - FP session - Electrophysiology - protocols & applications

CASTELO-BRANCO M , KRASTEL H

3561	13:30	Flash adaptometry in congenital stationary night blindness *KRASTEL H , Zyganow M , Mai M , Schlichtenbrede F - Neckargemünd*
3562	13:42	Comparison of perceptual eye positions among patients with different degrees of anisometropia *ZENG J , Yang C , Yang X , Yan L - Guangzhou*
3563	13:54	Retinal microcysts associated with optic atrophy in children - visual electrophysiology studies *THOMPSON D , Henderson R , Moore W , Liasis A , Keenan J , Bowman R - London*
3564	14:06	Comparison of multifocal pattern ERG responses to luminance and chromatic contrast stimulations *CHARLIER J - Perenchies*
3565	14:18	A new electroretinogram function that can move the centre of the multifocal hexagonal stimulus array *SUZUKI N , Yamane K - Numazu*
3566 *rf*	14:30	Analysis of macular sensitivity using multifocal electroretinogram and microperimetry in Central Serous Chorioretinopathy patients after half-dose photodynamic therapy *ROCHA DE SOUSA A , Rosinha P , Rodrigues-Araújo J , Alves-Faria P , Costa A , Falcão-Reis F , Penas S - Porto*
3567 *rf*	14:36	Systematic assessment of clinical methods to diagnose and monitor diabetic retinal neuropathy *JENKINS K S , Rowan A , Layton C - Brisbane*

SIS

13:30 - 15:00 | GALLIENI 4

IM - How to publish your scientific work?

Scientific writing is not an easy task. This sessions aims is to equip you with the basic knowledge and skills to transform your ideas and findings into a research article. It further will give you insights into the role as author, editor and reviewer in the publication process.
Who should attend?:
This session provides all individuals (at all levels) interested in scientific publishing an opportunity to deepen their knowledge.
What can you expect?:
The panelists will offer practical advices in the process of writing up. In addition, the personal view from an authors and editors perspective will be given in a vivid discussion with the participants.

PLEYER U

3571	13:30	What do we need as author, editor and publisher? *DUA H S - Nottingham*
3572	13:52	Essentials of a good article *STEFANSSON E - Reykjavik*
3573	14:14	How to keep your work published? *KIVELÄ T - Helsinki*
3574	14:36	The review process - Reviewer friend or foe? *PLEYER U - Berlin*

FP

13:30 - 15:00 | GALLIENI 5

MBGE - FP session - MBGE

BUJAKOWSKA K , SCHWARZ N

3581	13:30	Molecular study of the MFRP gene in patients with posterior microphthalmia (MCOP) supports its role in autosomal recessive MCOP pathogenesis *ALMOALLEM B , Arno G , De Zaeytijd J , Hull S , Suzani M , De Ravel T J L , Webster A , Leroy B P , Moore T , De Baere E - Ghent*
3582	13:42	Phenotype of maculopathy in primary hyperoxaluria type 1 *DERVEAUX T , Delbeke P , Walraedt S , Raes A , Van Laecke S , Leroy B P , De Zaeytijd J - Gent*
3583	13:54	Molecular mechanisms of X-linked retinitis pigmentosa *ZHANG X , Shu X - Glasgow*
3584	14:06	Gene transfer of prolyl hydroxylase domain 2 inhibits hypoxia-inducible angiogenesis in a model of choroidal neovascularization *ANDRE H , Mammadzada P , Tunik S , Takei A , Ekström M , Yu M , Aronsson M , Kvanta A - Stockholm*
3585	14:18	Autophagy is affected by Mitf in mouse primary RPE cells *GARCIA LLORCA A , Ogmundsdóttir M H , Steingrimsson E , Eysteinsson T - Reykjavík*
3586	14:30	Splice-site mutation in the Bmpr1b gene of the mouse causes optic nerve head dysgenesis and retinal gliosis *GRAW J , Yan X , Amarie O V , Puk O , Sabrautzki S , Klaften M , Thiele F , Fuchs H , Hrabe de Angelis M - Neuherberg*

POS

15:00 - 16:00 | POSTER AREA

NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History

F001 - F047

BORRUAT F , BREMOND-GIGNAC D

F001 *rf* Automated evaluation of peripapillary choroidal thickness in nonarteritic anterior ischemic optic neuropathy
MUNOZ - NEGRETE F J , Rebolleda G , Perez Sarriegui A , De Juan V - Madrid

F002 Optical coherence tomography in patients with amyotrophic lateral sclerosis
ROJAS LOZANO M P , Salobrar-García E , Salazar J J , Ramírez A , Urcelay Segura J L , Muñoz Blanco J L , Ramírez J M - Madrid

F003 Retinal nerve fiber layer atrophy in patients with multiple sclerosis: Longitudinal 5 years study
GARCIA MARTIN E , Satue M , Rodrigo M J , Obis J , Cipres Alastuey M , Vilades E , Otin S , Polo V , Larrosa J M , Pablo L , Gracia H - Zaragoza

F004 Assessment of visual function and structural retinal changes in Zen meditators
GARCIA MARTIN E , Satue M , Rodrigo M J , Obis J , Cipres Alastuey M , Vilades E , Otin S , Polo V , Larrosa J M , Pablo L , Gracia H - Zaragoza

F005 Reduction in peripapillary retinal thickness after Thalidomide Treatment in Patients with POEMS Syndrome
HIROTAKA Y , Toshiyuki O , Masayasu K , Takayuki B , Shuichi Y - Chiba

F006 Visual dysfunction and retinal changes in patients with multiple sclerosis
RODRIGO M J , Obís J , Cipres Alastuey M , Vilades E , García-Martín E , Satué M - Zaragoza

F007 Effects of current treatments in progressive retinal nerve fiber layer loss in multiple sclerosis patients
SATUE M , Rodrigo M J , Obis J , Cipres Alastuey M , Vilades E , Garcia-Martin E - Zaragoza

F008 Evaluation of progressive visual dysfunction and degeneration of the retinal nerve fiber layer and macular thickness in patients with Parkinson disease.
SATUE M , Rodrigo M J , Obis J , Cipres Alastuey M , Vilades E , Garcia-Martin E - Zaragoza

F009 Visual dysfunction and its correlation with retinal changes in patients with Alzheimer´s disease
VILADES E , Garcia-Martin E , Satue M , Rodrigo M J , Obis J , Cipres Alastuey M - Zaragoza

F010 Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease
VILADES E , Garcia-Martin E , Satue M , Rodrigo M J , Obis J , Cipres Alastuey M - Zaragoza

F011 Optical Coherence Tomography to distinguish parkinson disease versus supranuclear progressive palsy
REBOLLEDA G , Sanchez Sanchez C , Martinez Castrillo J C , Gonzalez Lopez J J , Oblanca Llamazares N , Muñoz-Negrete F J - Madrid

F012 Analysis of retinal and choroidal thickness in the macular area in patients with Parkinson´s disease using swept-source optical coherence tomography
OBIS J , Cipres Alastuey M , Villades E , Garcia-Martin E , Satue M , Rodrigo M J - Zaragoza

F013 Analysis of the peripapillary retinal nerve fiber layer and choroidal thickness in patients with Parkinson´s disease using swept-source optical coherence tomography
OBIS J , Cipres Alastuey M , Villades E , Garcia-Martin E , Satue M , Rodrigo M J - Zaragoza

F014 Macular thickness and retinal layer measurements in multiple sclerosis patients using new Swetpt-Source Optical coherence tomography Triton device
CIPRES ALASTUEY M , Vilades Palomar E , Garcia Martín E , Satué M , Rodrigo M J , Obis Alfaro J - Zaragoza

Friday, Oct 7 - Poster session 2

15:00 - 16:00 | POSTER AREA

NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History

F001 - F047

F015		Retinal nerve fiber layer measurements in multiple sclerosis patients using new Swetpt-Source Optical coherence tomography Triton device *CIPRES ALASTUEY M , Vilades Palomar E , Garcia Martín E , Satué M , Rodrigo M J , Obis Alfaro J - Zaragoza*
F016		Normative values for optical coherence tomography parameters in children and inter-examiner agreement of choroidal thickness measurements *ERKAN TURAN K , Taylan Sekeroglu H , Baytaroglu A , Bezci F , Karahan S - Ankara*
F017		Early changes in mild Alzheimer's disease in the neuroretinal rim segmentation *SALOBRAR-GARCIA E , Leal M , Hoyas I , Salazar J J , Ramirez A I , De Hoz R , Rojas B , Gil P , Yubero R , Triviño A , Ramirez J J - Madrid*
F018		Maculopapillary analysis in the posterior pole in patients with mild Alzheimer's disease *SALOBRAR-GARCIA E , Garcia Y , Lostao C , Jañez L , De Hoz R , Rojas B , Salazar J J , Ramirez A I , Gil P , Yubero R , Triviño A , Ramirez J M - Madrid*
F019	*rf*	Visual outcomes of fractionated radiotherapy in optic nerve sheath meningioma *KHEIR V , Borruat F X - Lausanne*
F021		Papilledema secondary to internal jugular veins thrombosis in a peritoneal dialysis patient *BRAGA J , Loureiro M , Barros P , Gomes A M , Meira D - Vila Nova de Gaia*
F022		MonPack One and multiple sclerosis *RODRIGO M J , Obís J , Cipres Alastuey M , Vilades E , García-Martín E , Satué M - Zaragoza*
F023		Wave-amplitude differences between corneal and conjunctival electrodes for multifocal electroretinogram *MUNOZ - NEGRETE F J , Rebolleda G , Garcia Garcia A - Madrid*
F024	*	Treatment of visual impairment in patients with Leber's Hereditary Optic Neuropathy (LHON) using Idebenone (Raxone®) *METZ G , Hasham S , Catarino C , Klopstock T - Liestal*
F025		Clinical and radiological evidence of meningioma growth due to gestational or exogenous hormones: 2 cases *MARCELIS W , Sys C , Acou M , Leroy B P , Kestelyn P , De Schryver I - Gent*
F026		Pupillary reaction according to a balance autonomic nervous organ of vision in healthy children *BUSHUYEVA N , Dukhayer S , Slobodianyk S - Odessa*
F027		Paraneoplastic retinopathy and optic neuropathy with Waldenström Macroglobulinemia *OZTURK N , Havelange V , Draganova D , Boschi A - Bruxelles*
F028		Eye position under general anesthesia in orthophoric children *MANOLI P , Auckburally M , Jullienne R , Thuret G , Gain P , Lebranchu P , Pechereau A - Saint Etienne*
F029		Learning curves for strabismus surgery in two ophthalmologists *MOOSANG K - Chuncheon*
F030		Surgical Effect of Medial Rectus Posterior pulley fixation in Esotropia greater at near fixation *CHOI H Y , Jeon H - Busan*

POS

15:00 - 16:00 | POSTER AREA

NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History

F001 - F047

F031	Strabismus in Children with Periventricular leukomalacia: MRI correlation *CHOI H Y , Jeon H - Busan*
F032	Normal Range of Eye Movement and Its Relationship to Age *SHIN Y , Lim H W , Kang M H , Seong M , Cho H , Kim J H - Guri*
F033	Surgical treatment of pediatric strabismus (PS): series of 148 patients *RAHMANIA N , Van Rompay T , Morfeq H , Promelle V , Milazzo S - Amiens*
F034	Long term results of concomitant strabismus treatment based on operation preliminary modeling using three-dimensional biomechanical eye model *BUSHUYEVA N , Romanenko D - Odessa*
F035	Accommodation and fusion in patients with constant and intermittent exotropia *BOYCHUK I , Aloui T - Odessa*
F036	Early childhood blindness – etiologies and comorbidity *LOFGREN S , De Verdier K , Ek U , Fernell E - Stockholm*
F037	Symmetric tarsal show is crucial in creating upper eyelid symmetry *DE GROOT V - Edegem*
F038	Orbital cellulitis in a child with sickle cell anemia *MARTINEZ M , Pérez D , Ramiro P , Remón L , Bartolomé I , Berniolles J , ASCASO J - Zaragoza*
F039	ROP laser treatment based on fluorescein angiography classification *GUAGLIANO R , Barillà D , Bertone C , Maffia A , Verticchio Vercellin A C , Bianchi P E - Pavia*
F040	Normative values of retinal vessel oximetry in healthy children against adults *WAIZEL M , Kazerounian S , Türksever C , Todorova M G - Basel*
F041	Evaluation of monotherapy of intravitreal Bevacizumab in retinopathy of prematurity stage 3 plus *SHIRZADEH S - Mashhad*
F042	Phakic intraocular lens (Verisyse) implantation for correction of high anisometropia in pediatric patients *AUTRATA R , Krejcirova I , Griscikova L - Brno*
F043	Excimer laser correction for myopic anisometropic amblyopia in pediatric patients-Long term results *AUTRATA R , Krejcirova I , Griscikova L - Brno*
F044	Comparaison of the Plusoptix A12 and the 2WIN with the Retinomax K-plus 3 in a pediatric population *BOUVIER R , Heripret A , Promelle V , Milazzo S - Amiens*
F045	Rupture of Descemet's membrane associated with forceps delivery *IDOATE A , Ascaso F , Perez D , Remón L , Perez I , Almenara C , Esteban O , Martinez M , Sanchéz J I , Berniolles J , Bartolomé I - Zaragoza*
F046	Congenital aniridia: an epidemiological approach on 105 patients *SALVIAT F , Robert M , Michel S , Bremond-Gignac D - Paris*
F047	Does macular pigment optical density really matter in children? *ERKAN TURAN K , Cankaya A B , Taylan Sekeroglu H , Inam O , Karahan S - Ankara*

POS

15:00 - 16:00 | POSTER AREA

RV - Retina/Vitreous

F048 - F114

DE LAEY JJ , BAILLIF S

F048 *rf*
Unexplained vision loss with intra-ocular silicone oil tamponade in situ; a case series
SILVESTER A , Cazabon S - West Kirby

F049
Macular hole angle as a surgery prognostic factor
ROCHA DE SOUSA A , Silva M I , Morais A S , Falcao M , Falcao-Reis F - Porto

F050
Novel clinical method for preventing condensation in noncontact wide-angle viewing systems
KWON S , Choi D , Park I , Lee J P - Anyang-Si

F051
Retinal toxicity by intravitreal liquid perfluorocarbon
MONTERO MORENO J A , Ruiz-Moreno J M , Fernandez-Munoz M , Amat-Peral P - Valladolid

F052
Late reopening of successfully treated macular holes after combined phaco-vitrectomy ILM peel and gas
PONOMARENKO M , Lochhead J - Cowes

F053
Silicone oil tamponade in the treatment of persistent macular holes
GRAJEWSKI L , Carstens J , Krause L - Dessau

F054
Unusual presentation of an intraocular foreign body with double – perforation and retention in lateral rectus muscle
PONOMARENKO M , Lochhead J - Cowes

F055
Correlation between intraocular pressure and bottle heights during vitrectomy
MOOSANG K - Chuncheon

F056
Iatrogenic Ozurdex® injection into the crystalline lens and surgical management
SANCHEZ MARIN J I , Ascaso F , Pérez Navarro I , Almenara C , Martínez V. M , Estebán Floría O , Idoate A , Berniolles J , Bartolomé I - Zaragoza

F057 *
A review of intraocular foreign body injuries and their management in the Palestinian territories 2000-2009
KANAVATI S , Almuhtaseb H , Sargent N , Kanawati C - Southampton

F058 *rf*
Static retinal vessel analysis in routine optometric practice
FRENCH C , Heitmar R - Birmingham

F059 *rf*
Trial study to automatically distinguish small haemorrhages in early diabetic retinopathy from image artefacts
SUZUKI N , Yamane K - Numazu

F060
Age macular degeneration: clinical, biological, morphologic, structural biomarkers for neovascular complication
GONZALEZ C - Toulouse

F061
Age macular degeneration: clinical, biological, morphologic, structural biomarkers for atrophy complication
GONZALEZ C - Toulouse

F062
Retinal astrocytic hamartomas: 2 cases of atypical clinical presentation
BOUTELEUX V , Tick S , El Chehab H , Mendes M , Agard E , Russo A , Dot C - Lyon

F063
Fundus autofluorescence and SD-OCT in progressive cone dystrohy
HASSAIRI A , Falfoul Y , Turki A , Maamouri R , El Matri K , Chebil A , El Matri L - Tunis

F064
En-face Imaging of epiretinal membrane using swept source optical coherence tomography
KIM J T , Chung H - Seoul

POS

15:00 - 16:00 | POSTER AREA

RV - Retina/Vitreous

F048 - F114

F065		Visualization of neovascular changes by swept source OCT angiography *SZAFLIK J P , Szaflik M - Warszawa*
F066		En face OCT of uncomplicated angioid streaks *PERESTRELO S - Porto*
F067		Outer retinal reflectivity on En-face OCT as a new tool to detect early stage hydroxychloroquine maculopathy *VIOTTE A , Bigan G , Flores M , Girard C , Delbosc B , Saleh M - Besancon*
F068		Modern diagnostic methods used in macular telangiectasia *ROMANOWSKA DIXON B , Karska Basta I , Lesniak A - Krakow*
F069		Ganglion cell-inner plexiform layer thickness and visual improvement after vitrectomy for rhegmatogenous retinal detachment *LEE J Y , Kim D Y , Kim J Y - Jeju-siJeju-do*
F070		Spectral domain optical coherence tomography for detecting retinal arterial macroaneurysm *ASCASO F J , Berniolles J , Bartolomé I , Martínez M , Esteban O , Sánchez I , Almenara C , Del Buey M A - Zaragoza*
F071	*	Enhanced visualization of retinal vasculature in fundus images through image processing *KIM Y T , Choi S H - Seoul*
F072		The effect of center shift on the measurement of macular thickness: A spectral domain optical coherence tomography study *KIM J Y , SHIN K S , Lim H B , Shin I H - Daejeon*
F073	*rf*	Tomographic analysis of the retinal layers in diabetic macular edema treated with dexamethasone intravitreal implant *MEDEIROS PINTO J , Prates Canelas J , Rosa R , Coelho C , Vaz-Pereira S - Lisbon*
F074	* *rf*	Deep learning approach for diabetic retinopathy screening *COLAS E , Besse A , Orgogozo A , Schmauch B , Meric N , Besse E - Paris*
F075	*rf*	Iluvien monotherapy for diabetic macular oedema in vitrectomised and non-vitrectomised eyes: one year data *HAWRAMI A , Laviers H , Patra S , Zambarakji H - London*
F076	*rf*	Frequency doubling technology perimetry and retinal fiber layer correlation in type 2 diabetics without retinopathy *ALDAHAM S , Martín-Ridaura M D C , Puell M C - Madrid*
F077	*rf*	Diabetic maculopathy screening in England; are we seeing too much? *BEGUM S , Macgregor C , Meredith P , Cansfield J , Meredith S - Portsmouth*
F078	*rf*	Correlation between choroidal and retinal thickness in diabetic patients without diabetic retinopathy *CARDIGOS J , Proenca R , Vicente A , Marques N , Cunha J P , Abegao Pinto L , Ferreira J - Lisbon*
F079	*rf*	SD-OCT for study of retinal layers segmentation in patients under Hydroxychloroquine treatment *COSTA L , Basílio A L , Proença R , Cunha J P , Vieira L , Flores R , Santos A - Lisbon*
F080		Vitreous and serum VEGF levels after intravitreal injection of bevacizumab, ranibizumab and triamcinolone acetonide in patients with proliferative diabetic retinopathy *SOZEN-DELIL F I , Cekic O , Haklar G - Istanbul*

POS

15:00 - 16:00 | POSTER AREA

RV - Retina/Vitreous

F048 - F114

F081		The change of Ganglion cell layer and Inner plexiform layer thickness in Type 2 DM with non-proliferative diabetic retinopathy *CHOI C , Mun S J - Iksan-si*
F082		Improvement of diabetic macular edema after micropulse laser therapy *EL MATRI L , Falfoul Y , Chebbi Z , Kortli M , El Matri K , Chebil A - Tunis*
F083		Novel OCT prognostic indicators in diabetic macular oedema *MANNS R , Begum S , Mourtzoukos S - Portsmouth*
F084		Macular thickness in diabetic eyes without clinical macular edema *GARCIA ZAMORA M , Montero Moreno J A , Gonzalez Uruena C , Frances Caballero E , Fernandez-Munoz M - Valladolid*
F085		Contribution of wide field angiography to diabetic macular edema *MAAMOURI R , Bouraoui R , Kort F , Falfoul Y , El Matri K , El Matri L - Tunis*
F086		Peripheral vessel leakage in diabetic retinopathy using Wide field retinal angiography *MAAMOURI R , Bouraoui R , Fedra K , Hassairi A , El Matri L - Tunis*
F087		The predictive value of retinal fixation for the visual outcome after anti-VEGF treatment of diabetic macular oedema with center involvement *STÆHR JAKOBSEN N , Ancher Larsen D , Bek T - Aarhus C*
F088		Selective Retina Therapy (SRT) for diabetes macular edema in Korean patients: 12-months results *PARK Y G , Roh Y J - Seoul*
F089		Comparison of efficacy of intravitreal ranibizumab and aflibercept in eyes with diabetic macular edema *OSHITARI T , Shimizu N , Tatsumi T , Takatsuna Y , Arai M , Sato E , Yamamoto S - Chiba*
F090		Factors influencing intravitrealBevacizumaband triamcinolone treatment in patients with diabetic macular edema *LEE M Y - Uijeongbu-Si*
F091	*rf*	Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention *FRUSCHELLI M , Fazio S , Capozzoli M , Chimenti G , Hadjistilianou T , Sicuranza A , Aprile L , Puccetti L - Siena*
F092		Analysis of SD-OCT prognostic factors in macular edema associated with retinal vein occlusion *BOURAOUI R , Bouladi M , Dhouib N , Mghaieth F , Limaiem R , Chaker N , El Matri L - Tunis*
F093		Correlation of foveal bulge on SD-OCT and visual acuity in resolved macular edema associated with branch retinal vein occlusion *BOURAOUI R , Dhouib N , Bouladi M , Zerei N , Maamouri R , Chaker N , El Matri L - Tunis*
F094		Electric shock-induced retinal vein occlusion: a propos of two cases *ASCASO F J , Bartolomé I , Berniolles J , Esteban O , Martínez M , Almenara C , Sánchez I , Honrubia A , Núñez E - Zaragoza*
F095		Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion *KONIDARIS V , Gorgoli K , Burgula S , Deane J , Banerjee S , Empeslidis T - Leicester*

POS

15:00 - 16:00 | POSTER AREA

RV - Retina/Vitreous

F048 - F114

F096 Relationship between visual outcomes and initial optical coherence tomographic findings in macular edema secondary to branch retinal vein occlusion after bevacizumab treatment
KWON Y H , Kim S T , Ahn H - Busan

F097 Characteristics of retinal vein occlusion (RVO) patients with macular edema who lasted remission more than 6 months after single injection of intravitreal bevacizumab.
LEE M Y - Uijeongbu-Si

F098 The 1 year outcome of intravitreal dexamethasone implant for macular edema secondary to central retinal vein occlusion
KIM H W , Chung I Y , Lee J E , Kim K - Busan

F100 Changes in choroidal thickness after ranibizumab and aflibercept Therapy for treatment-naïve wet age-related macular degeneration
KANG H G , Kim J S , Lee J H , Kim Y I , Lee S H - Daegu

F101 Impact of intravitreous bevacizumab injections on perceived quality of life in a cohort of patients with exudative age related macular degeneration. Real life results at 4 years
MONTERO MORENO J A , Arnaiz C , Martinez-Perez L , De la Fuente A , Gonzalez Uruena C - Valladolid

F102 Prevalence and incidence of epimacular membranes in patients with wet AMD
RICOUARD F , Foveau P , Zimmermann A , Conart J B , Gaucher D , Saleh M - Besancon

F103 Spontaneous anatomical improvement on OCT findings in patients with neovascular age-related macular degeneration without anti-VEGF treatment.
KIM K H , Yang S J - Gangneung-siGangwon-do

F104 Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age-related macular degeneration patients
KWON Y H , Min J S , Ahn H - Busan

F105 Licence to save - A UK survey of anti-VEGF use for the eye in 2015
SHALABY A , Lockwood A , Bush A , Lewis K , Di Simplicio S , Meredith P - Solihull

F106 The long-term effect of intravitreal bevacizumab injection in central serous chorioretinopathy
MUN S J , Choi C , Jeong J G - Jeonju

F107 Spironolactone in the treatment of nonresolving central serous chorioretinopathy: A comparative analysis
LEE J Y , Kim D Y , Kim J Y - Jeju-siJeju-do

F108 Retinal microangiopathy as primary manifestation of systemic lupus erythematosus
ALMENARA C , Núñez E , Ascaso F , Pérez I , Martínez M , Esteban O , Sánchez J I , Idoate A , Bartolomé I , Berniolles J , Cristóbal J A - Zaragoza

F109 Ophthalmic findings before carotid endarterectomy in the ipsilateral and contralateral eye
ALA-KAUHALUOMA M , Vikatmaa P , Vikatmaa L , Ijäs P , Nuotio K , Koskinen S , Silvennoinen H , Lindsberg P , Soinne L , Summanen P - Helsinki

F110 Short-term efficacy of intravitreal aflibercept depending on subtypes of polypoidal choroidal vasculopathy: polypoidal choroidal neovascularization or idiopathic choroidal vasculopathy
SAGONG M , Jeong S - Daegu

POS

15:00 - 16:00 | POSTER AREA

RV - Retina/Vitreous

F048 - F114

F111	Vitreous and serum Hsp 70 levels in rhegmatogenous retinal detachment *SOZEN-DELIL F I , Cekic O , Haklar G - Istanbul*
F112	Assessment of choroidal thickness and retinal nerve fiber layer thickness before and after G training using swept-source optical coherence tomography *KIM D Y , Song J H , Kim J H , Hyung S , Choi K , Kim J Y , Chae J B - Cheongju*
F113	Itraconazole inhibits laser-induced choroidal neovascularization in rats by suppressing VEGFR2 expression *BAE J H , Kim S H , Lee J H , Kim D Y , Kim H T , Lee S C - Seoul*
F114	A case of bilateral central serous chorioretinopathy secondary to Cobimetinib treatment *MARTINEZ M , Idoate A , Honrubia A , Esteban O , Sánchez J I , Perez I , Almenara C , Ascaso J - Zaragoza*

Friday, Oct 7 - Second afternoon session

16:00 - 17:30 | RHODES 4

EUPO session 4 - Neuro-ophthalmology

Recognizing the Emergencies: From Symptom to Diagnosis

EUPO Programme, see pages 134-135.

BM

16:00 - 16:30

Section Business Meetings

- **ACB ..... Gallieni 4**
- **COS ..... Rhodes 2**
- **EOVS ..... Rhodes 1**
- **G ..... Rhodes 1**
- **IM ..... Gallieni 1+2**
- **LC ..... Gallieni 5**
- **MBGE ..... Gallieni 1+2**
- **NSPH ..... Rhodes 2**
- **PBP ..... Rhodes 3**
- **PO ..... Rhodes 3**
- **RV ..... Hermes**

Agenda

1. Report of the chair of section

2. Report of the programme secretary

3. Next year's meeting:
    - nomination of the 2017 section programme secretary (different from the section chair)
    - proposals of 2017 Special Interest Symposia (SIS)
    - proposals of 2017 Courses
    - proposals for 2018 Keynote speakers

4. Comment on the EVER activities

5. Other business

In addition to the agenda, the sections COS and G will nominate at least 2 candidates for section chair 2017 - 2021

Friday, Oct 7 - Second afternoon session

16:30 - 18:00 | HERMES

FAN Club

Cases with retinal imaging are presented and discussed with a panel.
Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates.
Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

www.fan-int.org

16:30 - 18:00 | RHODES 1

G - Implications of neuro-glial interactions in neurodegenerative diseases

Retinal neurons rely on oxygen and nutrient supply as well as on the removal of toxic neurotransmitters and metabolites from the interstitial space. The maintenance of this homeostasis depends on tightly regulated neuro-glial interactions. Increasing evidence indicates that neurodegenerative conditions and optic nerve diseases are associated with dysfunctional glial cells leading to neuronal damage. However, the mechanisms that promote and maintain neuro-glial energy exchange are poorly understood. The proposed symposium seeks to create a multidisciplinary discussion on the importance of neuro-glial interaction and its regulation in the pathogenesis of optic nerve, retinal and brain neurodegenerative diseases.

KOLKO M , WAAGEPETERSEN H

3621	16:20	Is glutamate dehydrogenase in astrocytes one of the keys to control brain glutamate homeostasis? *WAAGEPETERSEN H - Copenhagen*
3622	16:42	Is neurodegenerative retinal diseases the result of disturbed energy metabolism in Müller cells? *KOLKO M - Roskilde*
3623	17:04	Current neuroprotective strategies in glaucoma – implications of neuro-glial interactions *CORDEIRO M F - London*
3624	17:26	Optic nerve energy metabolism: the role of astrocyte glycogen *RANSOM B - Seattle*

SIS

16:30 - 18:00 | RHODES 2

COS - Corneal neovascularization and immune privilege

This SIS provides an overview of current developments in corneal neovascularization, anti-VEGF approaches and molecular mechanisms of the corneal immune privilege.

HORI J , CHEN L , ZHANG H

3631		16:20	New insights into corneal lymphangiogenesis *CHEN L - Berkeley*
3632		16:38	MiRNA-126 regulation in corneal neovascularization *ZHANG H -*
3633		16:56	Identifying VEGF-independent factors for targeted antiangiogenic therapy in the cornea *LAGALI N , Mukwaya A , Mirabelli P , Jensen L , Xeroudaki M , Ali Z , Peebo B - Linköping*
3634		17:14	Molecular mechanisms of immune privilege of the cornea - as a potential of Immune checkpoint therapy *HORI J - Tokyo*
3635		17:32	Corneal neovascularization: clinical aspects and the role of the immune system *BONINI S - Rome*

JM

16:30 - 18:00 | RHODES 3

PO: OOG Session 1

KIVELÄ T , HADJISTILIANOU T

3641		16:30	Late intraocular relapses in retinoblastoma *HADJISTILIANOU T , Borri M , Defrancesco S , Munier F , Galluzzi P , Bracco S , Galimberti D , Menicacci F , Coriolani G - Sienna*
3642		16:42	Management of unilateral retinoblastoma with buphthalmia *ANGI M , Lumbroso Le Rouic L , Levy C , Desjardins L , Cassoux N - Milan*
3643		16:54	Intraarterial and intravitreal chemotherapy in the combined treatment in children with group C and D intraocular retinoblastoma *SAAKYAN S - Moscow*
3644		17:06	New challenges in retinoblastoma treatment *DESJARDINS L , Angi M , Levy C , Lumbroso Le Rouic L , Aerts I , Freneaux P , Brisse H , Cassoux N - Paris*
3645	*rf*	17:18	Clinical and morphometric investigation of retinopathy in children with retinoblastoma treated with chemotherapy *SAAKYAN S - Moscow*
3646	*rf*	17:24	Congenital Malignant Ciliary Body Medullepithelioma in Two newborns *HADJISTILIANOU T , Mittica P , Bagaglia S , Fruschelli M , Menicacci C , Fusco F , Defrancesco S , Borri M , Galluzzi P - Sienna*
3647		17:30	Unravelling the potential of secreted frizzled related protein 3 as a vascular marker *MADIGAN M , Gu R , Gilan P , Eamegdool S - Sydney*

C

16:30 - 18:00 | GALLIENI 1+2

PBP - Ocular pulse amplitude - from pole to pole

Intermediate

OPA is defined as the difference between systolic and diastolic intraocular pressure (IOP) and represents the pulsatile wave front produced by the varying amount of blood in the eye during the cardiac cycle. It is an important parameter in ocular blood flow and has been shown to vary be able to provide information concerning the autonomic nervous system input. Furthermore, it can be influenced by the structural properties of the eye, such as corneal thickness, and ocular rigidity, as well as with systemic variables like heart rate, blood pressure, and left ventricular ejection fraction.
The concept of this course is to provide the audience with a oriented review of the current data on OPA, its physiological meaning and how we measure it. The strenghts and caveats of the measurement of this parameter will be discussed as well as the potential of translating this information into clinical practice.

ABEGAO PINTO L , MARQUES-NEVES C

3661	16:20	Fundamental principals and applied biophysics *MARQUES-NEVES C - Lisbon*
3662	16:42	OPA analysis - oscillatory and autonomic influence *SCHMIDL D - Vienna*
3663	17:04	Physiology and clinical relevance of this parameter *ABEGAO PINTO L - Lisbon*
3664	17:26	Use of OPA in ocular blood flow studies *WILLEKENS K , Van Keer K , Vandewalle E , Molenberghs G , Pinto L A , Barbosa-Breda J , Stalmans I - Leuven*

FP

16:30 - 18:00 | GALLIENI 4

IM - FP session - New insights in imaging in ocular immunology

HERBORT CP , NERI P

3671	16:30	EDI-OCT is less suited for close monitoring of primary stromal choroiditis when compared to Indocyanine green angiography *HERBORT C P , Balci O , Gasc A , Jeannin B - Lausanne*
3672	16:42	Analysis of choroidal folds in Acute Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography *NAKAI K , Tsuboi K - Osaka*
3673	16:54	Comparison of retinal and choroidal involvement in sarcoidosis chorioretinitis *EL AMEEN A , Herbort C P - Evian*
3674	17:06	Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt-Koyanagi-Harada disease *BALCI O , Jeannin B , Herbort C P - Istanbul*

JM

16:30 - 18:00 | GALLIENI 5

GOA - Update on severe allergic conjunctivitis

Severe allergic conjunctivitis in children may be severe causing loss of quality of life and visual impairment. Vernal keratoconjunctivitis and atopic keratoconjunctivitis are rare diseases but must be distinguished because of their evolution. Imaging of these diseases and systemic treatment are reviewed and developed. An overview of the innovating diagnosis, new imaging techniques and treatment are summarized for a better comprehension of severe allergic ocular surface diseases.

BREMOND-GIGNAC D , FAUQUERT J

3681	16:20	Atopic and vernal keratoconjunctivitis: differences and similarities *BREMOND-GIGNAC D - Paris*
3682	16:50	Imaging of allergic keratoconjunctivitis *CHIAMBARETTA F - Clermont Ferrand*
3683	17:20	Non-ocular treatments in ocular allergy *DELGADO L - Porto*

PS

18:00 - 18:30 | HERMES

EVER General Assembly

1. President's address by Aki Kawasaki
2. Minutes of the General Assembly 2015
3. Report of the Secretary General, Catherine Creuzot
4. Report of the Programme Secretary, Marcela Votruba
5. Report of the Treasurer, Steffen Heegaard :
    - approval of the accounts 2015
    - discharge to the directors
    - approval budget for 2016
6. Results of the elections
7. Presentation of the board 2017
8. Future congresses
9. Miscellanea
10. Handover of chain of office

EVER 2016
Saturday, Oct 8

SIS

8:30 - 10:00 | HERMES

NSPH/RV - The first ones in ophthalmology

This symposium will provide fascinating new insights into the first described case of some ophthalmological diseases and some of the great innovators and pioneers in diagnostic and therapeutic advances in Ophthalmology. This particular look to the history of our specialty begins with a paleopathological study of traumatic and infectious evidences of what seems to be the first documented case of orbital cellulitis in one the most complete and best preserved ancient hominid skulls ever found. The practice of Ophthalmology has a rich history that spans a lot of centuries. Since the first use of plants or surgery in the civilizations of the Fertile Crescent, the important discoveries have been generally simple, and one is apt to wonder why they were not made earlier. Then, we explore the beginnings of two important diagnostic imaging techniques: fluorescein angiography and ultrasonography. Finally, we include another example of historical interest: Charles-Michel Billard, the founder of Neonatology and an international figure in the field of Ophthalmology.

GRZYBOWSKI A , ASCASO F

4111	8:30	Homo heidelbergensis: the oldest case of odontogenic orbital cellulitis? *ASCASO F , Adiego M I - Zaragoza*
4112	8:48	The first cataract surgery *GRZYBOWSKI A - Olsztyn*
4113	9:06	The first steps in retinal angiography *DE LAEY J - J - Gent*
4114	9:24	The firsts in ophthalmic echography *KIVELÄ T - Helsinki*
4115	9:42	Charles-Michel Billard (1800-1832), the founder of neonatology and ophthalmology *FRANCESCHETTI A - Meyrin*

SIS

8:30 - 10:00 | RHODES 1

COS - Keratoconus diagnosis and treatment in the clinical practice

The applicability of treatment options for keratoconus and the prognosis of functional outcome and freezing of progression is mainly determined by the stage/severity of the disease. In early stages contact lenses are a viable option for visual rehabilitation, whereas progressed stages may require specialized rigid gas permeable contact lenses or keratoplasty. New options such as crosslinking and intracorneal ring segments aim to retard or even stop progression. However, they require a minimum of residual stromal thickness. Therefore, screening and early diagnosis of keratoconus is key in order to timely react with therapeutic options. Corneal topography and tomography as well as the assessment of corneal biomechanical properties are established tools for diagnosis of early keratoconus and a variety of indices are available assisting the ophthalmologist in keratoconus diagnosis. We will discuss the topographic, tomographic and biomechanical features of keratoconus, how keratoconus indices could assist clinical diagnosis and how keratoconus can be distinguished from other corneal conditions. In addition, we show the application of corneal tomography in the monitoring of corneal stabilization after crosslinking.

SZENTMARY N , ZSOLT NAGY Z

4121	8:30	Central keratoconus and bilateral asymmetry of keratoconus *LANGENBUCHER A , Szentmary N , Eppig T - Homburg*
4122	8:48	Interpretation of keratoconus indices *EPPIG T , Spira-Eppig C , Szentmáry N , Langenbucher A - Homburg/Saar*
4123	9:06	Keratoconus, keratoglobus, keratotorus and pellucid marginal degeneration *SZENTMARY N - Homburg/Saar*
4124	9:24	Relevance of the posterior corneal surface for detection of early keratoconus and post-LASIK keratectasia *WYLEGALA E - Katowice*
4125	9:42	Corneal tomographical changes following crosslinking *ZSOLT NAGY Z - Budapest*

C

8:30 - 10:00 | RHODES 2

COS - Corneal infectious diseases

Intermediate

Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we'll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections. We will also see how new techniques such as Amniotic Membrane Transplantation and Crosslinking can help the clinician, when facing severe cases.

GICQUEL JJ , BREMOND-GIGNAC D

4131		8:30	New breakthrough in severe corneal infections: GMA, cross linking *GICQUEL J - Saint Jean d'Angély*
4132		9:00	Specificities of corneal infectious diseases in children *BREMOND-GIGNAC D - Paris*
4133	*	9:30	Prevention of Herpes and Zoster keratitis *LABETOULLE M , Rousseau A - Le Kremlin Bicêtre*

JM

8:30 - 10:00 | RHODES 3

PO: OOG Session 2 & Business Meeting

HEEGAARD S , CASSOUX N

4141	*rf*	8:30	BAP1 germline mutations in uveal melanoma patients without family history of eye cancer *TURUNEN J , Markkinen S , Wilska R , Raivio V , Täll M , Lehesjoki A E , Kivelä T - Helsinki*
4142		8:42	Chromosomal aberration predict uveal melanoma mutation status *KILIC E , Yavuzyigitoglu S , Drabarek W , Obulkasim A , Brands T , Eussen B , De Klein A - Rotterdam*
4143		8:54	Inflammatory Cell Infiltrates in Metastatic Uveal Melanoma *KRISHNA Y , McCarthy C , Kalirai H , Coupland S - Liverpool*
4144	*rf*	9:06	Histomorphological changes of uveal melanoma (UM) following proton beam therapy (PBR) *QURESHI S , Hussain R , Kalirai H , Heimann H , Coupland S - Liverpool*
4145	*rf*	9:12	UM Cure 2020 - A Consortium of European experts in Uveal Melanoma to identify new therapies for patients with metastatic disease *COUPLAND S , Kalirai H , Jager M , Jochemsen A G , Van der Velden P A , Snaar-Jagalska B E , Dhomen N , Marais R , Romanowska Dixon B , Elas M , Mione M C , Valente A , Ryll B , Ruijtenbeek R , Prestat A , Hafsi H , Barnhill R , Cassoux N , Decaudin D , Lantz O , Piperno-Neumann S , Stern M H , Roman-Roman S - Liverpool*

9:18 ***Business meeting***

Saturday, Oct 8 - First morning session

8:30 - 10:00 | RHODES 4

EUPO session 5 - Strabismus

Paralytic Strabismus: Diagnosis, Evaluation and When to Treat

EUPO Programme, see pages 134-135.

8:30 - 10:00 | GALLIENI 1+2

FRO: Belgian Fund for Research in Ophthalmology 1

FRO candidates present their work to an international jury.

TASSIGNON MJ , CASPERS L

4161	8:30	Neuroinflammation as fuel for axonal regeneration: unravelling the underlying molecular players *ANDRIES L - Leuven*
4162	8:42	Metabolomic profile of surgical glaucoma patients *BARBOSA BREDA J - Porto*
4163	8:54	The interplay between dendrite and axon regeneration in central nervous system repair: which way to grow ? *BECKERS A - Leuven*
4164	9:06	Enhanced donor selection in the treatment of LSCD using advanced imaging techniques *BEHAEGEL J - Brussels*
4165	9:18	Intravitreal injection of mRNA containing nanoparticles to introduce sustained expression of neurothrophic factors in Müller celles *DEVOLDERE J - Ghent*
4166	9:30	Tissue engineering in Ophthalmology: Regenerating the anterior cornea using synthetic collagen-mimicking nanoscaffolds and Limbal Epithelial Stem Cells *HAAGDORENS M - Edegem*
4167	9:42	Role of TonEBP inthe inflammatory response of ARPE-19cells subjected to hyperosmolar stress *MASSET M - Bruxelles*
4168	9:54	3D printed recombinant human collagen scaffolds for corneal tissue engineering: an in vivo study of biocompatibility *MATTHYSSEN S - Edegem*

PS

10:20 - 10:50 | HERMES

Ophthalmic Research Lecture by Marie-José TASSIGNON

Introduction by José CUNHA-VAZ

4211

The cataract surgeon and the anterior interface

TASSIGNON MJ - Antwerpen

Summary:

Performing a posterior capsulorhexis on a routine basis related to the implantation of the bag-in-the-lens IOL has opened new frontiers in helping understanding the Berger space and its relation with the vitreous. It is only recent that this space could be observed life during surgery thanks to new OCT devices. This observation may open new understandings on the pathogenesis of vitreo-retinal complications after cataract surgery.

Award presentation of the EVER Certificate of Honour

Biography Marie-José TASSIGNON:

Marie-José Tassignon is born in 1952 in the French speaking part of Belgium. She was raised in French by her father and in Dutch by her mother. She completed her studies of medical doctor at the Free University of Brussels. She defended her PhD thesis in Leiden, The Netherlands, in 1990 and was appointed Chief of the Department of Ophthalmology of the Antwerp University Hospital and Chair of the Department of Ophthalmology of the Faculty of Medicine of the University of Antwerp in 1991. In 2007 she became Medical Director of the Antwerp University Hospital after having been Vice-Dean of the Faculty of Medicine of the University of Antwerp from 2003 to 2006. She is full professor at the University of Antwerp since 2003 and closely implicated in the national trainees educational program.

She was president and past-president of the European Society of Cataract and Refractive Surgeons (ESCRS) from 2004 until 2007 and was president and past-president of the European Board of Ophthalmology (EBO) from 2007 until 2008. She is member of 18 international societies in ophthalmology and was board member in 5 out of them. She was elected chair "L" of the International Academy of Ophthalmology (AOI) in 2007 and was elected chair "V" of the European Academy of Ophthalmology in 2008. She became Alumni of Pretoria University of South Africa in 2008 and full member of the Ukraine Academy of Medicine in 2012. She became member of the Royal Academy of Medicine of Belgium in 2009. She became boardmember of the International Council of Ophthalmology in 2016.

Seven patents have been approved out of which the patent of the original lens design called the bag-in-the-lens implantation technique and the caliper ring to perform a calibrated anterior capsulorhexis. This lens has been commercialized in Belgium in 2004 and is currently on its way to be accepted worldwide as technique to eradicate posterior capsule opacification. This technique has attracted quite some international ophthalmic surgeons as well as pediatric cataract surgeons to Antwerp since it eradicates the occurance of PCO in all patients regardless the age of surgery. It is also very attractive for vitreo-retinal surgeons because it keeps the visual axis free and is also attractive for complex optics intraocular lenses since it allows customized IOL centration.

Marie-José Tassignon was awarded the Kritzinguer award in 2003; the Binkhorts medal at ESCRS in 2011; the Norman Galloway award, Nottingham University, United Kingdom in 2014, the Academia Ophthalmologica Internationalis lecturer 2015; the Peter Eustace medal 2015 by European Board of Ophthalmology for excellence in education; the Montgomery lecture at the Royal College of Surgeons delivered by the Irish Council of Ophthalmology in 2015; the Tadeusz Krwawicz award at WOC 2016 and the Moroccan Ophthalmological award in 2016. She was honorary guest at the 27th International Congress of German Ophthalmic Surgeons, DOC in Nürnberg and guest professor at Michigan Eye Kellog's University in 2013 and at Harvard Massachusetts Eye and Ear in 2014. She received three best paper awards at ASCRS and five best video awards at videorefractiva, ESCRS and WOC. Marie-José Tassignon is author of 248 publications and of 23 chapters of 21 books but she is primarily mother of two children and grandmother of three grandchildren to date.

Saturday, Oct 8 - Second morning session

10:30 - 12:30 | RHODES 4

EUPO session 6 - Strabismus

Case Presentations I: Odd and Unusual Things in Strabismus Amblyopia , Nystagmus and Secondary Strabismus

EUPO Programme, see pages 134-135.

POS

10:50 - 12:00 | POSTER AREA

ACB - Anatomy/Cell Biology

S001 - S021

PETROVSKI G , KAARNIRANTA K

S001	Resvega induces autophagy and prevents ARPE-19 cell damage during proteasome inhibition *KOSKELA A , Reinisalo M , Olmiere C , Petrovski G , Sinha D , Karjalainen R , Kaarniranta K - Kuopio*
S002	Taking a roller coaster ride with autophagy markers p62 and LC3 *KOSKELA A , Reinisalo M , Kaarniranta K - Kuopio*
S003	Warfarin use among wet AMD patients *PATERNO J J , Ahola O , Järvikallio R , Kiviluoma J , Turtiainen H , Vuorinen I , Kaarniranta K - Kuopio*
S004	Melissa officials L. extracts protect human retinal pigment epithelial cells against oxidative stress-induced apoptosis. *KANG S , Shin J A , Oh J , Rho C R - Daejeon*
S005	Possible association with obesity-related loci and outcome of wet AMD *KAARNIRANTA K , Helisalmi S , Birling A , Saavalainen L , Tolppola O , Vajanto V , Uusitupa M , Paterno J J - Kuopio*
S006	HuR/ELAVL1 expression in the human cataractous lens *AMADIO M , Marchesi N , Govoni S , Pascale A , Petrovski G - Pavia*
S007	SMA+perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model *GRILLO-ANTONELLI S , Mauro V , Cimbolini N , Feraille L , Elena P P - La Gaude*
S008	Blepharospams treated with eyelid suspension : long terme follow up and outcomes *LATHIERE T , Robert P Y , Adenis J P - Limoges*
S009	Unexpected orbital swelling after injection of hydrogel self inflating expanders *GRIVET D , Ronin C , Boutet C , Thuret G , Gain P - Saint-Etienne*
S010	Surgical outcome of minimal resection with full thickness rotating suture technique for lower lid epiblepharon *Jeong H C , Sohn E J , Kwon Y H , AHN H - Busan*
S011	Nasolacrimal duct reconstitution with radiofrequency: case report *CARVALHO B , Machado M A C , Ferrari da Silva J A , Alonso Garcia E - Lisbon*
S012	The digital slide scanner applied to the ocular anatomopathology *KASPI M , Grivet D , Forest F , Douchet C , Dumollard J M , Peoc'h M , Thuret G , Gain P - Saint Priest en Jarez*
S013	Measuring scleral thickness with optical coherence tomography in osteogenesis imperfecta: a case report *BREHON A , Jullienne R , Kaspi M , Perrot J L , Grivet D , Peoc'h M , Gain P , Thuret G - Saint-Priest en Jarez*
S014	Comparison of the retinal measurements of standard and neurological SD-OCT applications in MS patients *PATERNO J J , Kaarniranta K - Kuopio*
S015	Fate of donor sclera used to lengthen extraocular muscle in a rabbit model of strabismus surgery *CONDE C , Lindström M , Pedrosa Domellöf F - Umeå*
S016	A new method of exophthalmometry *AFANASYEVA D , Gushchina M , Borzenok S - Moscow*

Saturday, Oct 8 - Poster session 3

POS

10:50 - 12:00 | POSTER AREA

ACB - Anatomy/Cell Biology

S001 - S021

S017		Thickness of chorioretinal complex in the fovea in teenagers with myopia *BOYCHUK I , Shebil S , Ivanickaya E - Odessa*
S018		An investigation of the correlation between functional and structural changes in tilted and non-tilted high myopic eyes *EHSAEI A , Moghadas Sharif N , Shoeibi N - Mashhad*
S019		Reflectometric analysis of normal and ex-premature foveal microstructure in SD-OCT images - a comparison to image analysis using directional OCT and manual segmentation *SJOSTRAND J , Rosén R , Nilsson M , Popovic Z - Mölndal*
S020		Comparative analysis of the morphometric parameters of the macular area of the retina in patients with refractive, axial, mixed and combined tipes of myopia *BUSHUYEVA N , Maliieva O - Odessa*
S021	*rf*	Manufacturing of an ocular prosthesis based on the 3D printed anophthalmic socket *RUITERS S , Sun Y , De Jong S , Politis C , Mombaerts I - Leuven*

POS

10:50 - 12:00 | POSTER AREA

COS - Cornea/Ocular Surface

S022 - S064

GICQUEL J , FUCHSLUGER T

S022	* *rf*	Surface chemistry of the interactions of cationic nanoemulsions with human meibum films *DAULL P , Yokoi N , Nencheva Y , Georgiev G A - Evry*
S023	*rf*	Peter's anomaly in twins: a rare incidence with novel associations *ALZAHRANI S , Khayat H , Tayyib A , Alsulami R , Alkahtani A , Almarzoki H - Jeddah*
S024	*rf*	Severe ocular manifestations of rosacea in adult *HASSAIRI A , Limaiem R , Kortli M , Maamouri R , El Matri L - Tunis*
S025	*rf*	Pollen count compared with severity of symptoms and signs of dry eye disease in Norway *EIDET J R , Tashbayev B , Chen X , Ræder S , Badian R , Utheim Ø , Fostad I G , Dartt D A , Utheim T P - Oslo*
S026	*rf*	Graft functionality after DSAEK surgeries in Denmark from 2006 to 2009 *CORRELL M , Stormly Hansen M , Hovlykke M , Hjortdal J , Olsen Julian H - Glostrup*
S027		Erroneus measurement of the intraocular pressure with the goldmann aplanation tonometry in fuchs endothelial corneal dystrophy *BERNIOLLES J , Bartolomé I , Del buey M A , Martinez M , Esteban O , Ascaso J , Sánchez J I , Idoate A , Almenara C , Pérez I - Zaragoza*
S028		Peripheral refraction and retinal contour after FS-LASIK and orthokeratology *TARUTTA E , Khodzhabekyan N , Khandzhyan A , Milash S - Moscow*
S029		A new approach of presbyopia over a myopic population : PresbyLASIK using the myopic SUPRACOR Algorithm (preliminary results about 12 eyes) *TIMSIT A , Delbarre M , Rambault C , Marechal M , Charpentier S , Benisty D , Berguiga M , Froussart-Maille F - Clamart*
S030		Clinical evaluation of oculus keratograph corneal topographer in normal population *EHSAEI A , Yazdani N , Ostadimoghadam H , Shahkarami L - Mashhad*
S031		The prospects of using the radiation for the assessment of corneal and scleral hydration *IOMDINA E N , Seliverstov S , Sianosyan A , Teplyakova K , Rusova A , Goltsman G - Moscow*
S032		Comparison of MyoRing implantation with corneal collagen cross-linking in different combination for keratoconus treatment *KAZAKBAEVA G , Bikbov M , Usubov E - Ufa*
S033		The evaluation of intrastromal MyoRing implantation with corneal collagen cross-linking in keratoconus treatment *KAZAKBAEVA G , Bikbov M , Usubov E - Ufa*
S034		Assessment of postoperative corneal healing after epithelium-off cross-linking with a regenerating agent in progressive keratoconus patients *KYMIONIS G , Schmetterer L , Garhöfer G , Schmidl D , Chiambaretta F , Grouin J M , Gumus K - Athens*
S035		Tree years outcomes of small incision lenticule extraction: mild to moderate myopia vs. high myopia *KIM J R - Seoul*
S036		Electrospun polymer nanofibers as substrate/carrier for engineering of human corneal epithelium *MOMTAZI L , Shahdadfar A , Zell Thime H , Noer A , Nilsen O , Eidet J R - Oslo*
S037		Novel molecular design of culture substrates with amino acids *MOMTAZI L , Shahdadfar A , Zell Thime H , Noer A , Nilsen O , Eidet J R - Oslo*

POS

10:50 - 12:00 | POSTER AREA

COS - Cornea/Ocular Surface

S022 - S064

S038		DNA damage in human llmbal epithelial cells expanded ex vivo *LORENZO CORRALES Y , Haug Berg K , Noer A , R. Collins A , Nicolaissen B - Oslo*
S039		The effect of culture medium and carrier on explant culture of human limbal epithelium: a comparison of ultrastructure, keratin profile and gene expression *Pathak M , Olstad O K , Drolsum L , Moe M C , Katerina J , Nicolaissen B , NOER A - Oslo*
S040		The effect of silica nanoparticle exposure on cultured human keratocytes *YIM B , Park J , Park C Y - Goyang-siGyeonggi-do*
S041		Development of novel electrospun scaffolds for corneal tissue engineering *KADOR K , Ahearne M - Dublin*
S042		Ex-vivo porcine corneal storage using an innovative bioreactor *CROUZET E , Guindolet D , He Z , Perrache C , Forest F , Herbepin P , Gain P , Gabison E , Thuret G - Saint Priest en Jarez*
S043		OCT spectralis for terrien marginal degeneration diagnosis *BERNIOLLES J , Bartolome I , Idoate A , Sánchez J I , Ascaso J , Esteban O , Martinez M , Del buey M A , Almenara C , Pérez I - Zaragoza*
S044		AS-OCT utility for corneal lacerations in pediatric patients *SANCHEZ MARIN J I , Del Buey M A , Pérez Navarro I , Almenara C , Martínez V. M , Idoate A , Berniolles J , Bartolomé I - Zaragoza*
S045		Terrien marginal degeneration presenting with corneal perforation *PEREZ NAVARRO I , Ascaso F , Sánchez Marín J I , Almenara Michelena C , Estebán Floría O , Martínez Vélez M , Idoate A , Berniolles J , Del Buey Sayas M A - Zaragoza*
S046		Possible misdiagnosis of patients with ocular trauma in a Danish emergency room without ophthalmic assistance. A retrospective cohort study of 1824 patients *JAKOBSEN T M , Møller F , Storr-Paulsen T - Vejle*
S047		Corneal perforation during laser assisted blepharoplasty *LEE S , Moon D , Kang H - Daegu*
S048		Management of acute corneal hydrops in keratoconus with pre-Descemet's membrane sutures *BREHON A , Stephan S , Nguyen Kim P , Cochereau I , Gabison E - Saint-Priest en Jarez*
S049		Potential of High resolution Gabor-Domain optical coherence microscopy for early diagnosis of corneal disease *COURRIER E , Tankam P , He Z , Hindman H , Lepine T , Gain P , Thuret G , Rolland J - Saint Priest en Jarez*
S050		Corneal imaging and densitometry measurements to monitor fuchs progression and treatments outcomes *ALZAHRANI K , Carley F , Brahma A , Morley D , Hillarby M C - Manchester*
S051	*	Evaluation of the eyelid disorders in the daily ophthalmic practice in 9 European Countries: The MEIBUM* survey *DOAN S , Zagórski Z , Palmares J , Yagmur M , Kaercher T , Van Dooren B , Jonckheere P , Jensen P K , Benitez del Castillo J M - Paris*
S052	*	Semi-fluorinated alkanes for topical delivery of Cyclosporine *AGARWALL P , Scherer D , Günther B , Rupenthal I - Auckland*

POS

10:50 - 12:00 | POSTER AREA

COS - Cornea/Ocular Surface

S022 - S064

S053		Effects of TRPM8 and TRPV1 agonists on the neural activity of corneal cold thermoreceptors in tear-deficient guinea pigs *QUIRCE S , Luna C , Acosta M C , Kovacs I , Belmonte C , Gallar J - San Juan de Alicante*
S054		Cacicol® – neurotrophic keratopathy in systematic review *MRUKWA KOMINEK E , Rokicki D - Katowice*
S055		Regression of corneal neovascularization associated with corneal epithelial defect after treatment with regenerating agents (Cacicol®) *DEL BUEY M A , Esteban O , Lanchares E , Martinez M , Casas P , Ascaso F J , Cristobal J A - Zaragoza*
S056		Management and treatment of contact lens keratitis *PEREZ NAVARRO I , Ascaso F , Sánchez Marín J I , Martínez Vélez M , Estebán Floría O , Almenara Michelena C , Idoate A , Bartolomé I , Del Buey Sayas M A - Zaragoza*
S057		Topical N-acetylcystein on patients with refractory filamentary keratitis *KOH J W , Yang Y R - Gwangju*
S058		Comparison of autologous platelet-rich plasma with autologous serum eye drop in corneal epithelial disorder *SHIRZADEH S - Mashhad*
S059		Free living amoebae (FLA) keratitis *PINNA A , Porcu T , Boscia F , Cano A , Erre G , Mattana A - Sassari*
S060		Case of conjunctival amyloidosis with repeated subconjunctival hemorrhages *ANDOH T - Chiba*
S061	*	Osmoprotective activity of alpha-lipoic acid and taurine on hyperosmolar stress in cultured human corneal and conjunctival epithelial cells *SUAREZ T , Soria J , Chatard-Baptiste C - Derio*
S062		Taurine exerts antioxidant and osmoprotecting activity: an in vitro and in vivo study *BUCOLO C , Fidilio A , Platania C B M , Geraci F , Drago F - Catania*
S063		The effect of silica nanoparticles on human corneal epithelial cells *PARK J , Yim B , Park C Y , Chang M W - Goyang-siGyeonggi-do*
S064	*	Subgroup analysis of two phase III studies of 0.1% cyclosporine A cationic emulsion (CsA CE) in patients with dry eye disease *LEONARDI A , Garhöfer G , Amrane M , Garrigue J S , Ismail D , Sainz de la Maza M , Labetoulle M - Padova*

POS

10:50 - 12:00 | POSTER AREA

IM - Immunology/Microbiology

S065 - S073

NERI P , DICK A

S065		Macular OCT features in eyes with VKH disease *DIWO E , Stoykova V , Massamba N , Le Hoang P , Bodaghi B - Paris*
S066		Evolution of spectral-domain optical coherence tomography images in an acute stage of Vogt-Koyanagi-Harada disease *ALMENARA MICHELENA C , Ascaso F J , Núñez E , Martínez M , Pérez I , Esteban O , Idoate A , Sánchez J I , Bartolomé I , Berniolles J , Cristóbal J A - Zaragoza*
S067		Changes of central macular thickness and retinal nerve fiber layer thickness in eyes with Vogt-Koyanagi-Harada disease: a 2-year follow-up study *SHIN K S , Han Y S , Kim M S , Kim J Y - Daejeon*
S068		Ocular manifestations in dengue fever *REMOND A L , Butel N , Fardeau C , Errera M H , Le Hoang P , Bodaghi B - Paris*
S069		Evaluation of choroidal changes in patients with ocular toxoplasmosis using spectral domain optical coherence tomography *AKPOLAT C , Murat M , Celebi N - Istanbul*
S070		Ocular candidiasis in intravenous drug misusers *LAM D , Belazzougui R , Fardeau C , Touitou V , Le Hoang P , Edel Y , Bodaghi B - Paris*
S071	*	In vitro activity of Cacicol® on herpes simplex virus type 1 : a promising adjunct therapy of herpetic corneal infections ? *LABETOULLE M , Rousseau A , Breckler M , Molet L , Boutolleau D , Burrel S , Deback C - Le Kremlin Bicêtre*
S072	*	Modern aspects of demodex blepharitis treatment *Rykov S , PETRENKO O , Shargorodskaya I - Kyiv*
S073		Unilateral painful external ophthalmoplegia as the first manifestation of combined anterior and posterior scleritis *ESTEBAN O , Ascaso J , Idoate A , Sanchez J I , Berniolles J , Bartolomé I , Cristobal J A - Zaragoza*

POS

10:50 - 12:00 | POSTER AREA

LC - Lens and Cataract

S074 - S086

LÖFGREN S , ERCAL N

S074		Comparison of several transport activities of lens epithelial cells from cataract and healthy dog *OCHIAI H - Sagamihara Kanagawa*
S075		Exposure to subthreshold dose of UVR-B induces apoptosis in the lens epithelial cells and does not in the lens fiber cells *GALICHANIN K , Yu Z , Talebizadeh N , Burmakin M , Söderberg P - Uppsala*
S076		Prevention and reversal of selenite-induced cataracts by N-acetylcysteine amide in Wistar rats *Maddirala Y , Tobwala S , Karacal H , ERCALL N - Rolla*
S077		A dual therapeutic approach for the reversal of cataracts *Beltz J , Pfaff A , ERCALL N - Rolla*
S078		Human anterior lens epithelium in presenile cataract- scanning and transmission electron microscopy study *ANDJELIC S , Drašlar K , Hvala A , Hawlina M - Ljubljana*
S079		Composition of phacoemulsificated human lenses analyzed by infrared spectroscopy *CHANIECKI P , Miszczyk J , Rekas M , Paluszkiewicz C - Krakow*
S080	*	Ocular tolerance in rabbits of intracameral administration of Mydrane, a fixed combination of tropicamide, phenylephrine, and lidocaine for cataract surgery *OLMIERE C , Viaud-Quentric K - Clermot-Ferrand*
S081		Weill-Marchesani syndrome: displaced lens, displaced pupil, displaced diagnosis *HUSSAIN N , Jeyabaladevan S , Macapagal M , Tumbocon J - Kingston upon ThamesSurrey*
S082		Comparison of visual and refractive outcomes after implantation of a new diffractive trifocal toric lens, a trifocal lens and a monofocal toric lens *MARECHAL M , Delbarre M , Berguiga M , Rambaud C , Benisty D , Charpentier S , Timsit A , Froussart-Maille F - Clamart*
S083		Clinical features of cataract extraction with negative power intraocular lens implantation in high myopia patients *CHOI J B , SHIN W B , Kim M K - Seoul*
S084		Implantable Collamer Lens to treat high myopia : efficiency and safety *CHARPENTIER S , Graber M , Rambaud C , Monin J , Berguiga M , Delbarre M , Sendon D , Marechal M , Timsit A , Froussart-Maille F - Clamart*
S085		Outbreak of fungal endophthalmits following cataract surgery *MOON D , Lee S , You Y , Lee D - Daegu*
S086		Eleven year review of risk factors and visual outcomes of patients with posterior capsule rupture (PCR) as a complication of cataract surgery at a district general hospital *BEGUM S , Penwarden A , Saunders D , Balendra S I , Schulz C , Hunter M - Portsmouth*

Saturday, Oct 8 - Poster session 3

POS

10:50 - 12:00 | POSTER AREA

PO - Pathology/Oncology

S087 - S110

JAGER MJ , VAN GINDERDEUREN R

S087 *rf*
BAP1 germline mutations in uveal melanoma patients without family history of eye cancer
TURUNEN J , Markkinen S , Wilska R , Raivio V , Täll M , Lehesjoki A E , Kivelä T - Helsinki

S088
DNA methylation patterns in Uveal Melanoma derived FFPE samples correlate with survival
NESS C , Grüner C C , Meza Zepeda L , Moe M C , Noer A - Oslo

S089
Electroporation enhances chemosensitivity of uveal melanoma cells
FIORENTZIS M , Katopodis P , Kalirai H , Seitz B , Viestenz A , Coupland S E - Liverpool

S090
Uveal melanoma clonogenic response to proton beam irradiation
ROMANOWSKA DIXON B , Jasinska K , Michalik M , Madeja Z , Urbanska K , Elas M - Krakow

S091 *rf*
Histomorphological changes of uveal melanoma (UM) following proton beam therapy (PBR)
QURESHI S , Hussain R , Kalirai H , Heimann H , Coupland S - Liverpool

S092 *rf*
UM Cure 2020 - A consortium of European experts in uveal melanoma to identify new therapies for patients with metastatic disease
COUPLAND S , Kalirai H , Jager M , Jochemsen A G , Van der Velden P A , Snaar-Jagalska B E , Dhomen N , Marais R , Romanowska Dixon B , Elas M , Mione M C , Valente A , Ryll B , Ruijtenbeek R , Prestat A , Hafsi H , Barnhill R , Cassoux N , Decaudin D , Lantz O , Piperno-Neumann S , Stern M H , Roman-Roman S - Liverpool

S093
Choroidal nevi classification using swept source optical coherence tomography and infrared reflectance patterns at different wavelengths
PAPASTEFANOU V , Vázquez-Alfageme C , Degli-Esposti S , Cohen V M L , Patel P , Sagoo M S - London

S094
Wide-field autofluorescence and scanning laser ophthalmoscopy: a tool for differential diagnosis of intraocular tumors
ESPOSTI G , Denaro R , Hadjistilianou T , Chimenti G , Esposti P L - Siena

S095
Transpalpebral near-infrared LED transillumination for anteriorly located intraocular tumors imaging
ZADOROZHNYY O , Korol A , Kustryn T , Nasinnyk I , Pasyechnikova N - Odessa

S096 *rf*
The role of anterior segment optical coherence tomography (AS-OCT) and ultrasound biomicroscopy (UBM) in conjunctival nevi
LAUWERS N , Janssens K , Mertens M , De Keizer R J W , De Groot V - Edegem

S097 *rf*
Clinical and morphometric investigation of retinopathy in children with retinoblastoma treated with chemotherapy
SAAKYAN S - Moscow

S098 *rf*
Congenital malignant ciliary body medullepithelioma in two newborns
HADJISTILIANOU T , Mittica P , Bagaglia S , Fruschelli M , Menicacci C , Fusco F , Defrancesco S , Borri M , Galluzzi P - Sienna

S099 *rf*
Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma
HUSSAIN R , Hassan S , Ho V , Kacperek A , Errington D , Heimann H - Liverpool

S100 *rf*
Management strategies in vasoactive proliferative tumor of the retina
TUNC M - Ankara

S101
Intravitreal bevacizumab as an adjuvant treatment of choroidal metastasis
COSTA J , Braga J , Neves F , Meira D , Ribeiro L - Vila Nova de Gaia

POS

10:50 - 12:00 | POSTER AREA

PO - Pathology/Oncology

S087 - S110

S102		Primary intraocular lymphoma and flow cytometry analysis of the vitreous – a case report *ROMANOWSKA DIXON B , Karska Basta I , Kubicka-Trzaska A - Krakow*
S103	*rf*	Sequential bilateral optic nerve infiltration as the sole manifestation of relapsed T-cell lymphoblastic lymphoma: a case report. *KHAYAT H , Alsulami R , Alsobhi E , Alqahtani A , Alkahtani A , Alzahrani S - Jeddah*
S104	*rf*	Clinical and instrumental diagnostics in patients with orbital metastasis *SAAKYAN S - Moscow*
S105		An analysis of IgG4-related ocular disease among idiopathic orbital inflammations and mucosa- associated lymphoid tissue lymphoma *Sohn E J , Roh M S , Kwon Y H , AHN H - Busan*
S106		Orbital mucocele: Orbital Masquarading Syndrome *TUNC M - Ankara*
S107		First cases of ocular dirofilariasis caused by drofilaria repens in Belgium *SMETS M , De Potter P - Bruxelles*
S108	*rf*	Grading iris color of post-mortem human eyes *MADIGAN M , Cionaca V , Sitiwin E , Ton H T - Sydney*
S109	*	Histopathological findings after pars plana vitrectomy with a new hypersonic vitrector *IRION L , Pastor-Idoate S , Bonshek R , Zambrano I , Bishop P , Mironov A , Carlin P , Stanga P - Manchester*
S110		Application of laser radiation exposed Chlorpromazine for the treatment of pseudotumours induced in rabbit eyes *POPA CHERECHEANU A , Tozar T , Geamanu A , Iancu R , Duta S , Pirvulescu R - Bucharest*

SIS

13:00 - 14:30 | HERMES

Women 4 EVER

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed.

CREUZOT C

	13:00	Combined family life and ophthalmic oncology career *VAN GINDERDEUREN R, Leuven*
	13:30	Combining immunology, ophthalmology and personal life in Finland *KAUPPINEN A, Kuopio*
	14:00	Discussion

SIS

13:00 - 14:30 | RHODES 1

COS - Pseudophakic and phakic toric implants – from preoperative examination

Toric intraocular lenses (tIOL) are either implanted in the capsular bag in a regular cataract surgery or used as phakic or pseudophakic add-on tIOL in a refractive surgery procedure for correcting spherocylindrical refraction or for fine-tuning of refraction after cataract surgery. First, detailed clinical and instrument assisted diagnostics have to be performed for a proper indication as well as for calculating tIOL power. In this SIS we will discuss the diagnostic modalities such as corneal tomography and guide how to interpret the instrument data and how to derive a proper indication from clinical and instrument-based exams. In a next step, different options for calculating phakic and pseudophakic tIOL are shown and the calculation scheme is applied to clinical examples. In addition, we present an overview on WEB calculation platforms. In a next step, the peri- and intraoperative details of tIOL surgery is shown from axis marking to a proper positioning of the lens in the eye and axis alignment. In a last step, we show how to monitor the patient in the follow-up period and give advice for troubleshooting and how to deal with potential complications such as re-adjustment of the cylinder axis after rotation of the tIOL.

LANGENBUCHER A , SZENTMARY N , EPPIG T

4421	13:00	Spectrum of indications, patient selection, options for astigmatic corrections, pre- and postoperative patient care *SZENTMARY N - Homburg/Saar*
4422	13:18	Instrument assisted diagnostics – biometry, topography and wave-front analysis *EPPIG T , Spira-Eppig C , Szentmáry N , Langenbucher A - Homburg/Saar*
4423	13:36	How to calculate pseudophakic and phakic toric implants? *LANGENBUCHER A , Szentmary N , Eppig T - Homburg*
4424	13:54	Intraoperative optical coherence tomography (iOCT) assisted positioning of toric lens implants *WYLEGALA E - Katowice*
4425	14:12	Surgical aspects of toric lens implantation and complication management *BARRAQUER R I - Barcelona*

C

13:00 - 14:30 | RHODES 2

COS - Maximising success in deep anterior lamellar keratoplasty

Intermediate

The most popular technique for deep anterior lamellar keratoplasty (DALK) is the 'big bubble' (BB) technique wherein air is injected in the cornea to create a bubble that separates Descemet's membrane (DM) from the stroma. An attempt to create a BB often results in the cornea being filled with numerous small bubbles without the formation of a BB. Manual dissection is then required to complete the procedure.The goal of this course is to present an update on this popular surgical procedure and give tips and tricks from trained surgeons.

DUA HS , GICQUEL JJ

4431		13:00	Know your bubbles *DUA H S - Nottingham*
4432		13:30	What to do when no bubbles? and post operative pitfalls *GICQUEL J - Poitiers*
4433		14:00	Surgical tips through clips *SAID D - Nottingham*

JM

13:00 - 14:30 | RHODES 3

PO: OOG Session 3

ZOGRAFOS L , DESJARDINS L

4441		13:00	Long-term visual acuity preservation after proton therapy for peri- and parapapillary melanoma patients treated at the Paul Scherrer Institute *PICA A , Hrbacek J , Zografos L , Schalenbourg A , Wagner H , Vallat L , Walser M , Schneider R , Weber D C - Villigen*
4442		13:12	Outcomes after proton beam therapy for large choroidal melanomas in 492 patients *BENSOUSSAN E , Baillif S , Maschi C , Caujolle J P , Thariat J - Nice*
4443		13:24	Dry eye syndrome following proton therapy of ocular melanomas *MASCHI C , Sara L , Peyrichon M L , Baillif S , Herault J , Thariat J , Caujolle J P - Nice*
4444	*rf*	13:36	Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma *HUSSAIN R , Hassan S , Ho V , Kacperek A , Errington D , Heimann H - Liverpool*
4445		13:42	Case report of a choroidal ganglioneuroma *VAN GINDERDEUREN R , Missotten G - Leuven*
4446		13:54	Choroidal metastasis from thyroid cancer: a case series *MAMUNUR R , Kivelä T - Helsinki*
4447	*rf*	14:06	Management strategies in vasoactive proliferative tumor of the retina *TUNC M - Ankara*

Saturday, Oct 8 - First afternoon session

13:30 - 15:30 | RHODES 4

EUPO session 7 - Strabismus

Nonparalytic Esodeviations and Exodeviations

Case Presentations II: Odd and Unusual Things in Strabismus

EUPO Programme, see pages 134-135.

13:00 - 14:30 | GALLIENI 1+2

FRO: Belgian Fund for Research in Ophthalmology 2

FRO candidates present their work to an international jury.

TASSIGNON MJ , CASPERS L

4461	13:00	AON therapy for restoration of defective splicing in genes mutated in hereditary blindness *NAESSENS S - Gent*
4462	13:12	Exploring strategies to overcome the inner limiting membrane as a barrier for non-viral retinal gene therapy after intravitreal injection *PEYNSHAERT K - Ghent*
4463	13:24	Copy number variation analysis and whole exome sequencing of three unique Belgian keratoconus families *VALGAEREN H - Edegem*
4464	13:36	Regenerating the ocular surface using standardized, xeno-free, tissue-engineered conjunctival grafts for conjunctival reconstruction *VANACKER S - Antwerpen*
4465	13:48	Targeting specific pathways to enhance human corneal endothelial proliferation in vitro *VAN DEN BOGERD B - Edegem*
4466	14:00	Automated retinal vessel analysis toImprove the detection and management of ophthalmic and systemic diseases *VAN KEER K - Leuven*
4467	14:12	Hidden genetic variation in retinal dystrophies – exploring the contribution of copy number variations *VAN SCHIL K - Ghent*
4468	14:24	Confocal and optical coherence bleb imaging pre-and after filtering surgery *WILLEKENS K - Leuven*

PS

14:30 - 15:00 | HERMES

Prize Award Ceremony & Closing Remarks

Chair : Andrew Dick, President EVER 2017

Introduction of the Award Ceremony by Marcela Votruba, Programme Secretary

- Travel awards presentation by the section chairs
- Poster prize presentations by the section chairs

Presentation and report of the scientific sections meetings

Conclusion of the congress by the President 2016 Aki Kawasaki

EUPO 2016

Neuro-ophthalmology

Friday 7 October 2016 in Rhodes 4

08:30 Common Optic Neuropathies in Adults: Diagnosis, Treatment and Prognosis
Antonella BOSCHI, Valerie PURVIN

08:30	Idiopathic (demyelinating) optic neuritis	PURVIN V
08:50	Non-arteritic anterior ischemic optic neuropathy	SAARELA V
09:10	Compressive optic neuropathy: pituitary adenoma	BOSCHI A
09:30	Leber hereditary optic neuropathy	YU WAI MAN P
09:50	Discussion	
10:00	Break	

10:30 Case Presentations I: Odd and Unusual Things in Neuro-ophthalmology
Valerie PURVIN, Ville SAARELA

11:00 Systematic Approach to the Ocular Motor System
François-Xavier BORRUAT, Caroline TILIKETE

11:00	Central disorders of ocular motitliy	BORRUAT FX
11:25	Central disorders of ocular stability	TILIKETE C
11:50	Myasthenia	LEE M
12:15	Discussion	
12:30	Lunch	

13:30 Uncommon but Important Causes of Visual Loss
Fion BREMNER, Graham HOLDER

13:30	Inatrogenic visual loss: toxicities	PURVIN V
13:50	Acquired autoimmune retinopathies	HOLDER G
14:10	Posterior reversible encephalopathy syndrome (PRES)	KAWASAKI A
14:30	Neuromyelitis optica (NMO) and spectrum disorders	BREMNER F
14:50	Discussion	
15:00	Break	

16:00 Recognizing the Emergencies: From Symptom to Diagnosis
Catherine VIGNAL CLERMONT, Michael LEE

16:00	Transient monocular visual loss: carotid embolus vs giant cell arteritis	VIGNAL CLERMONT C
16:20	Diagnosis and management of giant cell arteritis	LEE M
16:40	Acute diplopia: third nerve palsy	BREMNER F
17:00	Acute anisocoria: aneurysm vs Horner syndrome	KAWASAKI A
17:20	Discussion	

17:30 Case Presentations II: Odd and Unusual Things in Neuro-ophthalmology
Patrick YU WAI MAN, Aki KAWASAKI

18:00 End

EUPO 2016

Strabismus

Saturday 8 October 2016 in Rhodes 4

08:30 Paralytic Strabismus: Diagnosis, Evaluation and When to Treat
Oliver EHRT, Heimo STEFFEN

08:30	Acquired cranial nerve palsies	STEFFEN H
08:55	Congenital cranial dysinnervation disorders	KAESER PF
09:20	Surgical indications and management of paralytic strabismus	EHRT O
09:45	Discussion	
10:00	Break	

10:30 Case Presentations I: Odd and Unusual Things in Strabismus
Dominique BREMOND GIGNAC, Camerson PARSA

11:00 Amblyopia , Nystagmus and Secondary Strabismus
Jan Tjeerd DE FABER, Pierre-François KAESER

11:00	Amblyopia: physiologic basis and management	PARSA C
11:20	Screening strategies for amblyopia	BREMOND GIGNAC D
11:40	Infantile nystagmus	KAESER PF
12:00	Secondary and iatrogenic strabismus	DE FABER JT
12:20	Discussion	
12:30	Lunch	

13:30 Nonparalytic Esodeviations and Exodeviations
Rosario GOMEZ de LIANO, Marcel TEN TUSSCHER

13:30	Esotropia : Considerations in Infants and Adults	TEN TUSSCHER M
13:55	Exodeviations	GOMEZ DE LIANO R
14:20	Nonsurgical management of strabismus	DE FABER JT
14:45	Discussion	

15:00 Case Presentations II: Odd and Unusual Things in Strabismus
Dominique BREMOND GIGNAC, Camerson PARSA

15:30 End

Science for Sight

XXth EVER CONGRESS

EVER 2017 NICE

SEPTEMBER 27-30

www.ever.be

EVER

European Association for Vision and Eye Research

EVER f

www.ever-f.eu

Awardees of the
EVER f Research Fellowships 2016

- Dr Mahajan DEEPTI, India
  host institute : Vision Lab, Cardiff Centre for Vision Sciences,
  Cardiff University, UK

- Dr Narine ADZHEMIAN, Russia
  host institute : Medical University of Vienna, Austria

European Association for Vision and Eye Research Foundation

The Obergurgl Optic Nerve Meeting

Focus Area -
Boosting optic nerve function

December 13-15

2016

www.optic-nerve-online.com

Organisation:

Jonathan Crowston
Professor of Ophthalmology, University of Melbourne

Franz Grus
Professor of Experimental Ophthalmology, Johannes Gutenberg University, Mainz

Keith Martin
Professor of Ophthalmology, University of Cambridge

EVER

Austria - Obergurgl
Hotel Edelweiss & Gurgl

ARVO Asia

February 5 – 8, 2017
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Bridging disciplines and disparities: Connecting eye research with health outcomes

The sixth ARVO-Asia meeting will explore the latest in basic, translational and clinical research through symposia, plenary, paper and poster sessions and special interest groups.

We discuss how we can build bridges that ensure our discoveries translate into effective prevention, diagnosis and treatments for patients with eye disease.

Chair: Mark H.B. Radford, MD, PhD

Co-chairs:
Justine R. Smith, FRANZCO, PhD, FARVO
Peter J. McCluskey, MD, FRANZCO

Early registration closes Dec. 12, 2016
Abstract submission: July 12 – Sept. 20, 2016
Online program available: Dec. 13, 2016

ARVO
The Association for Research in Vision and Ophthalmology

brisbane
australia's new world city

QUEENSLAND eye INSTITUTE

arvo.org/arvo-asia



Important Dates

- **Abstract submission**
  October 14 – December 2, 2016
- **Early meeting registration**
  Opens September 19, 2016

Travel grants are available. Apply when submitting your abstract.

ARVO®
The Association for Research in Vision and Ophthalmology

arvo.org/am

Karger publications in Ophthalmology

available at the Wisepress booth

ESASO Course Series, Vol. 8

Glaucoma

Editors: **Traverso, C.E.; Bagnasco, L.** (Geneva)
approx. 150 p., 2016
CHF 98.00 / EUR 92.00 / USD 115.00 (soft cover)
ISBN 978–3–318–05890–1
www.karger.com/esaso

ESASO Course Series, Vol. 7

Ocular Tumors

Editors: **Singh, A.D.** (Cleveland, Ohio); **Seregard, S.** (Stockholm)
VIII + 112 p., 66 fig., 62 in color, 13 tab., 2016
CHF 98.00 / EUR 92.00 / USD 115.00 (hard cover)
ISBN 978–3–318–05618–1
www.karger.com/esaso



Developments in Ophthalmology, Vol. 57

Pediatric Cataract

Editor: **Nucci, P.** (Milan)
VIII + 112 p., 22 fig., 19 in color, 3 tab., 2016
CHF 149.00 / EUR 139.00 / USD 175.00 (hard cover)
ISBN 978–3–318–05819–2
www.karger.com/deoph

Developments in Ophthalmology, Vol. 56

OCT Angiography in Retinal and Macular Diseases

Editors: **Bandello, F.** (Milan); **Souied, E.H.** (Créteil); **Querques, G.** (Milan)
XII + 184 p., 120 fig., 107 in color, 1 tab., 2016
CHF 198.00 / EUR 185.00 / USD 233.00 (hard cover)
ISBN 978–3–318–05829–1
www.karger.com/deoph

Developments in Ophthalmology, Vol. 55

Retinal Pharmacotherapeutics

Editors: **Nguyen, Q.D.** (Omaha, Nebr.); **Rodrigues, E.B.** (São Paulo); **Farah, M.E.** (São Paulo); **Mieler, W.F.** (Chicago, Ill.); **Do, D.V.** (Omaha, Nebr.)
XVI + 408 p., 83 fig., 71 in color, 33 tab., 2016
Liste Price: CHF 317.00 / EUR 296.00 / USD 373.00 (hard cover)
Special offer: CHF 159.00 / EUR 148.00 / USD 186.00
ISBN 978–3–318–05564–1
www.karger.com/deoph

Please use the promotional code: KI16414

KARGER

For further information and
easy ordering please go to our website
www.karger.com/ophthalmology

KI16414

Presenting First Authors

Four digit numbers refer to oral presentations

Day | Timeslot | Hall | Order in session

One letter and three digit numbers refer to posters



Day | Order in the postersession

ABEGAO PINTO, L: 1325, 3124, 3663
ABU EL ASRAR, A: 1335, 2332
AFANASYEVA, D: 1375, S016
AGARWAL, P: S052
AHMED, F: 2722
AHN, H: S010, S105
AKPOLAT, C: 2331, S069, T097
ALA-KAUHALUOMA, M: F109
ALDAHAM, S: 3326, F076
ALGHAMDI, A: 1555
ALI ALJASIM, L: T043, T044
ALLEN, C: 2333
ALMENARA MICHELENA, C: F108, S066
ALMOALLEM, B: 3581
ALVAREZ, L: T075
ALZAHRANI, K: S050
ALZAHRANI, S: 1145, S023
AMADIO, M: S006
AMBRESIN, A: 3115
ANDJELIC, S: S078
ANDOH, T: S060
ANDRE, H: 3584
ANDRIES, L: 4161
ANDROUDI, S: 1132
ANGI, M: 3642
ANISIMOV, S: 2674
ANTOUN, J: 3371
APTEL, F: 3122, T029
ARCINIEGAS, C: 2121
ARDAN, T: T106
ARJAMAA, O: 1371
ARNOULD, L: 1376
ARSENIJEVIC, Y: 1512
ASCASO, F: 2711, 4111, F070, F094
ATILLA, H: 2663, 2741
AUDO, I: 3181
AUTRATA, R: F042, F043
AUVINEN, A: 3383
BAE, JH: F113
BALCI, Ö: 3674
BALDESCHI, L: 2632
BALENDRA, S: 1162
BARBONI, P: 2363
BARBOSA BREDA, J: 4162, T017
BARRAQUER, J: 2353
BARRAQUER, RI: 4425
BATSON, J: 1341
BAUDIN, F: 2681
BECHRAKIS, NE: 2732, 3342, 3544
BECKERS, A: 4163
BEGUM, S: 2338, F077, S086
BEHAEGEL, J: 4164
BEHAR-COHEN, F: 3165
BEK, T: 1115
BENSOUSSAN, E: 4442
BERNIOLLES, J: S027, S043
BERROD, J: 1562, 3513
BEUERMAN, R: 1172, 2772
BITOUN, P: 1523
BJORKOY, G: 2173
BLASI, MA: 3142
BLOOM, P: 2724
BOBAT, H: T025
BODAGHI, B: 1535
BONINI, S: 3635
BONO, V: T023
BOSCHI, A: 2633
BOULADI, M: T008, T009
BOURAOUI, R: F092, F093
BOURNE, R: 1361
BOUTELEUX, V: F062
BOUVIER, R: F044
BOYA, P: 3521
BOYCHUK, I: F035, S017
BRAGA, J: F021
BRANDL, C: T081
BREHON, A: S013, S048
BREMOND-GIGNAC, D: 2662, 2744, 3681, 4132
BREUNIG, M: 3133
BRISCOE, D: 2654
BRON, A: 1521, 2616
BRUNNER, S: 2112
BUCOLO, C: S062
BUELENS, T: 3374
BUJAKOWSKA, K: 2762
BUSHUYEVA, N: F026, F034, S020
BUZNYK, O: 1143
CALONGE, M: 2771
CALVAS, P: 2661
CANDI, A: T104
CARDIGOS, J: 3327, F078, T015
CARELLI, V: 1552, 2364, 2424, 2426

Presenting First Authors

CARRASQUILLO, KG: 2373
CARVALHO, B: S011
CASSOUX, N: 2341, 2344, 3315, 3341, 3545
CASTELO-BRANCO, M: 2645
CAUJOLLE, JP: 3143
CELLINI, M: T006
CHANIECKI, P: S079
CHARLIER, J: 3564
CHARPENTIER, S: S084
CHEN, L: 3631
CHIAMBARETTA, F: 2743, 2834
CHIQUET, C: 2354
CHOI, C: F081
CHOI, H: F030, F031
CHOI, JB: S083
CIPRÉS ALASTUEY, M: F014, F015
COLAS, E: 2337, F074
CONDE, C: S015
CORDEIRO SOUSA, D: 2685, T045, T086
CORDEIRO, MF: 3623
CORRELL, M: 1146, 3335, S026
COSCAS, F: 3111
COSCAS, G: 3114
COSTA, J: S101
COSTA, L: 1347, 3328, F079, T024, T102
COUPLAND, S: 3145, 3317, 3365, 4145, S092
COURRIER, E: S049
CRAWLEY, L: 2723
CREUZOT, C: 1363
CRISÓSTOMO, S: T016
CROUZET, E: 1141, S042
CTORI, I: T079
CVEKL, A: 2351
CZAK, W: 2673
DABASIA, P: T027
DALGAARD, LM: 1522
DALKE, C: 3382
DAMATO, B: 3344
DANIELSON, P: 2734
DAULL, P: 2677, S022
DAVIS, B: 2323
DE BOEVER, P: 2683
DE GROEF, L: 1344
DE GROOT, V: F037
DE LAEY, JJ: 4113
DE ZAEYTIJD, J: T069
DECAUDIN, D: 3313
DEL BUEY, MA: S055, T004
DELCOURT, C: 1362, T078
DELGADO, L: 3683
DEN HOLLANDER, A: 1364
DENIER, C: 3372
DENNISTON, A: 2314
DERVEAUX, T: 3582
DESJARDINS, L: 2343, 3541, 3644
DEVOLDERE, J: 1544, 4165
DICK, A: 1131, 1136
DIWO, E: S065
DOAN, S: 2374, S051
DOBROWOLSKI, D: 2134, 2136
DOGAN, M: 2385, T107
DRAGANOVA, D: 3373
DUA, HS: 1576, 3571, 4431
DUCH, S: 2124
DYSLI, C: 2623
EHSAEI, A: S018, S030
EIDET, JR: 2676, S025
EL AMEEN, A: 3673, T034
EL MATRI, L: F082, T068
EPPIG, T: 4122, 4422
ERCAL, N: 2782, S076, S077
ERDURMUS, M: T098
ERKAN TURAN, K: F016, F047
ESPOSTI, G: S094
ESTEBAN, O: S073, T066
EYSTEINSSON, T: 2382
FENOLLAND, JR: 1528, T042
FERNÁNDEZ-NAVARRO, J: 1543
FERNÁNDEZ-PÉREZ, J: 3332
FERRARI, S: 3171
FIORENTZIS, M: S089
FITZKE, FW: 2164
FRANCESCHETTI, A: 4115
FRENCH, C: 2686, F058
FRENKEL, S: 3316
FRUSCHELLI, M: 3325, F091
FUCHSLUGER, T: 3132
FUNKE, S: 3525
GABRIELLE, P: 1546
GALICHANIN, K: S075
GALLEGO, BI: 2322
GARCÍA LLORCA, A: 3585, T076
GARCIA MARTIN, E: F003, F004
GARCIA-FEIJOO, J: 1322, 3123
GARCIA-ZAMORA, M: F084
GARCIA, M: T073
GARCIN, T: 3331
GARHÖFER, G: 2145
GAZZARD, G: 2721
GEORGIADIS, T: 1511
GIANNACCARE, G: T020
GICQUEL, J: 4131, 4432
GLITTENBERG, C: 2113
GOCHO, K: 2682
GOH, M: T082
GOMES ALVES DA CONCEICAO, R: T050
GONZALEZ, C: 3323, F060, F061
GRABSKA-LIBEREK, I: T040

GRAEFF, E: 2755
GRAJEWSKI, L: F053
GRAW, J: 3586
GREENWOOD, J: 2211
GRIFFITH, M: 3135
GRILLO-ANTONELLI, S: S007
GRIVET, D: S009
GRUENERT, A: 3532
GRZYBOWSKI, A: 1154, 2641, 2713, 4112
GUAGLIANO, R: F039
GUPTA, V: 1531
HAAGDORENS, M: 4166
HAAVISTO, A: T083
HADJISTILIANOU, T: 3641, 3646, S098
HAIKONEN, S: T090
HAMEL, C: 3182
HARDARSON, S: 2383
HASSAIRI, A: 1142, 2675, F063, S024
HAWRAMI, A: 2336, F075
HE, Z: 3334
HEEGAARD, S: 2653
HEISTERKAMP, A: 1575
HEITMAR, R: T089
HENDERSON, R: 2763
HENGERER, F: 2184
HEO, DW: T061
HERBORG, A: T091
HERBORT, CP: 1135, 1334, 1533, 3671
HERMANN, P: 2624
HERRERO-VANRELL, R: 2142
HIROTAKA, Y: F005
HOFFART, L: 1144
HOHBERGER, B: 3533
HOLDER, G: 2163, 3184
HOLOPAINEN, J: 1173, 2773
HORI, J: 3634
HORWITZ, A: 1168, T031
HOUILLIER, C: 2614
HU, T: 2387, T093
HUANG, O: 1166, T018
HUDSON, C: 1112
HUNTJENS, B: T074
HUSSAIN, N: S081
HUSSAIN, R: 1561, 4444, S099
IDOATE, A: F045
ILHAN, B: T011
IOMDINA, EN: 1343, S031, T037
IRION, L: S109
IRSCH, K: 1351, 1352, 1353
ISIK, M: T010
IYER, J: T038
JACKSON, TL: 1541
JAGER, MJ: 3144, 3311, 3343
JAKOBSEN, TM: S046
JAMES TE, 2433
JANISZEWSKA, D: 2133
JENKINS, KS: 3567, T013
JEPPESEN, SK: T094
JIRSOVA, K: 3531
JÓHANNESSON, G: 2731
KAARNIRANTA, K: 2174
KADOR, K: S041
KADZIAUSKIENE, A: T059
KALIRAI, H: 3312
KALOGEROU, M: T054
KANAVATI, S: F057
KANG, H: F100
KANG, S: S004, T100
KANNAN, R: 2172
KASPI, M: S012
KAUPPINEN, A: 1374
KAYA, S: 2432
KAZAKBAEVA, G: S032, S033
KELLY, C: 3333
KESSEL, L: 2784
KESTELYN, P: 2615
KHAIRALLAH, M: 1333, 1532
KHAN, A: 3324
KHATIB, T: 1165, T049
KHAYAT, H: 2756, S103
KHEIR, V: 1556, F019
KILIC, E: 4142
KIM, DY: F112
KIM, HW: F098
KIM, JR: S035
KIM, JT: F064
KIM, JY: F107
KIM, K: F103
KIM, Y: 1161
KIM, YT: F071
KIM, YY: T060
KINOSHITA, S: 2511
KIVELÄ, T: 2342, 3573, 4114
KLEYMAN, A: T032
KLOPSTOCK, T: 2421, 2425
KNOP, E: 2371
KOH, J: S057
KOLKO, M: 3622
KOMPELLA, UB: 2144, 3131
KONIDARIS, V: F095
KOSKELA, A: S001, S002
KOUSAL, B: T070
KRASTEL, H: 3561, T005
KRISHNA, Y: 4143
KUBICZ, A: T101
KUDRYAVTSEVA, O: 2381
KUGELBERG, M: 1152
KWOK, J: 3522

Presenting First Authors

KWON, S: F050
KWON, YH: F096, F104
KYMIONIS, G: S034
LABBE, A: T039
LABETOULLE, M: 1153, 4133, S071
LAGALI, N: 3633
LAGREZE, WD: 2422
LAM, D: S070
LANGENBUCHER, A: 4121, 4423
LATHIERE, T: S008
LAUWERS, N: 2751, S096
LAZREG, S: 2672, 2742, 2832
LE MER, Y: 3514
LEAL, I: 1164, T041, T046
LEE, JE: T087
LEE, JY: F069
LEE, MY: F090, F097
LEE, SH: S047
LEE, Y: T085
LEMAITRE, S: 2753
LENAERS, G: 2361
LEONARDI, A: S064
LEROY, BP: 1412, 1514, 2162, 2611, 3185
LIASIS, A: 1124
LIINAMAA, J: 1554
LISKOVA, P: 2764, 3183, T071
LOCKWOOD, A: T047
LOEFFLER, K: 3141
LÖFGREN, S: F036
LORENZO CORRALES, Y: S038
LOSHKAREVA, A: 2671
LUDGATE, M: 2631
LUHMANN, U: 3523
LUMBROSO, B: 3112
LYTVYNCHUK, L: 1564, 2115
MAAMOURI, R: F085, F086
MACLAREN, R: 1711
MADIGAN, M: 2758, 3647, S108
MAKLEY, L: 2785
MAMMADZADA, P: T096
MAMUNUR, R: 4446
MANNS, R: F083
MANOLI, P: F028
MARCELIS, W: F025
MARECHAL, M: S082
MARQUES-NEVES, C: 3661
MARTINEZ, M: F038, F114
MARTINUZZI, A: 2362
MASCHI, C: 4443
MASSET, M: 4167
MATTHYSSEN, S: 4168
MAUGET-FAYSSE, M: 2684
MEDEIROS PINTO, J: 2154, 2335, F073
MEKKI, MB: 2375
MENDES, M: T064
MERAYO-LLOVES, J: 2431
MESSMER, EM: 2833
METZ, G: F024
MICHAEL, R: 2182
MICHALEWSKA, Z: 2111, 2153
MILLA, E: 2123
MILLAN, M: 2183
MINIEWICZ, J: 2152
MIONE, M: 3314
MISSOTTEN, L: 1611
MOHAN, R: 1513
MOMTAZI, L: S036, S037
MONTERO MORENO, J: 1542, F051, F101
MOON, D: S085
MOORE, T: 3172
MOOSANG, K: F029, F055
MOSCHOS, M: 1312
MOULIN, A: 2752
MOURIAUX, F: 2651
MRUKWA-KOMINEK, E: S054
MUN, S: F106
MUNIER, F: 3546
MUNOZ-NEGRETE, FJ: 1557, F001, F023, T035
MUNOZ, M: 2122, T028
NAESSENS, S: 4461
NAGAOKA, T: 1111
NAKAI, K: 3672
NAU, C: 2372
NERI, P: 1133, 1534, 2311, 3361
NESS, C: S088
NOER, A: S039
NORMANDO, EM: 2621
NOWINSKA, A: 2131
NUBILE, M: 2312
OBIS, J: F012, F013
OCHIAI, H: S074
OLAFSDOTTIR, OB: T095
OLMIERE, C: S080
OSBORNE, N: 2643, 2644
OSHITARI, T: F089
OZIMEK, M: 3321
OZTURK, N: F027
PANFOLI, I: T105
PAPASTEFANOU, V: S093
PAPPAS, G: 1315
PARAOAN, L: 2171
PARK, J: S063
PARK, YG: F088
PATERNO, J: S003, S005, S014
PAZOS, M: 2321
PEBAY, A: 3524
PEDROSA, AC: 3322
PERESTRELO, S: F066

PEREZ NAVARRO, I: S045, S056
PETRENKO, O: S072
PETROVSKI, G: 3174
PEYNSHAERT, K: 1342, 4462
PICA, A: 4441
PIERSCIONEK, B: 2181
PIETRUCHA-DUTCZAK, M: T052
PINNA, A: S059
PINTO PROENÇA, R: 2334
PLAINIS, S: 1311
PLEYER, U: 1134, 1151, 1332, 3574
PONOMARENKO, M: F052, F054
POPA CHERECHEANU, A: S110, T056
POURNARAS, C: 1113, 2715, 3116, 3512
POURNARAS, J: 1313, 3515
PRIETO, P: 2781
PRUENTE, C: 2714
QIU, X: 2352
QUINLAN, R: 3381
QUIRCE, S: S053
QURESHI, S: 4144, S091
RAHMANIA, N: F033
RAMIREZ, AI: T030
RANSOM, B: 3624
REBOLLEDA, G: F011, T058, T063
REMAUT, K: 2143
REMOND, A: S068
RICOUARD, F: F102
ROBSON, A: 1123
ROCHA DE SOUSA, A: 1563, 3566, F049, T007
RODRIGO, MJ: F006, F022
ROELS, D: T012
ROEMER, S: 1551
ROJAS LOZANO, MP: F002
ROMANOWSKA DIXON, B: F068, S090, S102
ROULAND, JF: 1526, T033
ROUSSEAU, A: 3375
ROZET, J: 2664
RUITERS, S: 1377, S021
RUPENTHAL, ID: 2141
SAAKYAN, S: 2757, 3643, 3645, S097, S104
SAGONG, M: F110
SAGUET, P: T108
SAID, D: 4433
SAKSONOV, S: 2114
SALOBRAR-GARCIA, E: F017, F018
SALVI, M: 2634
SALVIAT, F: F046
SÁNCHEZ MARÍN, JI: F056, S044
SANDBERG MELIN, C: T062
SAPETA, S: 1572
SATUE, M: F007, F008
SCHALENBOURG, A: 3542
SCHMETTERER, L: 1411, 2642
SCHMIDL, D: 1573, 3662
SCHWARZ, N: 2761
SCOTT, A: 1321
SEPETIS, A: T077
SHAHDADFAR, A: 3173
SHALABY, A: F105
SHIH, KC: 1163
SHIN, KS: F072, S067
SHIN, Y: F032, T080
SHIRZADEH, S: F041, S058
SILVESTER, A: 2155, F048
SIMCOCK, P: 1314
SJÖSTRAND, J: S019
SKALICKÁ, P: T072
SKYTT, D: 1372
SMEDOWSKI, A: 2132, T051
SMETS, M: S107
SMITH, R: 1122, 1125
SODERBERG, P: 3161
SOMNER, J: 2733
SOUBRANE, G: 3113
SOUSA NEVES, F: 1545, T065
SOUSA, F: 2151
SOZEN-DELIL, FI: 1565, F080, F111
SPILEERS, W: 2161
STACHS, O: 1574
STÆHR JAKOBSEN, N: F087
STALMANS, I: 3121
STANGOS, A: 3511, T022
STAPPLER, T: 1316
STEFANSSON, E: 3535, 3572
STONE, D: T026
STRUPAITE, R: T067
SUÁREZ, T: S061
SULEIMAN, E: T019
SULLIVAN, DA: 2831
SUNARIC MEGEVAND, G: 1323, 1324
SUZUKI, N: 2687, 3565, F059
SZAFLIK, JP: F065, T053
SZENTMARY, N: 4123, 4421
TALEBIZADEH, N: 3163
TARUTTA, E: S028, T002
TASSIGNON, MJ: 2712, 4211
THOMPSON, D: 1121, 3563
THURET, G: 2313
TIMSIT, A: S029
TIRANTI, V: 2423
TOFT-KEHLER, AK: T048
TOTH, M: T021
TOUITOU, V: 2613
TRIOLO, G: 1524
TUNC, M: 2652, 2754, 4447, S100, S106
TURCK, N: 1345, 1346, T103
TURUNEN, J: 4141, S087

Presenting First Authors

ULLRICH, F: 3134, 3534
UUSITALO, H: 1171, 2774
VALGAEREN, H: 4463
VAN CALSTER, J: 3362, 3363
VAN DEN BOGERD, B: 4465
VAN GINDERDEUREN, R: 3364, 4445
VAN KEER, K: 1167, 2384, 4466, T057
VAN SCHIL, K: 4467
VANACKER, S: 4464
VANDEWALLE, E: 1527, 3125, T036
VEGA-ESTRADA, A: 2185
VIDAL-SANZ, M: 2324
VIGNAL-CLERMONT, C: 1553
VILADES, E: F009, F010
VIOTTE, A: F067
VOHRA, R: 1373
VOTRUBA, M: 3211
WAAGEPETERSEN, H: 3621
WAIZEL, M: F040
WALPERT, M: 2622
WEGENER, A: 3162
WEI, X: T088
WERKMEISTER, R: 1114, 1571
WILLEKENS, K: 1566, 3664, 4468, T055
WILLERMAIN, F: 1331, 2612
WOZNIAK, P: 2386, T092
WYLEGALA, E: 2135, 4124, 4424
YAZGAN, S: T014
YEKTA, AA: T001, T084
YIM, B: S040
YU-WAI-MAN, P: 2365
YU, Z: 3164
ZADOROZHNYY, O: S095, T099
ZENG, J: 3562
ZHANG, H: 3632
ZHANG, K: 2783
ZHANG, X: 3583
ZOGRAFOS, L: 2345, 3117, 3543
ZSOLT NAGY, Z: 4125

All Authors

All authors of abstracts are listed alphabetically

One letter and three digit numbers refer to posters
Four digit numbers refer to oral presentations
The digit numbers marked in **bold** indicate a first author abstract

AALTONEN, V: 1371
ABEGÃO PINTO, L: 1164, 3327, F078, T041, **1325**, **3124**, **3663**, 1167, 2334, 2384, 2685, T045, T057
ABROUG, N: 1333
ABU EL ASRAR, A: **1335**, **2332**
ACAR, N: 1521
ACOSTA, MC: S053
ACOU, M: F025
ADENIS, JP: S008
ADIEGO, MI: 4111
ADJADJ, E: 3372
AERTS, I: 3644
AFANASYEVA, D: **1375**, **S016**
AGARD, E: F062, T064
AGARWALL, P: **S052**
AGRAWAL, R: T088
AGUDO-BARRIUSO, M: 2324
AHEARNE, M: 3332, 3333, S041
AHMAD, S: T026
AHMED, F: 2621, **2722**
AHN, H: F096, F104, **S010**, **S105**
AHN, KS: T087
AHOLA, O: S003
AKEO, K: 2682
AKHTAR, S: T051
AKPOLAT, C: **2331**, **S069**, **T097**
ALA-KAUHALUOMA, M: **F109**
ALASSANE, S: 1376
ALBA-BUENO, F: 2183
ALDAHAM, S: **3326**, **F076**
ALGHAMDI, A: **1555**
ALI ALJASIM, L: **T043**, **T044**
ALI, RR: 3523
ALI, Z: 3633
ALIO, J: 2185
ALKAHTANI, A: 1145, 2756, S023, S103
ALLEN, C: 1341, **2333**
ALLEN, E: 3172
ALMARZOKI, H: 1145, S023
ALMENARA MICHELENA, C: S045, S056, **S066**
ALMENARA, C: F045, F056, F070, F094, F114, S027, S043, S044, T004, T066, **F108**
ALMOALLEM, B: **3581**
ALMUHTASEB, H: F057
ALONSO GARCIA, E: S011
ALONSO, AS: 2684
ALOUI, T: F035
ALQAHTANI, A: 2756, S103
ALSOBHI, E: 2756, S103
ALSULAMI, R: **2756**, 1145, S023, S103
ÁLVAREZ, L: **T075**, T073
ALVES-FARIA, P: 3566, T007
ALVES, M: 2334
ALZAHRANI, K: **S050**
ALZAHRANI, S: **1145**, 2756, **S023**, S103
AMADIO, M: T051, **S006**
AMADO, D: 1347, T102
AMARIE, OV: 3586
AMAT-PERAL, P: F051
AMATI-BONNEAU, P: 2361
AMBRESIN, A: **3115**
AMBROZAITYTE, L: T067
AMRANE, M: S064
ANATYCHUK, L: T099
ANCHER LARSEN, D: F087
ANDJELIC, S: **S078**
ANDLEY, U: 2785
ANDOH, T: **S060**
ANDRE, H: T096, **3584**
ANDRES-GUERRERO, V: 2142
ANDRIES, L: 1344
ANDROUDI, S: **1132**
ANGI, M: 3644, **3642**
ANISIMOV, S: **2674**
ANISIMOVA, S: 2674
ANJOS, R: T015, T016, T024
ANTON, A: T028
ANTOUN, J: **3371**
ANUMANTHAN, G: 1513
APRILE, L: 3325, F091
APTEL, F: 1526, 2354, T033, **3122**, **T029**
ARAI, M: F089
ARAPI, I: 3361
ARCHAKOV, A: T037
ARCINIEGAS-PERASSO, CA: **2121**
ARDAN, T: **T106**
AREDE, C: T065
ARJAMAA, O: **1371**
ARNAIZ, C: F101
ARNO, G: 3581
ARNOULD, L: **1376**
ARONSSON, M: 3584
ARRANZ, A: 2142
ARSENIJEVIC, Y: **1512**
ASCASO, F: F045, F056, F108, S045, S056, **2711**, **4111**
ASCASO, FJ: S055, S066, **F070**, **F094**
ASCASO, J: **F038**, F114, S027, S043, S073, T066
ASCHINGER, G: 1114, 2386, T092
ASOKLIS, R: T059, T067
ASSAD, G: 2681
ATES, H: T014
ATILLA, H: **2663**, **2741**
ATKINSON, M: 3382
ATKINSON, S: 3172
AUBELE, M: 3382
AUCKBURALLY, M: F028
AUDO, I: **3181**
AUTRATA, R: **F042**, **F043**
AVILÉS-TRIGUEROS, M: 2324
AYMARD, PA: 3372
AZIMI, A: T001
AZIMZADEH, O: 3382
BABAEI-JADIDI, R: 1341
BABL, S: 3133
BADIAN, R: 2676, S025
BAE, JH: **F113**
BAEKELANDT, V: 1344
BAGAGLIA, S: 3646, S098
BAGNIS, A: T020
BAHRAMI, M: 2181
BAILLIF, S: 4442, 4443
BALCI, Ö: 3671, **3674**
BALDUCCI, N: 2363
BALENDRA, SI: S086, **1162**
BALNE, PK: T088
BANDELLO, F: T078
BANERJEE, S: F095
BARAC, C: T056
BARATA, A: 1545
BARATHI, A: T088
BARBEAUX, P: T104
BARBER, AC: T050
BARBONI, P: **2363**
BARBOSA BREDA, J: 1167, T057, **T017**
BARBOSA-BREDA, J: 1563, 3664
BARILLÀ, D: F039
BARNHILL, R: 4145, S092
BARRAQUER, J: **2353**
BARRAQUER, RI: 2182, **4425**
BARROS, P: F021
BARTOLOMÉ, I: S043, F038, F045, F056, F070, F094, F108, S027, S044, S056, S066, S073
BARUFFA, D: 1534
BASCHE, M: 3523
BASÍLIO, AL: 3328, F079, T016
BASSET, T: 1141
BATA, AM: 2386, T092
BATES, D: 2333
BATES, DO: 1341
BATSON, J: **1341**
BAUDIN, F: **2681**
BAUDOUIN, C: T039
BAYTAROGLU, A: F016
BAZEER, S: T021
BEATO, J: 3322
BECHRAKIS, NE: **2732**, **3342**, **3544**
BECK-POPOVIC, M: 3546
BECK, S: 3525
BEDNARSKI, M: 2111
BEGUM, S: F083, **2338**, **F077**, **S086**
BEK, T: 2381, 2383, F087, T091, T094, T095, **1115**
BELAOUDMOU, R: 2375
BELAZZOUGUI, R: S070
BELMONTE, C: S053
BELTZ, J: S077
BEN MRAD, A: 1142
BENISTY, D: S029, S082
BENITEZ DEL CASTILLO, JM: S051
BENNETT, J: 1514
BENSOUSSAN, E: **4442**
BENZACKEN, L: 1523
BERAUD, G: T108
BERGANDI, F: 3334
BERGERSEN, LH: 1372, 1373
BERGUIGA, M: S029, S082, S084
BERNARD, A: 3331
BERNIOLLES, J: F038, F045, F056, F070, F094, F108, S044, S045, S066, S073, **S027**, **S043**
BERROD, JP: **1562**, **3513**
BERTONE, C: F039
BESSE, A: 2337, F074

All Authors

BESSE, E: 2337, F074
BESSMERTNY, A: T032
BEUERMAN, R: **1172**, **2772**
BEZCI, F: F016
BIANCHI, PE: F039
BIGAN, G: F067
BIGEY, P: 3375
BIGOTTE VIEIRA, M: T046, T086
BIKBOV, M: S032, S033
BINDER, S: 2115
BINQUET, C: 1363, 1376
BIRLING, A: S005
BISCEGLIA, P: 1133, 2311
BISHOP, P: S109
BISHT, R: 2141
BITOUN, P: **1523**
BJORKOY, G: **2173**
BLANN, A: T089
BLOOM, P: 2621, **2724**
BOBAT, H: **T025**
BODAGHI, B: 1555, S065, S068, S070
BOISSET, S: 2354
BOLZ, M: 2386, T092
BONINI, S: **3635**
BONINSKA, K: 2153
BONNEAU, D: 2361
BONNEL, S: 1528, T042
BONO, V: **T023**
BONSHEK, R: S109
BORRI, M: 3641, 3646, S098
BORRUAT, FX: 1556, F019
BORZENOK, S: 1375, S016
BOSCHI, A: F027, **2633**
BOSCIA, F: S059
BOUAFIA, K: 1523
BOUGUERFA, R: 2375
BOULADI, M: F092, F093, **T008**, **T009**
BOUQUET, C: 1553
BOURAOUI, R: F085, F086, T008, T009, **F092**, **F093**
BOURNE, R: **1361**
BOUTELEUX, V: T064, **F062**
BOUTET, C: S009
BOUTOLLEAU, D: S071
BOUVIER, R: **F044**
BOWMAN, R: 3563
BOYCHUK, I: **F035**, **S017**
BRACCO, S: 3641
BRAECKMANS, K: 2143
BRÆNDSTRUP, C: T048
BRAGA, J: S101, T065, **F021**
BRAHMA, A: S050
BRANDLL, C: **T081**
BRANDS, T: 4142
BRASNU, E: T039
BRAVO-OSUNA, I: 2142
BRECKLER, M: S071
BREHON, A: **S013**, **S048**
BREMOND-GIGNAC, D: 3372, F046, **2662**, **2744**, **3681**, **4132**
BRÉTILLON, L: 1521
BREUNIG, M: **3133**
BRISCOE, D: **2654**
BRISSE, H: 3644
BRON, A: 1363, 1376, 1546, 2681, **1521**, **2616**
BRUNNER, S: **2112**
BUCOLO, C: **S062**
BUDENZ, DL: 1524
BUELENS, T: **3374**
BUJAKOWSKA, K: 2764, T070, **2762**
BURGOYNE, C: 2321
BURGULA, S: F095
BURMAKIN, M: S075
BURREL, S: S071
BUSH, A: F105
BUSHUYEVA, N: **F026**, **F034**, **S020**
BUTEL, N: S068
BUZNYK, O: **1143**
BYON, IS: T087
CABARGA, C: T058
CABRERIZO, J: 3335
CACOUB, P: 1555
CAGINI, C: 3114
CAIADO, F: 2154
CALIENNO, R: 2312
CALONGE, M: **2771**
CALVAS, P: 2664, **2661**
CALVO PEREZ, P: 1542
CALYAKA, E: 3331
CALZIA, D: T105
CAMPOS, E: T006, T020
CANDI, A: **T104**
CANKAYA, AB: F047
CANO, A: S059
CANSFIELD, J: 2338, F077
CAO, J: 3144
CAPELLO, G: 2362
CAPOZZOLI, M: 3325, F091
CARDIGOS, J: T016, T024, **3327**, **F078**, **T015**
CARDOSO, M: T015, T016
CARELLI, V: **1552**, **2364, 2424, 2426**
CAREY, J: 2782
CARLEY, F: S050
CARLIN, P: S109
CARNEIRO, Â: 3322
CARRASQUILLO, KG: **2373**
CARROZZI, G: 1133
CARSTENS, J: F053
CARTA, F: 2382
CARVALHO, B: **S011**
CASAS LLERA, P: T058
CASAS, P: S055
CASEIRO, P: 2752
CASPERS, L: 2612, 3371, 3373, 3374
CASSOUX, N: 2753, 3642, 3644, 4145, S092, **2341**, **2344**, **3341**, **3545**
CASTELO-BRANCO, M: **2645**
CATARINO, C: F024
CAUJOLLE, JP: 4442, 4443, **3143**
CAZABON, S: 2155, F048
CEKIC, O: 1565, 2331, F080, F111, T097
CELEBI, N: S069
CELIK, T: T014
CELLINI, M: **T006**
CEPURNA, W: 2321
CESARE, M: 1534
CESARI, C: 1133
ÇETINKAYA, A: T098
CHAE, JB: F112
CHAKER, N: F092, F093, T008, T009
CHAMBARD, JP: 1523
CHAN, YK: 1561
CHANG, MW: S063
CHANIECKI, P: **S079**
CHAO DE LA BARCA, J: 2361
CHAPELLE, P: 1523
CHARIF, M: 2361
CHARLIER, J: **3564**
CHARLOT, F: T108
CHARPENTIER, S: S029, S082, **S084**
CHASSAING, N: 2661, 2664
CHATARD-BAPTISTE, C: S061
CHAUNG, J: T082
CHAURASIA, S: 1513
CHEBBI, Z: F082
CHEBIL, A: F063, F082, T068
CHEN, L: **3631**
CHEN, X: 2676, S025
CHEN, YS: 2141
CHENG, R: 1112
CHEUNG, HC: 1561
CHIAMBARETTA, F: 2743, **2834**, 3682, S034
CHIMENTI, G: 3325, F091, S094
CHIQUET, C: **2354**
CHO, H: F032, T080
CHO, SY: T060
CHO, WK: T100
CHOI, C: F106, **F081**
CHOI, D: F050
CHOI, HY: **F030**, **F031**
CHOI, JB: S083
CHOI, K: F112
CHOI, SH: F071
CHORAGIEWICZ, T: 3321
CHRISTIAN, P: 3132
CHRISTIE, K: 3172
CHUDICKOVA, M: 3531
CHUNG, DC: 1514
CHUNG, H: F064
CHUNG, IY: F098, T087
CHUNG, JH: T080
CIMBALISTIENE, L: T067
CIMBOLINI, N: S007
CIONACA, V: 2758, S108
CIPRES ALASTUEY, M: F003, F004, F006, F007, F008, F009, F010, F012, F013, F022, **F014**, **F015**
COCA-PRADOS, M: T073, T075
COCHEREAU, I: S048
COELHO, C: 2335, F073
COHEN, VML: S093
COLAS, E: **2337**, **F074**
COMBAL, JP: 1553
CONART, JB: 1562, F102
CONDE, C: **S015**
CONRAD-HENGERER, I: 2184
CORAZZA, F: 2612, 3373
CORDEIRO SOUSA, D: 1164, T041, T046, **2685**, **T045**, **T086**
CORDEIRO, MF: 1162, 1344, 2621, 2622
CORIOLANI, G: 3641
CORRELL, M: **1146**, **3335**, **S026**
COSCAS, F: 3114
COSCAS, G: **3114**
COSTA, A: 3566, T007
COSTA, J: **S101**
COSTA, L: T015, **1347**, **3328**, **F079**, **T024**, **T102**
COSTA, LM: T016
COSTAGLIOLA, C: T023
COUCEIRO, R: T046, T086
COUPLAND, S: 4143, 4144, S091, **3145**, **3365**, **4145**, **S092**
COUPLAND, SE: S089
COURRIER, E: **S049**
COUTURAUD, B: 2753

CRAVEN, R: T026
CRAWLEY, L: 2621, **2723**
CREUZOT, C: 1376, 1521, 1546, 2681, **1363**
CRISÓSTOMO, S: T015, T024, **T016**
CRISTÓBAL, JÁ: S055, S073, T004, F108, S066
CROUZET, E: 3335, **1141**, **S042**
CSONT, T: 1371
CTORI, I: T074, **T079**
CUNHA, JP: 2334, 3327, 3328, F078, F079
CVEKL, A: **2351**
CZAK, W: **2673**
CZUGALA, M: 3132
D'ANTIN, JC: 2182
DABASIA, P: T027
DAIEN, V: 1376
DALGAARD, LM: **1522**
DALKE, C: **3382**
DAM-VAN LOON, NHT: 3371
DAMATO, B: **3344**
DANIELSON, P: **2734**
DARTT, DA: 2676, S025
DAULL, P: **2677**, **S022**
DAVIS, B: 1344, **2323**
DAVIS, BM: 1162
DAVIS, E: 2661
DE BAERE, E: 3581
DE BAT, F: 2684
DE BOEVER, P: **2683**
DE GRACIA, P: 2322
DE GROEF, L: **1344**
DE GROOT, V: 2751, S096, **F037**
DE HERTOGH, G: 2332
DE HOZ, R: 1543, F017, F018, T030, 2322
DE JONG, S: 1377, S021
DE JUAN, V: 1557, F001, T058, T063
DE KEIZER, RJW: 2751, S096
DE KLEIN, A: 4142
DE LA FUENTE, A: F101
DE NICOLA, C: 2312
DE POTTER, P: S107
DE RAVEL, TJL: 3581
DE SCHRYVER, I: F025
DE SMEDT, S: 1342, 1544, 2143
DE VERDIER, K: F036
DE VRIESE, A: 2387, T093
DE ZAEYTIJD, J: 3581, 3582, **T069**
DEANE, J: F095
DEBACK, C: S071
DEBAUGNIES, F: 3373
DECAUDIN, D: 4145, S092
DEFRANCESCO, S: 3641, 3646, S098
DEGAN, P: T105
DEGLI-ESPOSTI, S: S093
DEL BUEY SAYAS, MÁ: S045, S056
DEL BUEY, MA: S027, S043, F070, S044, **S055**, **T004**
DEL NOCE, C: T020
DELAVENNE, X: 1141
DELBARRE, M: S029, S082, S084
DELBEKE, P: 3582
DELBOSC, B: F067
DELCAMPE, A: 2374
DELCOURT, C: **1362**, **T078**
DELTAS, C: T054
DEN HOLLANDER, A: **1364**
DENARO, R: S094
DENIER, C: **3372**
DENION, E: T108
DENIS, P: T029
DENNISTON, A: **2314**
DERVEAUX, T: **3582**
DESJARDINS, L: 2753, 3642, **2343**, **3541**, **3644**
DEVOLDERE, J: 2143, **1544**
DHOMEN, N: 4145, S092
DHOUIB, N: F092, F093
DI SIMPLICIO, S: F105
DICK, A: **1131**, **1136**
DIEZ ALVAREZ, L: T058
DIONÍSIO, P: 1164, 2685
DIWO, E: **S065**
DOAN, S: **2374**, **S051**
DOBROWOLSKI, D: **2134**, **2136**
DOGAN, M: **2385**, **T107**
DOR, M: 1345, 1346, T103
DORMI, A: T020
DORNONVILLE DE LA COUR, M: 3335
DOT, C: F062, T064
DOUCHET, C: S012
DOWSETT, L: T077
DRABAREK, W: 4142
DRAGANOVA, D: 2612, F027, **3373**
DRAGO, F: S062
DRASLAR, K: S078
DROLSUM, L: S039
DUA, HS: **1576**, **4431**
DUCH, S: **2124**
DUCHATEAU, L: 1541
DUDAKOVA, L: 2764, T070, T071, T072
DUKHAYER, S: F026
DUMOLLARD, JM: S012
DUTA, S: S110, T056
EAMEGDOOL, S: 3647
EDEL, Y: S070
EDGAR, D: T027
EDWARD, D: T043
EHSAEI, A: **S018**, **S030**
EIDET, JR: 3324, S036, S037, **2676**, **S025**
EK, U: F036
EKSTRÖM, M: 3584
EL AMEEN, A: **3673**, **T034**
EL CHEHAB, H: F062, T064
EL KOUHEN, N: 1562
EL MATRI, K: F063, F082, F085, T068
EL MATRI, L: 1142, 2675, F063, F085, F086, F092, F093, S024, T008, T009, **F082**, **T068**
ELAINE, J: 2321
ELAS, M: 2152, 4145, S090, S092
ELENA, PP: S007
ELIASDOTTIR, T: 2383, T095
EMPESLIDIS, T: F095
ENGBERSEN, J: 2143
EPERON, S: 1345, 1346, T103
EPPIG, T: **4122**, **4422**, 4121, 4423
ERB, C: T035
ERCAL, N: **2782**
ERCALL, N: **S076**, **S077**
ERDURMUS, M: **T098**, T010
ERKAN TURAN, K: T011, **F016**, **F047**
ERRE, G: S059
ERRERA, MH: S068
ERRINGTON, D: 4444, S099
ESCRIBANO, J: T030, T073
ESCRIOU, V: 3375
ESPOSTI, G: **S094**
ESPOSTI, PL: S094
ESTEBÁN FLORÍA, O: F056, S045, S056
ESTEBAN, O: F045, F070, F094, F108, F114, S027, S043, S055, S066, **S073**, **T066**
ESTEVENY, L: 1566
EUSSEN, B: 4142
EYSTEINSSON, T: 3585, T076, T095, **2382**
FALCÃO-REIS, F: F049, 1563, 3322, 3566, T007
FALCÃO, M: F049, 3322
FALFOUL, Y: F063, F082, F085, T068
FARDEAU, C: S068, S070
FARES-TAÏE, L: 2661, 2664
FAZEKAS, F: 2683
FAZIO, S: 3325, F091
FEDRA, K: F086
FENOLLAND, JR: **T042**, **1528**
FERAILLE, L: S007
FERNANDEZ-MUNOZ, M: F051, F084
FERNANDEZ-NAVARRO, J: **1543**
FERNÁNDEZ-PÉREZ, J: **3332**
FERNANDEZ-VEGA, Á: T073
FERNANDEZ-VEGA, B: T073
FERNANDEZ-VEGA, L: T073
FERNANDEZ, Á: T073
FERNÁNDEZ, B: T075
FERNELL, E: F036
FERRARI DA SILVA, JA: S011
FERRARI, S: 3174, **3171**
FERREIRA, J: 1347, 3327, F078, T102
FERRERO, A: 1521
FEUER, WJ: 1524
FEYEN, JH: T104
FEYEN, JHM: 1566, 2387, T093
FIDILIO, A: S062
FINK, M: 1513
FIORE, T: 3114
FIORENTZIS, M: **S089**
FITOUSSI, S: 1553
FITZKE, FW: **2164**
FIRAT, T: T098
FLORES, M: F067
FLORES, R: 1545, 3328, F079
FONDI, K: 2386, T092
FONTEYN, L: T104
FOREST, F: S012, S042
FOROUZESH, S: T001
FOSTAD, IG: 2676, S025
FOUDA, C: 1345, 1346, T103
FOVEAU, P: F102
FRADOT, V: 1342
FRANCES CABALLERO, E: F084
FREITAS, A: T017
FRENCH, C: **2686**, **F058**
FRENEAUX, P: 3644
FRESINA, M: T020
FROUSSART-MAILLE, F: S029, S082, S084
FRUSCHELLI, M: 3646, S098, **3325**, **F091**
FU, L: 1163
FUCHS, H: 3586
FUCHSLUGER, T: **3132**

All Authors

FUNK, RHW: T105
FUNKE, S: **3525**
FUSCO, F: 3646, S098
GABISON, E: 2313, S042, S048
GABRIELLE, PH: **1546**
GAILLARD, MC: 3546
GAIN, P: 1141, 2313, 3331, 3334, 3335, F028, S009, S012, S013, S042, S049
GALICHANIN, K: 3161, 3163, **S075**
GALIMBERTI, D: 3641
GALLAR, J: S053
GALLEGO, BI: 1543, **2322**
GALLUZZI, P: 3641, 3646, S098
GALY, A: 1553
GAMBERT-NICOT, S: 1521
GARCIA GARCIA, A: F023
GARCIA LLORCA, A: **3585**, **T076**
GARCIA MARTÍN, E: **F003**, **F004**, F014, F015
GARCÍA ZAMORA, M: **F084**
GARCÍA-ANTÓN, M: T030
GARCÍA-CABALLERO, C: 2142
GARCÍA-FEIJOO, J: **1322**, **3123**, 2142, T030
GARCÍA-MARTÍN, E: F007, F008, F009, F010, F012, F013, F006, F022
GARCIA-MARTINEZ, J: 1542
GARCÍA, M: **T073**, T075
GARCIA, Y: F018
GARCIN, T: **3331**
GARDINER, S: 2321
GARDRAT, S: 2753
GARHÖFER, G: **2145**, 2386, S034, S064, T092
GARRETT, L: 3382
GARRIGUE, JS: S064
GASC, A: 3671
GAUCHER, D: F102
GAZZARD, G: T021, **2721**
GEAMANU, A: S110
GEBOES, K: 2332
GEDDE, SJ: 1524
GEORGIADIS, T: **1511**
GEORGIEV, GA: 2677, S022
GEORGIOU, T: T054
GERACI, F: S062
GERBER, S: 2361, 2664
GESTWICKI, J: 2785
GHAZAL, W: 1528, T042
GIANNACCARE, G: **T020**
GIBBONS, B: 1341
GIJBELS, A: 1566
GIL, P: F017, F018
GILAN, P: 3647
GILL, K: 3524
GIOVANNINI, A: 2311, 3361
GIRARD, C: F067
GIRAUD, JM: 1528, T042
GIULIANO, E: 1513
GIZZI, C: T020
GLIBERT, G: 3374
GLITTENBERG, C: **2113**
GOCHO, K: **2682**
GOH, MJ: **T082**
GOLTSMAN, G: S031
GOMES ALVES DA CONCEICAO, R: **T050**
GOMES DA COSTA, A: T046, T086
GOMES, AM: F021
GOMES, T: T015, T016, T024
GOMOLKA, M: 3382
GONÇALVES-PINHO, M: T017
GONZALEZ LOPEZ, JJ: F011
GONZALEZ URUENA, C: 1542, F084, F101
GONZÁLEZ-IGLESIAS, H: T073, T075
GONZALEZ, C: **3323**, **F060**, **F061**
GORGOLI, K: F095
GOSWAMI, N: 2683
GOTTFREDSDOTTIR, MS: T095
GOURLAOUEN, M: T077
GOVONI, S: S006
GRABER, M: S084
GRABSKA-LIBEREK, I: **T040**
GRACIA, H: F003, F004
GRACIÀ, MDLA: 1346, T103
GRAEFF, E: **2755**
GRAJEWSKI, L: **F053**
GRAW, J: 3382, **3586**
GRAY, J: T047
GREENWOOD, J: T077
GREENWOOD, J[JGREENWOOD@UCLACUK] **2211**
GREITER, M: 3382
GRIFFITH, M: 1143, **3135**
GRILLO-ANTONELLI, S: **S007**
GRISCIKOVA, L: F042, F043
GRIVET, D: S012, S013, **S009**
GROOP, PH: T090
GROOT-MIJNES, J: 3371
GROUIN, JM: S034
GRUENERT, A: **3532**
GRÜNER, CC: S088
GRUS, FH: 3525
GRZYBOWSKI, A: **1154**, **2641**, **2713**, **4112**
GU, R: 3647
GUAGLIANO, R: **F039**
GUDIÑA, S: T028
GUDMUNDSDÓTTIR ASPELUND, S: T076
GUDMUNDSSON, J: T096
GUENANCIA, C: 1376
GUEX-CROZIER, Y: 1345
GUINDOLET, D: 2313, S042
GUMUS, K: S034
GUNEY, Y: 2754
GÜNTHER, B: S052
GUO, L: 1162
GUPTA, S: 1513
GURUBARAN, I: T048
GURUBARAN, IS: 1372
GUSHCHINA, M: 1375, S016
GUTER, M: 3133
GUTMAN, E: T039
GUVEN YILMAZ, S: T014
GUYOT, L: 1144
GUZMÁN, M: 2142
HAAVISTO, AK: **T083**
HABIBI, I: T068
HADJISTILIANOU, T: 3325, F091, S094, **3641**, **3646**, **S098**
HAFSI, H: 4145, S092
HAIKONEN, S: **T090**
HAINARD, A: 1345
HAKLAR, G: F080, F111
HALAT, AÖ: 2385
HAMARD, P: T039
HAMÉDANI, M: 1345, 1346, T103
HAMEL, C: 2361, **3182**
HAMMOND, C: T074
HAN, YS: S067
HARDARSON, AO: 2382
HARDARSON, S: T095, **2383**
HARUTYUNYAN, S: T002
HASHAM, S: F024
HASHEMI, H: T001, T084
HASHEMI, K: 1551
HASSAIRI, A: F086, **1142**, **2675**, **F063**, **S024**
HASSAN, S: 4444, S099
HAUG BERG, K: S038
HAVELANGE, V: F027
HAWLINA, M: S078
HAWRAMI, A: **2336**, **F075**
HAYASHI, T: 2682
HAYES, S: 3135
HE, Z: 1141, 3331, 3335, S042, S049, **3334**
HEEGAARD, S: **2653**, 3335
HEID, IM: T081
HEIMANN, H: 4144, 4444, S091, S099
HEINIG, N: T105
HEISTERKAMP, A: **1575**
HEITMAR, R: 2686, F058, **T089**
HELBIG, H: T081
HELISALMI, S: S005
HELMER, C: 1376
HENDERSON, R: 3563
HENGERER, F: **2184**
HEO, DW: **T061**
HERAULT, J: 4443
HERAVIAN, J: T001
HERBEPIN, P: 3331, S042
HERBORG, A: **T091**
HERBORT, CP: 3673, 3674, **1135**, **1334**, **1533**, **3671**
HERIPRET, A: F044
HERNANDEZ, D: 3524
HERRERAS, JM: 2771
HERRERO-VANRELL, R: **2142**
HESEMANN, N: 1513
HEWITT, A: 3524
HIGH, KA: 1514
HILLARBY, MC: S050
HINDMAN, H: S049
HIROTAKA, Y: **F005**
HJORTDAL, J: 1146, S026
HO, V: 4444, S099
HOEH, A: T077
HOESCHEN, C: 3382
HOFFART, L: **1144**
HOHBERGER, B: **3533**
HOLAN, V: 3531
HOLDER, G: 2611, **2163**
HOLLAND, A: 2622
HOLOPAINEN, J: T083, **2773**
HÖLTER, SM: 3382
HONG, EH: T080
HONRUBIA, A: F094, F114
HONZIK, T: T071
HOR, G: 3331
HORI, J: **3634**
HORNHARDT, S: 3382
HORWITZ, A: **1168**, **T031**
HOSHINO, M: 2181
HOU, R: 2783
HOUILLIER, C: **2614**
HOVLYKKE, M: 1146, S026
HOYAS, I: F017
HRABE DE ANGELIS, M: 3586
HRBACEK, J: 4441
HRNCIAROVA, E: T106

HTOON, H: 1166, T018
HU, TT: T104, **2387**, **T093**
HUANG, O: **1166**, **T018**
HUDSON, C: **1112**
HULL, S: 3581
HUNG, S: 3524
HUNTER, M: S086
HUNTJENS, B: T079, **T074**
HUSSAIN, N: **S081**
HUSSAIN, R: 4144, S091, **1561**, **4444**, **S099**
HUTTUNEN, H: T090
HVALA, A: S078
HYTTI, M: 1374
HYUNG, S: F112
IAKYMENKO, S: 1143
IANCU, R: S110
IDIL, A: **T011**
IDOATE, A: F056, F108, F114, S027, S043, S044, S045, S056, S066, S073, **F045**
IJÄS, P: F109
ILHAN, B: T011
ILHAN, I: T011
INAGAKI, M: 3381
INAM, O: F047, T010
IOMDINA, E: T032
IOMDINA, EN: **1343**, **S031**, **T037**
IRION, L: **S109**
IRSCH, K: **1351**, **1352**, **1353**
ISIK, M: **T010**
ISLAM, MM: 1143
ISMAIL, D: S064
ITOH, N: 2682
IVANICKAYA, E: S017
IYER, J: **T038**
JACKSON, TL: **1541**
JAGER, M: 4145, S092
JAGER, MJ: **3144**, **3343**
JAISWAL, J: 2141
JAKOBSEN, TM: **S046**
JAMES, TE: **2433**
JAÑEZ, L: F018
JANSSENS, K: 2751, S096
JANSSENS, T: 1566
JÄRVIKALLIO, R: S003
JASINSKA, K: S090
JEANNIN, B: 3671, 3674
JELLITI, B: 1532
JENKINS, KS: **3567**, **T013**
JENSEN, L: 3633
JENSEN, LT: 1522
JENSEN, PK: S051
JEON, H: F030, F031
JEONG, HC: S010
JEONG, JG: F106
JEONG, S: F110
JEPPESEN, SK: **T094**
JEYABALADEVAN, S: S081
JIANG, Y: 2352
JIMÉNEZ-LÓPEZ, M: 2324
JIN, J: 2141
JIRSOVA, K: **3531**
JOCHEMSEN, AG: 4145, S092
JÓHANNESSON, G: **2731**
JONAS, JB: T005
JONCKHEERE, P: S051
JONCKX, B: 1566
JUDICE RELVAS, L: 3371
JULLIENNE, R: F028, S013
JUN, AS: 3334
JUNEMANN, A: 3321
KAARNIRANTA, K: 1371, 1374, S001, S002, S003, S014, T051, **2174**, **S005**
KACPEREK, A: 4444, S099
KADOR, K: **S041**
KADZIAUSKIENE, A: **T059**
KAERCHER, T: S051
KAHLOUN, R: 1532
KALIRAI, H: 4143, 4144, 4145, S089, S091, S092
KALLAY, L: 3334
KALLIGERAKI, A: 3381
KALOGEROU, M: **T054**
KÄMÄRÄINEN, JK: T090
KAMEYA, S: 2682
KAMGANG SEMEU, P: 3374
KAMPIK, D: 3523
KANAVATI, S: **F057**
KANAWATI, C: F057
KANG, H: S047
KANG, HG: **F100**
KANG, MH: F032, T080
KANG, S: **S004**, **T100**
KANNAN, R: **2172**
KAPLAN, J: 2361, 2661, 2664
KARACAL, H: S076
KARAHAN, S: F016, F047
KARALAR, M: T107
KARJALAINEN, R: S001
KARLSSON, RA: 2383
KARSKA BASTA, I: F068, S102
KASPI, M: S013, **S012**
KATERINA, J: S039
KATOPODIS, P: S089
KAUPPI, JP: T090
KAUPPINEN, A: 1371, **1374**
KAWASAKI, A: 1551
KAWASAKI, R: 1376
KAYA, G: 2752
KAYA, S: **2432**
KAZAKBAEVA, G: **S032**, **S033**
KAZEROUNIAN, S: F040
KE, CY: T085
KEARNS, L: 3524
KEENAN, J: 3563
KELES, I: 2385
KELLY, C: **3333**
KEMPF, SJ: 3382
KESSEL, L: **2784**
KESTELYN, P: F025, **2615**
KHABAZKHOOB, M: T001, T084
KHAIRALLAH, M: **1333**, **1532**
KHAN, AZ: **3324**
KHANDEKAR, R: T043
KHANDELWAL, N: T088
KHANDZHYAN, A: S028, T002
KHATIB, T: **1165**, **T049**
KHAYAT, H: 1145, S023, **S103**, 2756
KHEIR, V: **1556**, **F019**
KHOCHTALI, S: 1333
KHODZHABEKYAN, N: S028, T002
KIILGAARD, J: 3335
KILIC, E: **4142**
KIM, CS: T061
KIM, DY: F069, F107, F113, **F112**
KIM, HJ: T087
KIM, HT: F113
KIM, HW: T087, **F098**
KIM, JH: F032, F112
KIM, JR: **S035**
KIM, JS: F100
KIM, JT: **F064**
KIM, JY: **F072**, F069, F107, F112, S067
KIM, K: F098
KIM, KH: **F103**
KIM, KN: T061
KIM, MK: S083
KIM, MS: S067
KIM, SH: F113
KIM, ST: F096
KIM, Y: **1161**
KIM, YI: F100
KIM, YT: **F071**
KIM, YY: **T060**
KINNUNEN, K: 1374
KINOSHITA, S[K-MAJ: **2511**
KIRWAN, JF: T025
KISELEVA, O: T019, T032, T037
KISHAZI, E: 1346, T103
KIVELÄ, T: 4446, 4141, S087, **2342**, **3573**, **4114**
KIVILUOMA, J: S003
KIN TEKÇE, B: T098
KLAFTEN, M: 3586
KLEYMAN, A: **T032**
KLOPSTOCK, T: **2421**, **2425**, F024
KNAPP, S: 1341
KNEIHSL, M: 2683
KNOP, E: **2371**
KNOP, N: 2371
KOBYLIANSKYI, R: T099
KOCUROVA, G: T106
KODJIKIAN, L: 1546
KOEHRER, P: 2681
KOH, JW: **S057**
KOH, V: T082
KOLAROVA, H: T071
KOLKO, M: 1168, 1372, 1373, 1522, T031, T048, **3622**
KOLOVOS, P: T054
KOMPELLA, UB: **2144**, **3131**
KONDO, M: T012
KONIDARIS, V: **F095**
KORHONEN, E: 1374
KOROL, A: S095
KORT, F: F085
KORTLI, M: 2675, F082, S024
KOSKELA, A: **S001**, **S002**
KOSKINEN, S: F109
KOSTIC, C: 1512
KOUSAL, B: 2764, **T070**
KOVACS, I: S053
KRASTEL, H: **3561**, **T005**
KRAUSE, L: F053
KREJCIROVA, I: F042, F043
KRISHNA, Y: **4143**
KRONENBERG, F: T081
KRONSCHLÄGER, M: 3163, 3164
KUBARKO, A: T005
KUBICKA-TRZASKA, A: 2152, S102
KUBICZ, A: **T101**
KUDRYAVTSEVA, O: **2381**
KUGELBERG, M: **1152**
KÜKNER, A: T098
KÜKNER, AS: T098
KULASEKARA, S: 1112
KULKA, U: 3382
KUNZE, S: 3382
KURT, M: 2331, T097
KUSTRYN, T: S095

All Authors

KUTLUKSAMAN, B: 2385, T107
KVANTA, A: 3584, T096
KWOK, J: **3522**
KWON, S: **F050**
KWON, YH: S010, S105, **F096**, **F104**
KYMIONIS, G: **S034**
KYTÖ, J: T090
LABA, A: 2673
LABBE, A: **T039**
LABETOULLE, M: 3375, S064, **1153**, **4133**, **S071**
LACHKAR, Y: 1523
LADAIQUE, M: 1551
LAGALI, N: **3633**
LAGREZE, WD: **2422**
LAI, JSM: 1163
LAM, D: **S070**
LANCHARES, E: S055, T004
LANGENBUCHER, A: **4121**, **4423**, 4122, 4422
LANTZ, O: 4145, S092
LAPPA, A: 2312
LARROSA, JM: F003, F004
LATHIERE, T: **S008**
LAUWERS, N: **2751**, **S096**
LAVIERS, H: 2336, F075
LAWRENSON, J: **T027**
LAYTON, C: 3567, T013
LAZREG, S: T078, **2672**, **2742**, **2832**
LE HOANG, P: S065, S068, S070
LEAL, I: 2685, T045, T086, **1164**, **T041**, **T046**
LEAL, M: F017
LEBRANCHU, P: F028
LEE, D: S085
LEE, JE: F098, **T087**
LEE, JH: F100, F113
LEE, JP: F050
LEE, JY: **F069**, **F107**
LEE, MY: **F090**, **F097**
LEE, S: S085, **S047**
LEE, SC: F113
LEE, SH: F100
LEE, TE: T060
LEE, YH: T061
LEE, YJ: **T085**
LEFEVERE, E: 1344
LEHESJOKI, AE: 4141, S087
LEHOANG, P: 1555
LEIVO, T: T083
LEMAITRE, S: **2753**
LEMIJ, H: T035
LENAERS, G: **2361**
LEONARDI, A: **S064**
LEPINE, T: 2313, S049
LEROY, BP: **1412**, 1562, **2162**, **2611**, **3185,** 3581, 3582, F025, T012, T069, **1514**
LESCRAUWAET, B: 1541
LESINSKAS, E: T059
LESNIAK, A: F068
LEVY-GABRIEL, C: 2753
LEVY, C: 3642, 3644
LEWIN-KOWALIK, J: T051, T052
LEWIS, K: F105, T047
LEWIS, PN: 3135
LI, D: 2352
LIANG, H: 3524
LIASIS, A: 3563, **1124**
LIEBL, R: 3133
LIINAMAA, J: **1554**
LIM, F: T038
LIM, HB: F072
LIM, HW: F032, T080
LIM, S: 3524
LIMAIEM, R: 1142, 2675, F092, S024, T008, T009
LIMI, S: 2351
LIN, PK: T085
LINDSBERG, P: F109
LINDSTRÖM, M: S015
LINSENMEIER, R: 1114
LISKOVA, P: T070, T072, **2764**, **3183**, **T071**
LISZKA, A: 3135
LO, ACY: 1163
LOCHHEAD, J: F052, F054
LOCKWOOD, A: F105, T025, **T047**
LOEFFLER, KU: **3141**
LÖFGREN, S: **F036**
LOMBARDI, M: T039
LOPEZ GAONA, A: 1542
LOPEZ, N: T086
LORENZO CORRALES, Y: **S038**
LOSHKAREVA, A: **2671**
LOSS, J: T081
LOSTAO, C: F018
LOUREIRO, M: F021, T065
LU, Y: 1561, 2352
LUDGATE, M: **2631**
LUFT, N: 2386, T092
LUHMANN, U: **3523**
LUMBROSO LE ROUIC, L: 3642, 3644
LUMBROSO, B: **3112**
LUNA, C: S053
LUOMARANTA, T: 1554
LUPIDI, M: 3114
LUX, AL: T108
LUZHNOV, P: T032
LYBERG, T: 3324
LYTVYNCHUK, L: **1564**, **2115**
LYUBIMOV, G: T037
MAAMOURI, R: 2675, F063, F093, S024, T068, **F085**, **F086**
MACAPAGAL, M: S081
MACGREGOR, C: 2338, F077
MACHADO, MAC: S011
MACKEY, D: 3524
MACLAREN, R[MNU: **1711**
MADDIRALA, Y: 2782, S076
MADEJA, Z: S090
MADIGAN, M: **2758**, **3647**, **S108**
MAFFIA, A: F039
MAGERL, W: T005
MAGUIRE, AM: 1514
MAHROO, O: T074
MAI, M: 3561
MAIRS, L: 3172
MAJSTEREK, I: T053
MAKHOUL, D: 3371
MAKLEY, L: **2785**
MALAS, S: T054
MALEKIFAR, A: T084
MALIIEVA, O: S020
MALMBERG, F: T062
MALMQIST, L: 3161
MAMELETZI, E: T022
MAMMADZADA, P: 3584, **T096**
MAMUNUR, R: **4446**
MANNS, R: **F083**
MANOLI, P: **F028**
MARAIS, R: 4145, S092
MARCELIS, W: **F025**
MARCHESI, N: S006
MARECHAL, M: S029, S084, **S082**
MARIOTTI, C: 2311, 3361
MARKKINEN, S: 4141, S087
MARKOWITSCH, S: 3525
MARQUES-NEVES, C: 1164, 2151, 2154, 2685, T041, T046, T086, **3661**
MARQUES, N: 3327, F078
MARTENS, T: 2143
MARTÍN-RIDAURA, MDC: 3326, F076
MARTIN, K: 1165, T049
MARTIN, KR: T050
MARTINEZ CASTRILLO, JC: F011
MARTINEZ DE LA CASA, JM: 3123
MARTÍNEZ V, M: F056, S044
MARTÍNEZ VÉLEZ, M: S045, S056
MARTINEZ-PEREZ, L: F101
MARTÍNEZ, M: F045, S027, S043, S055, T066, **F114**, F038, F070, F094, F108, S066
MARTINUZZI, A: **2362**
MASAYASU, K: F005
MASCHI, C: 4442, **4443**
MASSAMBA, N: S065
MASSIN, P: 1546
MASTROPASQUA, A: 2312
MATOS, R: 1545
MATTANA, A: S059
MAUGET-FAYSSE, M: **2684**
MAULL, R: T028
MAURIN, M: 2354
MAURIZI, E: 3172
MAURO, V: S007
MAY, K: T047
MAYCHUK, D: 2671
MCCARTHY, C: 4143
MCGREAL, R: 2351
MCLEAN, I: 3172
MEDEIROS PINTO, J: **2154**, **2335**, **F073**
MEEK, KM: 3135
MEERS, C: 1566
MEHTA, J: 1166, T018
MEILLON, C: 2681
MEIRA, D: F021, S101
MEKKI, MB: **2375**
MENDES, M: F062, **T064**
MENICACCI, C: 3646, S098
MENICACCI, F: 3641
MERAYO-LLOVES, J: **2431**
MEREDITH, P: 2338, F077, F105
MEREDITH, S: 2338, F077
MERIC, N: 2337, F074
MERTENS, M: 2751, S096
MESSMER, EM: **2833**
METZ, G: **F024**
MEUNIER, I: 2361
MEYER, L: 3162
MEZA ZEPEDA, L: S088
MGHAIETH, F: F092, T008, T009
MICHAEL, R: **2182**
MICHALEWSKA, Z: **2111**, **2153**
MICHALEWSKI, J: 2111, 2153
MICHALIK, M: S090
MICHAUD, J: 2661
MICHEL, S: 3372, F046
MILASH, S: 1343, S028
MILAZZO, S: F033, F044
MILLÁN, MS: **2183**
MIN, JS: F104

MINGUEZ, E: T004
MINIEWICZ, J: **2152**
MIONE, MC: 4145, S092
MIRABELLI, P: 3633
MIRONOV, A: S109
MISIUK - HOJLO, M: 2673
MISSOTTEN, G: 4445
MISSOTTEN, L[MKAB: **1611**
MISTRUKOV, A: 2674
MISZCZYK, J: S079
MITCHELL, A: T047
MITTICA, P: 3646, S098
MIU, J: T056
MOE, MC: S039, S088
MOGHADAS SHARIF, N: S018
MOHAMMAD, G: 2332
MOHAN, R: **1513**
MOISEEVA, I: T037
MOLASY, M: T053
MOLENBERGHS, G: 3664
MOLET, L: S071
MOLINA-MARTÍNEZ, IT: 2142
MØLLER, F: S046
MOMBAERTS, I: 1377, S021
MOMTAZI, L: **S036**, **S037**
MONIN, J: S084
MONSALVE, P: 1524
MONTENEGRO, GA: 2182
MONTERO MORENO, JA: F084, **1542**, **F051**, **F101**
MOON, D: S047, **S085**
MOONS, L: 1344
MOORE, J: 3172
MOORE, T: 3174, 3581, **3172**
MOORE, W: 3563
MOOSANG, K: **F029**, **F055**
MORA, C: T028
MORAIS, AS: F049
MOREIRA, S: 1164, 2685
MORENO-MONTAÑÉS, J: T063
MORFEQ, H: F033
MORILLA, A: T028
MORLEY, D: S050
MORRIS, JC: 1341
MORRISON, J: 2321
MOSCHOS, MM: **1312**
MOSS, S: T077
MOTLIK, J: T106
MOTULSKY, E: 3371
MOULIN, A: **2752**
MOURIAUX, F: T108, **2651**
MOURTZOUKOS, S: F083
MOUSA, A: 2332
MRUKWA KOMINEK, E: **S054**
MUKWAYA, A: 3633
MULAK, M: 2673
MUN, SJ: F081, **F106**
MUNCH, M: 1551
MUNIER, F: 3641, **3546**
MUNOZ - NEGRETE, FJ: **1557**, **F001**, **F023**, **T035**
MUÑOZ BLANCO, JL: F002
MUÑOZ-NEGRETE, FJ: F011, T058, T063
MUNOZ, M: **2122**, **T028**
MURAINE, M: 3334
MURAT, M: S069
MURDOCH, I: T027
MUSSON, C: 2354
MWANZA, JC: 1524
MYKHAILYK, O: 3132
MYRNENKO, V: T099
NABOVATI, P: T001, T084
NADAL-NICOLÁS, FM: 2324
NAGAOKA, T: **1111**
NAKAI, K: **3672**
NASCIMENTO, N: T045
NASINNYK, I: S095
NAU, C: **2372**
NAWAZ, MI: 2332
NAWROCKI, J: 2111, 2153
NAZARETYAN, R: T099
NEEDHAM, K: 3524
NEFF, F: 3382
NELSON, BJ: 3134
NENCHEVA, Y: 2677, S022
NERI, P: **1133**, **1534**, **2311**, **3361**
NESBIT, A: 3172
NESS, C: **S088**
NEVES, F: S101, T046, T086
NGUYEN KIM, P: S048
NICOLAE, A: T056
NICOLAISSEN, B: S038, S039
NILSEN, O: S036, S037
NILSSON, M: S019
NISHIGUCHI, K: 3523
NOÉLIA, L: T046
NOER, A: S036, S037, S038, S088, **S039**
NORMANDO, EM: **2621**, 1344, 2622
NOURI, MT: T078
NOWAKOWSKI, J: 2673
NOWINSKA, A: **2131**
NUBILE, M: **2312**
NUBOURGH, I: 3374
NÚÑEZ, E: F094, F108, S066
NUOTIO, K: F109
O'CONNOR, M: T077
OBERIC, A: 1346, T103
OBIS ALFARO, J: F014, F015
OBÍS, J: F003, F004, F007, F008, F009, F010, **F012**, **F013**, F006, F022
OBLANCA LLAMAZARES, N: F011
OBULKASIM, A: 4142
OCHIAI, H: **S074**
OGMUNDSDÓTTIR, MH: 3585, T076
OH, J: S004
OLAFSDOTTIR, OB: 2383, **T095**
OLDEN, M: T081
OLIVEIRA SANTOS, B: 2334
OLMIERE, C: S001, **S080**
OLSEN JULIAN, H: 1146, S026
OLSEN, NV: 1522
OLSTAD, OK: S039
OPDENAKKER, G: 2332
ORGOGOZO, A: 2337, F074
ORTÍN-MARTÍNEZ, A: 2324
OSBORNE, A: 1165, T049
OSBORNE, N: **2643**, **2644**
OSHITARI, T: **F089**
OSSEWAARDE-VAN NOREL, A: 3374
OSTADIMOGHADDAM, H: S030, T001, T084
OTIN, S: F003, F004
OWAIDHAH, O: T026, T044
ÖZCERIT, AT: T010
OZIMEK, M: **3321**
OZTURK, N: **F027**
PABLO, L: F003, F004
PAL, R: 3381
PALKOVITS, S: 2683
PALMARES, J: S051
PALUSZKIEWICZ, C: S079
PANFOLI, I: **T105**
PAPADIA, M: 1533
PAPADOPOULOS, M: T047
PAPAGREGORIOU, G: T054
PAPARELLA, G: 2362
PAPASTEFANOU, V: **S093**
PAPAYANNIS, A: 2362
PAPOILA, AL: 2334
PAPPAS, G: **1315**
PARAOAN, L: **2171**
PARK, CY: S040, S063
PARK, GH: T087
PARK, HYL: 1161
PARK, I: F050
PARK, J: S040, **S063**
PARK, SW: T087
PARK, YG: **F088**
PARRISH, RK: 1524
PASCALE, A: S006
PASSOS, I: 1347, T102
PASTOR-IDOATE, S: S109
PASTOR, L: T028
PASYECHNIKOVA, N: 1143, S095, T099
PATEL, P: S093
PATERNO, JJ: S005, **S003**, **S014**
PATHAK, M: S039
PATRA, S: 2336, F075
PAZOS, M: **2321**
PEAN, V: 1523
PEBAY, A: **3524**
PECHEREAU, A: F028
PEDRIOLI, DL: 3172
PEDROSA DOMELLÖF, F: S015
PEDROSA, AC: **3322**
PEEBO, B: 3633
PEIRO, B: T066
PENAS, S: 3566, T007
PENWARDEN, A: S086
PEOC'H, M: 1141, S012, S013
PEREIRA, S: 3334
PEREIRO, R: T075
PERESTRELO, S: **F066**
PÉREZ NAVARRO, I: **S045**, **S056**, F056, S044
PEREZ SARRIEGUI, A: 1557, F001
PÉREZ, D: F045, F038
PÉREZ, I: F045, F114, T004, T066, F108, S027, S043, S066
PERRACHE, C: 1141, S042
PERROT, JL: S013
PERTL, L: 2683
PERUMAL, N: 3525
PETACCHI, E: 2362
PETERSEN, L: T091
PETKA, O: 2152
PETRENKO, O: **S072**
PETROVSKI, BÉ: 1168, T031
PETROVSKI, G: 1168, 1371, S001, S006, T031, **3174**
PEYNSHAERT, K: 1544, 2143, **1342**
PEYRICHON, ML: 4443
PFAFF, A: S077
PFEIFFER, N: 3525
PICA, A: **4441**
PICAUD, S: 1342
PIERSCIONEK, B: **2181**
PIETRUCHA-DUTCZAK, M: T051, **T052**
PIIPPO, N: 1371, 1374
PINHEIRO-COSTA, J: 3322
PINILLA CORTÉS, L: 2182

All Authors

PINILLA, I: T004
PINNA, A: **S059**
PINTO PROENÇA, R: **2334**
PINTO, F: T046, T086
PINTO, J: 2151
PINTO, LA: 3664, T055, T095
PIPERNO-NEUMANN, S: 4145, S092
PIRANI, V: 1133, 1534, 2311, 3361
PIRES, G: 1347, T102
PIRVULESCU, R: S110, T056
PISELLA, PJ: T034
PLATANIA, CBM: S062
PLEYER, U: **1134**, **1151**, **1332**, **3574**
POCCARDI, N: 3375
PODRACKA, L: T051
POLITIS, C: 1377, S021
POLO, V: F003, F004
PONOMARENKO, M: **F052**, **F054**
POPA CHERECHEANU, A: **S110**, **T056**
POPOVIC, Z: S019
PORCU, M: T104
PORCU, T: S059
POSTELMANS, L: 2612, 3373, 3374
POURNARAS, C: **1113**, **2715**, **3116**, **3512**
POURNARAS, JA: **1313**, **3515**
PRATES CANELAS, J: 2335, F073
PRESTAT, A: 4145, S092
PRIETO, P: **2781**
PRIVATO, F: 2362
PROCACCIO, V: 2361
PROENÇA, H: T046, T086
PROENÇA, R: 3327, F078, 1347, 3328, F079, T102
PROKOPIOU, K: T054
PROMELLE, V: F033, F044
PROSDOCIMO, G: 2362
PRUENTE, C: **2714**
PRZYBYLOWSKA-SYGUT, K: T053
PUCCETTI, L: 3325, F091
PUELL, MC: 3326, F076
PUJOL, O: T028
PUK, O: 3586
QIU, X: **2352**
QUINLAN, R: **3381**
QUIRCE, S: **S053**
QURESHI, S: **4144**, **S091**
R COLLINS, A: S038
RAAPPANA, A: 1554
RÆDER, S: 2676, S025
RAES, A: 3582
RAGGE, N: 2661, 2664
RAHMANIA, N: **F033**
RAIKWAR, S: 1513
RAIVIO, V: 4141, S087
RAMBAUD, C: S082, S084
RAMBAULT, C: S029
RAMÍREZ, A: F002
RAMIREZ, AI: 1543, 2322, F017, F018, **T030**
RAMIREZ, JJ: F017
RAMÍREZ, JM: 1543, 2322, F018, F002, T030
RAMIRO, P: F038
RANSOM, B: **3624**
RAYHAN, H: 1142
REBOLLEDA, G: 1557, F001, F023, **F011**, **T058**, **T063**
REDDY, J: 3135
REGINI, J: 2181
REINA, M: T015
REINISALO, M: S001, S002
REINSTEIN MERJAVA, S: 3531
REJDAK, R: 3321
REKAS, M: S079
REMAUT, K: 1342, 1544, **2143**
REMÓN, L: F038, F045
REMOND, AL: **S068**
RENARD, JP: 1528, T042
REPPE, S: 3324
RESINA, C: T046, T086
REYNAERTS, D: 1566
REYNIER, P: 2361
RHO, CR: S004, T100
RIBEIRO, L: 1545, S101
RICOUARD, F: **F102**
RIEGER, F: 1513
RÍOS-LÓPEZ, I: 2183
ROALD, BBH: 3324
ROBERT, M: 3372, F046
ROBERT, PY: S008
ROBSON, A: **1123**
ROCA, A: 1563
ROCHA DE SOUSA, A: **1563**, **3566**, **F049**, **T007**
ROCHA SOUSA, A: T017
RODRIGO, MJ: F003, F004, F007, F008, F009, F010, F012, F013, F014, F015, **F006**, **F022**
RODRIGUES-ARAÚJO, J: 3566, T007
RODRÍGUEZ, SM: T075
ROEHLECKE, C: T105
ROELS, D: **T012**
ROEMER, S: **1551**
ROH, MS: S105
ROH, YJ: F088, T100
ROJAS LOZANO, MP: **F002**
ROJAS, B: 1543, 2322, F017, F018, T030
ROKICKI, D: S054
ROLLAND, J: 2313, S049
ROMAN-ROMAN, S: 4145, S092
ROMANENKO, D: F034
ROMANOWSKA DIXON, B: 2152, 4145, S092, **F068**, **S090**, **S102**
RONCEA, T: T056
RONG, X: 2352
RONIN, C: S009
ROSA, R: 2335, F073
ROSE, K: 1112
ROSEMANN, M: 3382
ROSÉN, R: S019
ROSENBERG, R: 1528, T042
ROSINHA, P: 3566, T007
RÖSSLER, U: 3382
ROUBERTIE, A: 2361
ROULAND, JF: T029, **1526**, **T033**
ROUSSEAU, A: 4133, S071, **3375**
ROVERE, G: 2324
ROWAN, A: 3567, T013
ROWLINSON, J: 1341
ROY, P: 3375
ROZET, JM: 2361, 2661, **2664**
RUÃO, M: 1545
RUIJTENBEEK, R: 4145, S092
RUITERS, S: **1377**, **S021**
RUIZ DEL TIEMPO, P: 1542
RUIZ-MORENO, JM: 1542, F051
RUIZ-MORENO, O: 1542
RUPENTHAL, I: S052
RUPENTHAL, ID: **2141**
RUSOVA, A: S031
RUSSELL, SR: 1514
RUSSO, A: F062, T064
RYKOV, S: S072
RYLL, B: 4145, S092
SA CARDOSO, M: T024
SAADOUN, D: 1555
SAAKYAN, S: **2757**, **3643**, **3645**, **S097**, **S104**
SAARELA, V: 1554
SAAVALAINEN, L: S005
SABRAUTZKI, S: 3586
SAGONG, M: **F110**
SAGOO, MS: S093
SAGUET, P: **T108**
SAHEL, J: 1553
SAHEL, JA: T039
SAHRARAVAND, A: T083
SAI, BB: T088
SAINZ DE LA MAZA, M: S064
SAKAMOTO, T: 1561
SAKSONOV, S: **2114**
SALAZAR, JJ: 1543, 2322, F002, F017, F018, T030
SALEH, M: F067, F102
SALGARI, N: 2312
SALINAS-NAVARRO, M: 2324
SALOBRAR-GARCÍA, E: **F017**, **F018**, F002
SALVI, M: **2634**
SALVIAT, F: **F046**
SALVISBERG, C: 1345
SÁNCHEZ MARÍN, JI: **F056**, **S044**, S045, S056
SANCHEZ SANCHEZ, C: F011
SANCHEZ, A: T078
SÁNCHEZ, I: F070, F094
SANCHÉZ, JI: S073, S043, F108, F114, S027, S066, F045
SANDBERG MELIN, C: 3161, **T062**
SANDVIK, L: 3324
SANTOS, A: 3328, F079
SANZ-MEDEL, A: T075
SAPETA, S: **1572**
SARA, L: 4443
SARGENT, N: F057
SARNA, M: 2152
SATO, E: F089
SATUÉ, M: F003, F004, F009, F010, F012, F013, **F007**, **F008**, F006, F014, F015, F022
SAUNDERS, D: S086
SCHALENBOURG, A: 2752, 4441
SCHELTER, SC: T081
SCHERER, D: S052
SCHIROLI, D: 3172
SCHLICHTENBREDE, F: 3561
SCHMAUCH, B: 2337, F074
SCHMELTER, C: 3525
SCHMETTERER, L: 1114, 2386, S034, T059, T092, **2642**
SCHMIDL, D: 2386, S034, T092, **1573**, **3662**
SCHNEIDER, R: 4441
SCHOEVAERDTS, L: 1566
SCHORNACK, M: 2372
SCHULMEISTER, K: 3164
SCHULZ, C: S086
SCHUMANN, U: T105
SCHWARZ, N: **2761**
SCOTT, A: **1321**
SEBASTIANI, S: T006, T020
SEITZ, B: S089
SELIVERSTOV, S: S031

SEMCHISHEN, V: 1343
SENDON, D: 1528, S084, T042
SEONG, M: F032, T080
SEPETIS, A: **T077**
SEQUEIRA, J: T065
SETO, S: T071
SHAHDADFAR, A: 3174, S036, S037
SHAHKARAMI, L: S030
SHALABY, A: **F105**
SHAMAEV, D: T032
SHARGORODSKAYA, I: S072
SHARMA, A: 1513
SHEBIL, S: S017
SHIH, KC: **1163**
SHIMIZU, N: F089
SHIN, IH: F072
SHIN, JA: S004
SHIN, KS: **S067**, F072
SHIN, WB: **S083**
SHIN, Y: **F032**
SHIN, YU: **T080**
SHIRZADEH, S: **F041**, **S058**
SHOEIBI, N: S018
SHU, X: 3583
SHUICHI, Y: F005
SHUM, HC: 1561
SIANOSYAN, A: 1343, S031
SICURANZA, A: 3325, F091
SIDDIQUEI, MM: 2332
SIERRA-RODRÍGUEZ, MA: 1542
SILVA, MI: F049
SILVENNOINEN, H: F109
SILVESTER, A: **2155**, **F048**
SINGER, B: 3132
SINHA, D: S001
SINHA, N: 1513
SINHA, P: 1513
SITIWIN, E: 2758, S108
SJOSTRAND, J: **S019**
SKALICKÁ, P: T070, **T072**
SKYTT, D: T048
SKYTT, DM: 1373, **1372**
SLOBODIANYK, S: F026
SMEDOWSKI, A: **2132**, **T051**, T052
SMETS, M: **S107**
SMITH, AJ: 3523
SMITH, R: **1122**, **1125**
SNAAR-JAGALSKA, BE: 4145, S092
SÖDERBERG, P: **3161**, 3163, 3164, S075, T062
SOHN, EJ: S010, S105
SOINNE, L: F109
SOMERS, A: 1527, T036
SOMNER, J: **2733**
SONG, JH: F112
SORIA, J: S061
SOUBRANE, G: **3113**
SOUSA NEVES, F: **1545**, **T065**
SOUSA, F: **2151**
SOUSA, T: 3322
SOYDAN, A: T098
SOZEN-DELIL, FI: **F080**, **1565**, **F111**
SPILEERS, W: **2161**
SPIRA-EPPIG, C: 4122, 4422
SROUR, M: 2661
STACHS, O: **1574**
STÆHR JAKOBSEN, N: **F087**
STALMANS, I: 1167, 1527, 2384, 3664, T029, T035, T036, T055, T057, T095, **3121**
STALMANS, P: 1566, T055
STANGA, P: S109
STANGOS, A: **3511**, **T022**
STARK, KJ: T081
STATHOPOULOS, C: 3546
STEFÁNSSON, E: **3572**, 2383, T095
STEIN, A: T037
STEINGRIMSSON, E: 3585, T076
STEPANKA, S: T071
STEPHAN, S: S048
STERN, ME: 2771
STERN, MH: 4145, S092
STONE, D: **T026**
STORMLY HANSEN, M: 1146, S026
STORR-PAULSEN, T: S046
STOYKOVA, V: S065
STRADLING, J: T089
STRELKAUSKAITE, E: T059
STREUER, A: T005
STRUPAITE, R: **T067**
SUÁREZ, T: **S061**
SULEIMAN, E: **T019**
SULLIVAN, DA: **2831**
SUMMANEN, P: F109, T090
SUN, Y: 1377, S021
SUNARIC MEGEVAND, G: T022, **1323**, **1324**
SUNDAR, G: T082
SUPURAN, CT: 2382
SUZANI, M: 3581
SUZUKI, N: **2687**, **3565**, **F059**
SVIRSKIS, D: 2141
SYS, C: F025
SZAFLIK, J: T053
SZAFLIK, JP: **F065**, **T053**
SZAFLIK, M: F065, T053
SZENTMÁRY, N: 4121, 4423, **4123**, **4421**, 4122, 4422
SZYMANEK, K: T053
TAIBI, A: 2375
TAKAHASHI, H: 2682
TAKATSUNA, Y: F089
TAKAYUKI, B: F005
TAKEI, A: 3584
TAKISSIAN, J: 3375
TALEBIZADEH, N: 3161, 3164, S075, **3163**
TÄLL, M: 4141, S087
TAN, D: 1166, T018
TANAKA, H: 3381
TANKAM, P: S049
TAPIO, S: 3382
TARUTTA, E: 1343, **S028**, **T002**
TASHBAYEV, B: 2676, S025
TASSIGNON, M-J: **4211**
TASSIGNON, MJ: **2712**
TATSUMI, T: F089
TAVARES FERREIRA, J: 2334
TAYLAN SEKEROGLU, H: F016, F047
TAYYIB, A: 1145, S023
TEISTER, J: 3525
TEPLYAKOVA, K: S031
TERZI, EH: T098
TESAROVA, M: T071
TESLENKO, A: 2114
THARIAT, J: 4442, 4443
THIELE, F: 3586
THOMASSON, N: 1553
THOMPSON, D: **1121**, **3563**
THURET, G: 1141, 3331, 3334, 3335, F028, S009, S012, S013, S042, S049, **2313**
TICK, S: F062
TIMSIT, A: S082, S084, **S029**
TIRANTI, V: **2423**
TITAH, O: 2375
TOBWALA, S: 2782, S076
TODOROVA, MG: F040
TOFT-KEHLER, AK: 1372, **T048**
TOLPPOLA, O: S005
TON, HT: 2758, S108
TONG, L: T038
TOOP, HD: 1341
TORP-PEDERSEN, C: 1168, T031
TOSHIYUKI, O: F005
TOTH, M: **T021**
TOUBEAU, D: 3334
TOUITOU, V: 1555, S070, **2613**, 2614
TOZAR, T: S110
TRAVERSO, CE: T020, T105
TRIOLO, G: **1524**
TRIPATHI, R: 1513
TRIVIÑO, A: 2322, 1543, F017, F018, T030
TROUNCE, I: 3524
TROZIC, I: 2683
TRZECIECKA, A: T051
TSUBOI, K: 3672
TUMBOCON, J: S081
TUNC, M: **2652**, **2754**, **4447**, **S100**, **S106**
TUNIK, S: 3584
TURCK, N: **1345**, **1346**, **T103**
TURKI, A: F063, T068
TURKI, R: 1142
TÜRKSEVER, C: F040
TURNBULL, C: T089
TURTIAINEN, H: S003
TURUNEN, J: **4141**, **S087**
TZOURIO, C: 1376
UENO, S: T012
UESUGI, K: 2181
ULLRICH, F: **3134**, **3534**
UNGER, K: 3382
URBANSKA, K: S090
URCELAY SEGURA, JL: F002
URETSKY, S: 1553
USUBOV, E: S032, S033
UTHEIM, Ø: 2676, S025
UTHEIM, TP: 2676, 3324, S025
UTKUS, A: T067
UUSITALO, H: **1171**, **2774**
UUSITUPA, M: S005
VAGGE, A: T020
VAJANTO, V: S005
VALENTE, A: 4145, S092
VALIENTE-SORIANO, FJ: 2324
VALLAT, L: 4441
VAN BERGEN, N: 3524
VAN CALSTER, J: **3362**, **3363**
VAN DEN EYNDE, K: 2332
VAN DEN HAUTE, C: 1344
VAN DER VELDEN, PA: 4145, S092
VAN DOOREN, B: S051
VAN GINDERDEUREN, R: **3364**, **4445**
VAN KEER, K: T095, 3664, **1167**, **2384**, **T057**
VAN LAECKE, S: 3582
VAN ROMPAY, T: F033
VANDER POORTEN, E: 1566
VANDERMEER, G: T034
VANDEWALLE, E: **T036**, 1167, 2384, 3664, T055, T057, T095, **1527**, **3125**
VANHEUKELOM, V: 2387, T093
VARANDAS, R: T065
VASCO SANTOS, J: T017

All Authors

VASSEUR, V: 2684
VAVLA, M: 2362
VAZ-PEREIRA, S: 1545, 2335, F073
VÁZQUEZ-ALFAGEME, C: S093
VAZQUEZ, LE: 1524
VEGA-ESTRADA, A: **2185**
VEGA, F: 2183
VEGA, Z: T028
VERMORGEN, K: 1527, T036
VERSTRAETEN, T: 1541
VERTICCHIO VERCELLIN, AC: F039
VIAUD-QUENTRIC, K: S080
VIBÆK, J: 1522
VICENTE, A: 2334, 3327, F078
VIDAL-SANZ, M: **2324**
VIEIRA, L: 3328, F079, T015
VIESTENZ, A: S089
VIGNAL CLERMONT, C: **1553**
VIKATMAA, L: F109
VIKATMAA, P: F109
VILADES PALOMAR, E: F014, F015
VILADES, E: F003, F004, F006, F007, F008, F022, **F009**, **F010**
VILLADES, E: F012, F013
VILLEGAS-PÉREZ, MP: 2324
VILLOTA, E: T073
VIOTTE, A: **F067**
VITOVSKA, O: 2114
VOHRA, R: 1372, **1373**
VOSKANYAN, L: 3123
VOTRUBA, M: T071
VOTRUBA, M[AU: **3211**
VUORINEN, I: S003
WAAGEPETERSEN, H: **3621**
WAGNER, H: 4441
WAIZEL, M: **F040**
WALCZAK, A: T053
WALPERT, M: **2622**
WALRAEDT, S: 3582
WALSER, M: 4441
WANG, S: 2783
WEARMOUTH, SF: 1341
WEBER, BH: T081
WEBER, DC: 4441
WEBSTER, A: 3581
WECHSLER, B: 1555
WEGENER, A: **3162**
WEGER, M: 2683
WEI, X: **T088**
WELLMAN, J: 1514
WERKMEISTER, R: **1114**, **1571**
WERKMEISTER, RM: 2386, T092
WIDDOWSON, P: 1165, T049
WILLEKENS, K: 1167, T057, **1566**, **3664**, **T055**
WILLERMAIN, F: 3371, 3373, 3374, **1331**, **2612**
WILLIAMS, K: T074
WILSKA, R: 4141, S087
WITKOWSKA, KJ: 2386, T092
WOLFF, B: 2684
WONG, B: 1112
WONG, D: 1561
WONG, R: 3524
WONG, T: 1166, T018, T038
WOZNIAK, PA: **2386**, **T092**
WU, J: 1561
WU, JJ: 3381
WURST, W: 3382
WYLEGALA, E: 2132, **4124**, **4424**
XEROUDAKI, M: 3633
XIE, Q: 2351
YAGI, N: 2181
YAGMUR, M: S051
YAHIAOUI, S: 2375
YAMAMOTO, S: F089
YAMANE, K: 2687, 3565, F059
YAN, L: 3562
YAN, X: 3586
YAN, Y: 2783
YANG, C: 3562
YANG, H: 2321
YANG, SJ: F103
YANG, X: 3562
YANG, YR: S057
YANG, Z: T038
YASIN, N: 2141
YAVUZYIGITOGLU, S: 4142
YAZDANI, N: S030, T001
YAZGAN, S: **T014**
YEKTA, AA: **T001**, **T084**
YEKTA, R: T001
YIM, B: S063, **S040**
YOKOI, N: 2677, S022
YOO, C: T060
YOU, Y: S085
YU-WAI-MAN, P: **2365**
YU, M: 3584
YU, Z: 3161, 3163, S075, **3164**
YU, ZF: 1514
YUBERO, R: F017, F018
ZADOROZHNYY, O: **S095**, **T099**
ZAGÓRSKI, Z: S051
ZAMBARAKJI, H: 2336, F075
ZAMBRANO, I: S109
ZEITZ, C: T069
ZELL THIME, H: S036, S037
ZENG, J: **3562**
ZENOUDA, A: T039
ZEPPA, L: T023, T023
ZEREI, N: F093
ZHANG, H: **3632**
ZHANG, J: 1341
ZHANG, K: **2783**
ZHANG, X: **3583**
ZHAO, L: 2783
ZHAO, Y: 2351
ZHENG, D: 2351
ZHU, J: 2783
ZHURAVLEVA, A: T019
ZIMMERMANN, A: F102
ZIMMERMANN, ME: T081
ZITZELSBERGER, H: 3382
ZOGRAFOS, L: 2752, 4441, **2345**, **3117**, **3543**
ZSOLT NAGY, Z: **4125**
ZYGANOW, M: 3561

Authors by Country

ALGERIA....2
AUSTRALIA....3
AUSTRIA....9
BELGIUM....47
CANADA....1
CHINA....2
CYPRUS....1
CZECH REPUBLIC....6
DENMARK....16
FINLAND....15
FRANCE....77
GERMANY....23
GREECE....5
HONG KONG, CHINA....1
HUNGARY....2
ICELAND....5
INDIA....2
IRAN....3
IRELAND....3
ISRAEL....2
ITALY....24
JAPAN....9
LITHUANIA....2
NETHERLANDS, THE....3
NEW ZEALAND....2
NORWAY....8
POLAND....17
PORTUGAL....19
ROMANIA....1
RUSSIA....9
SAUDI ARABIA....4
SINGAPORE....6
SLOVENIA....1
SOUTH-KOREA....35
SPAIN....45
SWEDEN....15
SWITZERLAND....24
TAIWAN....1
TUNISIA....6
TURKEY....11
UKRAINE....7
UNITED KINGDOM....70
UNITED STATES....13

	HERMES	RHODES 1	RHODES 2	RHODES 3	RHODES 4	GALLIENI 1&2	GALLIENI 4	GALLIENI 5
Wednesday, October 5, 2016								
11:30 - 13:00	PBP/RV - Retinal perfusion imaging *SCHMETTERER L - NAGAOKA T*	EOVS - A clinician's guide to visual electrophysiology: a road map for neuro-ophthalmology *THOMPSON D - SMITH R*	IM - EBO course: intra-ocular inflammation and infection - part I *BODAGHI B - HERBORT CP*	COS - FP session - Corneal grafting *GICQUEL J - THURET G*	LC - Controversies in cataract surgery pharmacology *LÖFGREN S - GRZYBOWSKI A*	G - FP session - Advances in glaucoma *BRON A - NORMANDO EM*	ACB - Tear fluid proteome *UUSITALO H*	
14:00 - 15:30	RV - Management of Aphakia *POURNARAS JA - PAPPAS G*	G - The ideal glaucoma rotation *ABEGAO PINTO L - SUNARIC MEGEVAND G*	IM - EBO course: intraoc-ular inflammation and infection - part II *BODAGHI B - HERBORT CP*	PBP - FP session - Drug delivery and biomarkers for ocular disease *SCHMETTERER L - HARDARSON S*	EOVS - Optical principles of state-of-the-art ophthal-mic instrumentation *IRSCH K*	MBGE - Epidemiology of eye diseases *GRAW J*	ACB - FP session - Cell biology and imaging of retina and orbit *PETROVSKI G - KOLKO M*	
15:30 - 15:40	Coffee break							Exhibition area
15:40 - 15:50	Opening Ceremony: Welcome by the President EVER 2016 - *KAWASAKI A*							Hermes
15:50 - 16:00	Highlights of EVER✓ and Update on EVER in EU-EYE - *SCHMETTERER L*							Hermes
16:00 - 16:30	EVER Past President lecture: Lessons from the Fascinating World of Bestrophinopathies - *LEROY B*							Hermes
16:30 - 16:50	Coffee break							Exhibition area
16:50 - 18:20	MBGE/RV - Advances in gene-based therapies for ocular disorders *LISKOVA P*	G - FP session - New technologies in glaucoma *CORDEIRO MF - ROUSSEAU A*	IM - Inflammatory versus non-uveitic posterior segment diseases *NERI P - HERBORT CP*	RV - FP session - Surgery I *BERROD J-P - VAN CALSTER J*	NSPH - FP session - Neuro-ophthalmology and paediatric ophthalmology *YU-WAI-MAN P - BOSCHI A*	RV - FP session - Surgery II *LEYS A - HUSSAIN R*	PBP - High-resolution imaging of the anterior eye segment *WERKMEISTER R*	
18:35 - 19:00	European Ophthalmology Heritage Lecture: Magnificat - *MISSOTTEN L*							Hermes
19:00 - 19:30	Keynote Lecture: Developing new treatments for inherited retinal degenerations - *MACLAREN R*							Hermes
19:30 - 21:30	EVER Welcome Reception							Exhibition area
Thursday, October 6, 2016								
08:30 - 10:00	RV - Diabetic retinopathy *LYTVYNCHUK L - WIEDEMANN P*	G - You tube: different tubes for different glaucomas *DUCH S - MILLA E*	COS - Corneal dystrophies - diagnosis and treatment *WYLEGALA E - DOBROWOLSKI D*	PBP - Drug delivery sys-tems for the back of the eye. Translational research *HERRERO-VANRELL R - RUPENTHAL I D*	RV - FP session - Surgery III *PRUENTE C - POURNARAS JA*	EOVS/MBGE - Doctor, I can't see in the dark *HOLDER G*	ACB - Proteostasis in the pathogenesis of age-related macular degeneration *KAARNIRANTA K - UUSITALO H*	LC - Lens and IOL- optics and accommodation *BARRAQUER RI - MICHAEL R*
10:00 - 10:20	Coffee break							Exhibition area
10:20 - 10:50	EVER-Acta Lecture: The pathogenic role of LRG1 in ocular neovascularisation: From discovery to targeted therapy - *GREENWOOD J*							Hermes
11:00 - 12:30	IM - OCT in inflammatory ocular diseases : beneath and beyond the retina *WILLERMAIN F - NERI P*	G - Mathematical modelling in glaucoma *VIDAL-SANZ M - CORDEIRO MF*	RV - FP session - Diabetes *SOUBRANE G - COSCAS F*	PO/RV - Mistakes in the diagnosis of fundus tumors *DESJARDINS L -ZOGRAFOS L*	LC - FP session - Lens and cataract *ZHANG K - MAKLEY L*	MBGE/NSPH - Mitochondrial optic neuropathies - disease mechanisms and therapies *VOTRUBA M - YU-WAI-MAN P*	ACB/COS - How I fell in love with scleral lenses - the attractive lens paradox *KNOP E - KNOP N*	PBP - FP session - Oxygen delivery and regulation of vascular tone *OSBORNE N - GARHÖFER G*
12:40 - 13:40	Industry-sponsored lunchtime symposium: Leber's hereditary optic neuropathy (LHON): latest advances in diagnosis, staging and patient management - *KLOPSTOCK T - CARELLI V*							Rhodes 1
12:40 - 13:40	Industry-sponsored lunchtime symposium: Demodex: innocent or guilty in blepharitis? - *JAMES TE*							Rhodes 2
13:50 - 14:20	Keynote Lecture: Medical science and clinical research in corneal regenerative medicine - *KINOSHITA S*							Hermes
14:30 - 16:00	IM/RV - Challenges and controversies in ophthal-mology: When the patient overlap between different subspecialties *CASPERS L - WILLERMAIN F*	G/PBP - OCT spectralis in neurodegeneration - Young investigator presentations *CORDEIRO MF - NORMANDO EM*	NSPH - Update in graves' orbitopathy *BOSCHI A - BALDESCHI L*	PBP/RV - ABC in retina structure and function *GRZYBOWSKI A - OSBORNE N*	PO - Challenges in management of orbital tumors *TUNC M*	NSPH - Update in clinical features and genetics in microphthalmia *BREMOND-GIGNAC D - ATILLA H*	COS - FP session - Ocular surface diseases update *LAZREG S - GICQUEL J*	RV - FP session - Imaging *LUMBROSO B - STANGOS A*
16:00 - 17:00	Poster session 1: Electrophysiology, Physiological Optics, Vision Sciences • Glaucoma • Molecular Biology / Genetics / Epidemiology • Physiology / Biochemistry / Pharmacology							Poster area
16:00 - 17:00	Meet the Experts							Poster area
17:00 - 18:30	RV - Controversies in vitreoretinal practice *GRZYBOWSKI A - ASCASO F*	G - Laser - the force reawakens. New concepts in established technology *CRAWLEY L - BLOOM P*	G - YOS for EVER - young ophthalmologist/scientist *JÓHANNESSON G*	NSPH - Hot topic in ocular surface in children *BREMOND-GIGNAC D - ATILLA H*	PO - FP session *MOURIAUX F - MOULIN A*	MBGE/NSPH - Syndromic retinopathies *LISKOVA P*	ACB - Tear proteome, inflammation and wound healing *UUSITALO H - BEUERMAN R*	LC - Non-surgical cataract treatment *LÖFGREN S - BARRAQUER RI*
18:30 - 20:00			Modern understanding of dry eye *SULLIVAN DA*					

	HERMES	RHODES 1	RHODES 2	RHODES 3	RHODES 4	GALLIENI 1&2	GALLIENI 4	GALLIENI 5
Friday, October 7, 2016								
08:30 - 10:00	RV - Confrontation of OCT-angiography and fluoresceine angiography *POURNARAS C - ZOGRAFOS L*	G - New technologies in glaucoma surgery *VANDEWALLE E - STALMANS I*	COS - Nanotechnology in ophthalmology *KOMPELLA UB - GRIFFITH M*	PO - Conjunctival tumors *COUPLAND S - CAUJOLLE JP*	EUPO 1 Neuro-ophthalmology	LC - Ocular damage from ambient optical radiation *SÖDERBERG P - WEGENER A*	ACB - Stem cells and cell therapy advances in ophthalmology *PETROVSKI G - MOE M*	MBGE - Grand rounds in ophthalmic genetics *LEROY B - HAMEL C*
10:10 - 10:40	Keynote Lecture: OPA1 gene and mitochondrial optic neuropathy: disease mechanisms and potential therapies - *VOTRUBA M*							Hermes
10:40 - 11:00	Coffee break							Exhibition area
11:00 - 12:30	ARVO@EVER - Animals in ocular oncology *COUPLAND S*	RV - FP session - AMD & miscellaneous *SOUBRANE G - LEYS A*	COS - FP session - Corneal transplantation from the lab to the OR *GICQUEL J - FUCHSLUGER T*	PO - Controversies in posterior uveal melanoma *MOURIAUX F - CASSOUX N*	EUPO 2 Neuro-ophthalmology	PO/IM - Cytology of atypical inflammation or tumors *VAN GINDERDEUREN R - VAN CALSTER J*	IM - FP session - Novelties in diagnosis and treatment in ocular immunology *BODAGHI B - WILLERMAIN F*	MBGE/LC - Radiation induced cataracts *AINSBURY L - WEGENER A*
13:30 - 15:00	RV - Retinal detachment *POURNARAS JA - E MERY*	G - EVER Obergurgl optic nerve meeting symposium: the ageing optic nerve *GRUS F - CROWSTON J - MARTIN K*	COS/RV - Emerging solutions in ophthalmology *FUCHSLUGER T - STEFANSSON E*	PO - Topical and intravitreal pharmacotherapy in ocular oncology *ZOGRAFOS L - DESJARDINS L*	EUPO 3 Neuro-ophthalmology	EOVS - FP session - Electrophysiology - protocols & applications *CASTELO-BRANCO M - KRASTEL H*	IM - How to publish your scientific work? *PLEYER U*	MBGE - FP session *BUJAKOWSKA K - SCHWARZ N*
15:00 - 16:00	Poster session2: Neuro-ophthalmology / Strabismology / Paediatric/History • Retina / Vitreous							Poster area
16:00 - 16:30	Business meeting RV	Business meeting EOVS / G	Business meeting COS / NSPH	Business meeting PO / PBP	EUPO 4 Neuro-ophthalmology	Business meeting IM / MBGE	Business meeting ACB	Business meeting LC
16:30 - 18:00	FAN Club Case presentations	G - Implications of neuro-glial interactions in neurodegenerative diseases *KOLKO M - WAAGEPETERSEN H*	COS - Corneal neovascularization and immune privilege *HORI J - CHEN L - ZHANG H*	OOG Session 1 *KIVELÄ T - HADJISTILIANOUT*		PBP - Ocular pulse amplitude - from pole to pole *ABEGAO PINTO L - MARQUES-NEVES C*	IM - FP session - New insights in imaging in ocular immunology *HERBORT CP - NERI P*	GOA - Update on severe allergic conjunctivitis *BREMOND-GIGNAC D - FAUQUERT J*
18:00 - 18:30	EVER General Assembly							Hermes
Saturday, October 8, 2016								
08:30 - 10:00	NSPH/RV - The first ones in ophthalmology *GRZYBOWSKI A - ASCASO F*	COS - Keratoconus diagnosis and treatment in the clinical practice *SZENTMARY N - ZSOLT NAGY Z*	COS - Corneal infectious diseases *GICQUEL J - BREMOND-GIGNAC D*	OOG Session 2 & Business Meeting *HEEGAARD S - CASSOUX N*	EUPO 5 Strabismus	FRO: Belgian Fund for Research in Ophthalmology - part 1 *TASSIGNON MJ - CASPERS L*		
10:00 - 10:20	Coffee break							Exhibition area
10:20 - 10:50	Ophthalmic Research Lecture: The cataract surgeon and the anterior interface - *TASSIGNON M-J*				EUPO 6 Strabismus			Hermes
10:50 - 12:00	Poster session 3: Anatomy / Cell Biology • Cornea / Ocular Surface • Immunology / Microbiology					Lens and Cataract • Pathology / Oncology		Poster area
12:00 - 13:00	Lunchtime							
13:00 - 14:30	Women 4 EVER *CREUZOT C*	COS - Pseudophakic and phakic toric implants – from preoperative examination *LANGENBUCHER A - SZENTMARY N - EPPIG T*	COS - Maximising success in deep anterior lamellar keratoplasty *DUA H S - GICQUEL J*	OOG Session 3 *ZOGRAFOS L - DESJARDINS L*	EUPO 7 Strabismus	FRO: Belgian Fund for Research in Ophthalmology - part 2 *TASSIGNON MJ - CASPERS L*		
14:30 - 15:00	Prize Award Ceremony & Closing Remarks							Hermes

SPONSORS AND EXHIBITORS

MAIN

ALLERGAN

MAJOR

BAYER

santhera Pharmaceuticals

CIS - INDUSTRY SPONSORED SYMPOSIA

santhera Pharmaceuticals

Théa

SIS - SPECIAL INTEREST SYMPOSIA

HEIDELBERG ENGINEERING

Théa

EXHIBITORS

ALLERGAN

BAYER

bioptigen

CAMBRIDGE RESEARCH SYSTEMS

charles river | every step of the way.

diagnosys

HEIDELBERG ENGINEERING

Horus PHARMA

iris PHARMA

LKC

METROVISION

NOVARTIS

nuvision

santhera Pharmaceuticals

Théa

TOPCON

vito vision on technology

WISEPRESS

THANK YOU

CONSEIL GENERAL DES ALPES-MARITIMES

EVER would like to thank all of its past and present sponsors We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2016 Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information